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Monoclonal Antibody Production Via Fluidized Bioreactor Technology
Abstract
Monoclonal antibodies (mAbs) are biologically identical antibodies created by homogenous immune cells
originating from the same parent cell. MAbs target a specific epitope of an antigen on a cell’s surface,
allowing it to neutralize the antigen. This unique characteristic has made them a key tool in the
biopharmaceutical industry for the production of therapeutic drugs. One of these drugs is Rituxan®
(rituximab), a mAb drug for the treatment of various cancers and autoimmune diseases. Currently, most
mAb products are grown via cell suspension technology in stirred tank bioreactors. However, we have
found that by using an integrated bioprocessing model, including conventional cell suspension culture
tanks and fluidized bioreactor technology, overall product yield per day is increased by about 7-fold for the
production of Rituxan®. Additionally, an economic analysis shows the fluidized bioreactor process is
more profitable. Furthermore, though it requires a higher initial investment than the stirred tank process,
the differential present worth of the fluidized bioreactor process in comparison to the stirred tank process
is $13 billion. Overall, for the production of Rituxan®, the use of fluidized bioreactor technology is a more
productive and lucrative process than the conventional stirred tank process.
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Professor Leonard Fabiano
University of Pennsylvania
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Philadelphia, PA 19104
Dear Professor Fabiano,
Enclosed herewith is a detailed process design and economic analysis comparing two methods of
monoclonal antibody production. The traditional stirred tank bioreactor process currently used in
industry was compared to a hybrid process involving a fluidized bioreactor. A fluidized
bioreactor process was chosen as comparison because it allows for greater product formation and
ultimately a more profitable method to produce generic rituximab. The production goal was set
at 650kg of generic Rituxan® (rituximab), a monoclonal antibody currently sold by Roche.
However, it was determined that five parallel processes of the stirred tank process would be
required to meet the production requirement while only one fluidized bioreactor process is
necessary.
The report provides significant details regarding the process unit operations along with a detailed
design of the fluidized bioreactor, which is a new, unique and difficult concept. Furthermore, a
fluidized bioreactor model was also developed to model the growth of cells in the environment
along with the effect of various factors on product formation.
Based on the economic analysis, we recommend implanting the fluidized bioreactor process to
create product at the lowest dollar and time cost. This process can produce 650 kg of product
(after downstream purification) in 212 days. This design process will require an initial capital
investment of about $1.8 billion. The project will have an internal rate of return (IRR) of 225%
and a net present value (NPV) of $17 billion, assuming a 10-year operational life.
All calculations for the report were done based on literature values. Please contact us regarding
any questions or concerns that you may have about either process covered in the report.
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Monoclonal Antibody Production via Fluidized Bioreactor Technology

1. Abstract
Monoclonal antibodies (mAbs) are biologically identical antibodies created by homogenous
immune cells originating from the same parent cell. MAbs target a specific epitope of an antigen
on a cell’s surface, allowing it to neutralize the antigen. This unique characteristic has made
them a key tool in the biopharmaceutical industry for the production of therapeutic drugs. One of
these drugs is Rituxan® (rituximab), a mAb drug for the treatment of various cancers and
autoimmune diseases. Currently, most mAb products are grown via cell suspension technology
in stirred tank bioreactors. However, we have found that by using an integrated bioprocessing
model, including conventional cell suspension culture tanks and fluidized bioreactor technology,
overall product yield per day is increased by about 7-fold for the production of Rituxan®.
Additionally, an economic analysis shows the fluidized bioreactor process is more profitable.
Furthermore, though it requires a higher initial investment than the stirred tank process, the
differential present worth of the fluidized bioreactor process in comparison to the stirred tank
process is $13 billion. Overall, for the production of Rituxan®, the use of fluidized bioreactor
technology is a more productive and lucrative process than the conventional stirred tank process.

2. Introduction
2.1. Project Background
2.1.1. Rituxan®
While most mAbs are made on a small to medium scale for laboratory use,
successful mAb drugs used for medicinal treatment are responsible for a multibilliondollar industry with each mAb responsible for at least $1 million in sales for its
respective companies (U.S. Pharmaceutical Sales, National Research Council). For the
larger blockbuster drugs, the sales of mAb may bring in billions every year. In such large
domestic and international markets, there is great potential for generics. For the purpose
of this project, we will examine the production optimization for Rituxan® (rituximab). By
developing a more profitable process, a generic drug can be produced at a lower cost.
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Rituxan® (rituximab) is a CD-20 monoclonal antibody. It has an affinity for cells
that overexpress the CD-20 target receptor, a common sign of non-Hodgkins lymphoma,
Crohn’s disease, chronic lymphocytic leukemia, and rheumatoid arthritis. Rituxan®
depletes the body’s B-cells. It has three proposed mechanisms of action: complementdependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and apoptosis.
Though the mechanisms are not fully understood, all three essentially require the mAb to
bind to immune system B-cells by recognizing the protein receptor, CD-20, after which
the drug can successfully kill the target cell (Proposed Mechanism of Action).
2.1.2. Fluidized Bioreactor Process
Since the introduction of mAbs to the field of therapeutic medicine, factories have
adapted their designs to produce pure, high-quality mAbs. However, because mAbs
require strict purification processes and a moderately long production process in
comparison to small molecule drugs, plants are generally over-capacity. MAb production
is dependent significantly on the cell culture conditions, which commonly include
growing cells in suspension. Suspension culture is widely used because it presents the
simplest way of achieving a high cell density for a maximum product yield. With larger
batches, larger-scale purification is necessary, but cannot be accommodated by current
plant designs (Kelley 450). We propose to introduce a different cell culture technique for
application in large-scale mAb production – one that will provide several useful
advantages over traditional suspension culture techniques.
Many mammalian cell lines, including those most commonly used for mAb
production, such as Chinese Hamster Ovary (CHO) cells, are anchorage dependent unless
modified for suspension culture growth. By utilizing microcarriers, small porous particles
capable of remaining in suspension, cells can grow in psuedo-suspension by adhering on
or inside these particles. Two major advantages of this are increased production capacity
and reduced labor requirement in comparison to traditional suspension culture processes.
Due to a high surface area to volume ratio, the use of microcarriers provides higher cell
and product yields than is possible with a traditional suspension bioreactor. Another
advantage of using microcarriers is easier downstream purification. Because cells are
retained on the carriers and product is secreted into the medium, separation of cells and
product is achieved by a simple filtration step instead of the typical centrifugation step, a
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more costly process. Furthermore, microcarriers help protect against physical and
chemical stress. Since the cells grow inside the porous beads, they are protected from
shear stresses caused by the tip of the stirrer as well as the sparged oxygen bubbles.
Additionally, cells tolerate more chemical stress such as lactate build up when growing
inside the porous carriers (Rodrigues, et al.) (GE Microcarrier Handbook).
In the proposed design, a fluidized bioreactor with GE Cytoline™ 1 microcarriers
is used as the main production step for the product. These beads, shown in Figure 2.1, are
ellipsoid particles with 0.4-1.1mm thickness, 1.7-2.5mm length, and 10-400µm pores. A
recombinant CHO cell line will be used as the mAb-producing cell line. Though specific
cell productivity is likely to be less than that of the cell suspension process, overall
productivity will be higher due to a
higher

sustainable

cell

density.

A

traditional stirred tank process that
utilizes stirred tank bioreactors for both
seed train and production steps to a new
process containing a near-identical seed
train and a fluidized bioreactor as the
production step.

Figure 2.1 Cytoline 1 Microcarriers Covered with Cells
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2.2. Project Charter
Project Name
Project Leaders
Specific Goal
Project Scope

Deliverables

Time Line

Monoclonal Antibody Production via Fluidized Bioreactor Technology
Lydia Atangcho, Meghan McCullough, Shenali Parikh, Alexandra Stambaugh
Design a biopharmaceutical plant and process to produce a generic version of
Rituxan® (rituximab) using a fluidized bioreactor as the final production step
rather than using a traditional cell suspension culture.
In Scope:
• Manufacturing process for rituximab beginning from prepared inoculum
of cells to final growth step
o Design main process to include fluidized bioreactor technology as
the final production step
! Expected increase in overall volume productivity
o Design a traditional industry standard process without fluidized
bioreactor steps as a basis for comparison
• Post-manufacturing purification steps beginning from the first harvest
step (centrifugation or filtration) to final sterile filtration
• Meet current safety and health regulations for biological products
• Maintain process integrity and compliance by adhering to good
manufacturing practices (GMP)
• Determine which process (fluidized v. traditional) is best when compared
on basis of amount of drug produced per time per dollar
Out of Scope:
• Research and development of generic rituximab (produced in laboratory)
• Cell line development
• Clinical trials
• Packaging and distribution of drugs
• FDA approval of generic drug
• FDA approval of use of large-scale fluidized
Business opportunity assessment
• What is the market for generic production of Rituxan® and monoclonal
antibodies in general?
• How does the fluidized bioreactor process compare to the traditional
process?
Technical feasibility assessment
• Is it technically feasible to manufacture antibodies on a large scale using
a fluidized bioreactor setup?
Manufacturing capability assessment
• Can this facility be built and the process utilized without significant
capital investment?
• Will the process satisfy the stringent FDA requirements for a pure,
consistent product?
Facility and process design along with economic analysis within four months.

Process
Technology

Technical
Differentiation

Products

Customer-Value
Proposition

Reduced
crosscontamination

Disposable
(Single-Use)
Bag or
Stirred Tank
Bioreactor

Easy to
clean,
sterilize
and set-up

GE
WAVETM
Technology

Reduced
batch time

Stainless
Stirred
Tank
Bioreactor

Familiar
scale-up
principles

Industrial
Scale
CSTRs

Easy to
scale-up

Reduced
labor cost

Increased
cell
viability

Reduced
separation
steps

Fluidized
Bioreactor

Reduced
physical and
chemical
stress

GE Cytoline TM 1
Micro-carriers

Potential
reduced cost
of annual
expenses

Simplified
product
purification

Increased
overall
production
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2.3. Technology Readiness Assessment
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3. Concept Stage
In 2013, the sales of Rituxan® reached over $3.2 billion in the US market and $2.12 billion in
the European market. Since its introduction in the US market in 2011, Rituxan® has experienced
a general upward trend in sales, which is expected to continue until its patent expiration in 2014
in Europe and in 2018 in the United States. In general, the mAb market is expected to have a
compound annual growth rate of about 5.3% indicating almost $58 billion in sales globally (U.S.
Pharmaceutical Sales).
With an increase in monoclonal antibody drugs in the pipelines of big pharmaceuticals such
as Genentech and Abbott LabsTM and in increasing global demand for the drugs, current
production facilities must be able to meet the necessary production goals. As previously
mentioned, current facilities often struggle to produce more than a certain amount of antibody
per batch due to the restrictions of maximum cell density in a cell suspension culture. When a
fluidized bioreactor is used as the final upstream step, the cells can adhere to the microcarriers
and grow to a 100 times higher sustainable cell density than the traditional process. This allows
for an overall increase in cell productivity.

3.1. Competition in the Generic Market and Production Goal
Before drugs lose their patent protection, generic manufacturers have already begun to
manufacture a competitor for the market, which is ready to launch as soon as the patent
expires. Currently, Roche expects to maintain exclusivity in the international market well into
2015 because no other company has been able to gain approval for generic Rituxan®. This
opens up a great opportunity to potentially build a more lucrative and more productive
process and gain hold of the rituximab market once Roche’s patent expires. However, Teva
Laboratories may become a competitor since their mAb is in Phase III clinical trials (Roche:
Impact Of Rituxan Patent Expiration In Europe).
In 2013, over 2.2 million units of Rituxan® were sold in the US alone amounting to $3.2
billion in US revenue. In Europe, Rituxan® earned about $2.1 billion in revenue. Based on
the units of Rituxan® sold (each unit refers to either a 100mg/10mL or 500mg/50mL vials)
and the average price per dose of $586 (100mg/10mL vial) and $2,840 (500mg/50mL vial), a
production goal can be determined. Assuming that the facility will eventually produce
enough product to capture 70% of the domestic and European markets, 650 kg of generic
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rituximab will ultimately become the production goal (see Section 13.1) (U.S.
Pharmaceutical Sales).

3.2. Process and Facility Requirements
The new facility will be built on a brownfield site on the Delaware River. The East
Coast is the preferred location for the facility because it allows the facility easy access to land
and sea transportation. Furthermore, the Eastern seaboard, and in particular, the Philadelphia
and Delaware areas have become a hub of innovation for the biotechnology field. The
brownfield site will be retrofitted to match the desired needs of the new design. It will also
help reduce the initial investments cost for the land and building as well as equipment. Rather
than purchasing equipment, an annual fee can be paid in order to utilize the preexisting
equipment at the site.
The new facility requires a new-unique-and difficult design concept. The facility is
being designed for a company attempting to enter the generic monoclonal antibody market
wishing to specifically produce rituximab. Though out of scope for this project, the proposed
designs can be used to produce any mAb allowing for some minor changes. The new facility
will be equipped with the most updated, cost-effective equipment. Specifically, the facility
will be equipped with disposable unit operations wherever applicable. The rising trend of
using disposable bioreactors and tanks, the disposable route offers shorter batch times,
eliminates SIP and CIP procedures, and provides long-term savings. According to a report of
A. Sinclair, single-use bioreactors will help to save 30% of electrical energy for operation,
62% of the energy input for the production of the system, 87% of water and finally 95% of
detergents, all compared to conventional bioreactors.1

1

Sinclaire A., Leveen L. et al. (2008). "The Environmental Impact of Disposable Technologies".
BioPharm International Supplements.
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3.3. Block Flow Diagram
The diagram below depicts the overall process design for the stirred tank bioreactor and
fluidized bioreactor processes. The overall processes are very similar, but the fluidized
bioreactor process has a slightly different downstream purification process.
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4. Process Flow Diagrams
The following pages include the process flow diagrams (PFD) for the two main processes:
monoclonal antibody production via traditional stirred tank bioreactor process and production via
the fluidized bioreactor process. The overall diagram for each process is divided into two
sections: production and purification of product.

4.1. Production PFD for Stirred Tank Bioreactor Process (PFD 01)

4.1.1. Overall Mass Balance for PFD 01
PFD 01- Stirred Tank Inoculum Prep & Bioreaction
Component Input (kg/batch)
Output (kg/batch)
Cells
0.00524
356.32
Media
0.002
0
Water
0.098
19600
Endotoxin
0
36.34
Product
0
9.41

10

Monoclonal Antibody Production via Fluidized Bioreactor Technology

4.2. Purification PFD for Stirred Tank Bioreactor Process (PFD 02)

4.2.1. Overall Mass Balance for PFD 02
PFD 02- Stirred Tank Downstream Purification
Component Input (kg/batch)
Output (kg/batch)
Cells
356.32
0.0
Media
0.0
0.0
Water
19600
2000
Endotoxin
36.34
0.0
Product
9.41
7.76
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4.3. Production PFD for Fluidized Bioreactor Process (PFD 03)

4.3.1. Overall Mass Balance for PFD 03
PFD 03- Fluidized Bioreactor
Bioreaction
Component Input (kg/batch)
Cells
0.00524
Media
0.002
Water
0.098
Endotoxin
0.0
Product
0.0

Inoculum Prep &
Output (kg/batch)
2672.4
1.17x105
5.90x106
272.58
65.75
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4.4. Purification PFD for Fluidized Bioreactor Process (PFD 04)

4.4.1. Overall Mass Balance for PFD-04
PFD 4- Fluidized Bioreactor Downstream Purification
Component Input (kg/batch) Output (kg/batch)
Cells
2672.4
0.0
5
Media
1.17x10
0.0
6
Water
5.90x10
2000
Endotoxin
272.58
0.0
Product
65.74
54.21
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4.5. Microcarrier Handling PFD for Fluidized Bioreactor Process (PFD 05)
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5. Production Process Description
All seeding densities for cells were calculated to minimize cell growth time while
maximizing production rate (See Appendix F).

5.1. Media Preparation – Stirred Tank and Fluidized Bioreactor Process
Both processes will use Ex-Cell® ACF CHO Media from Sigma-AldrichTM. This is
chemically defined, serum-free, and protein-free media specially formulated for optimal
CHO cell growth. For efficiency, prepared media will be purchased directly from SigmaAldrichTM for the inoculum preparation steps. For the bioreactors the media will be prepared
in various mixing tanks (refer to process flow diagrams) by adding dry powder media to
water-for-injection (WFI). The prepared media solution will be filtered with a 0.2 micron
sterile filter to remove any foreign particles and large viruses. The media concentration will
remain at about 20 grams of dry media per liter of prepared solution.

5.2. CytolineTM Microcarrier Prep – Fluidized Bioreactor Process Only
To prepare the CyotlineTM 1 beads for sterilization, two volumes of distilled water are
added to one volume of microcarrier beads. Then, the mixture is degassed and autoclaved for
10 minutes at 121°C (1 bar). The water supernatant is removed with a sterilized pipette.
Fresh distilled water is added and the microcarriers are stirred for 10 minutes. Again, the
water supernatant is removed and 0.1M NaOH is added. The mixture is then incubated
overnight and washed with distilled water until the pH stabilizes. Next, the microcarriers are
autoclaved in distilled water or PBS at 121°C (1 bar) for 30 min.

5.3. Inoculum Preparation Section
5.3.1. Stirred Tank Bioreactor Process
To prepare the inoculum for seed bioreactor, twenty 0.2L disposable bag
bioreactors with 0.1 L working volume will each be inoculated with 2.0mL of cells at a
concentration of 1x108 cells/mL. Fifty percent of the total volume is used to allow for
proper agitation of the culture and allow for ample air space. The culture will require
about 3.5 days to grow to the desired cell density of 1.0x107 cells/mL. The temperature is
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monitored and controlled at 37°C, the pH at 7.0 and the dissolved oxygen level at 50%
via PID (positive-integral-differential) feedback controls.
5.3.2. Fluidized Bioreactor Process
To prepare the inoculum for the seed bioreactor, thirty 0.2L disposable bag
bioreactors with 0.1L working volume will each be inoculated with 2.0mL of cells at a
concentration of 1x108 cells/mL. Fifty percent of the total volume is used to allow for
proper agitation of the culture and allow for ample air space. The culture will require
about 3.5 days to grow to the desired cell density of 1.0x107 cells/mL. The temperature is
monitored and controlled at 37°C, the pH at 7.0 and the dissolved oxygen level at 50%
via PID (positive-integral-differential) feedback controls.

5.4. Seed Bioreactor Section
5.4.1. Stirred Tank Bioreactor Process
At the end of the inoculum preparation, 98L of prepared and sterilized media
solution will be added to a 200L bag seed bioreactor with 100L working volume. The cell
cultures from all inoculum bag bioreactors will be transferred via a peristaltic pump to the
seed bioreactor. The culture will be rocked continuously to ensure proper mixing. The
culture will be allowed to grow for four days with a target final cell density of 1.12x106
cells/mL. Assuming a product growth rate of 90 pg/cell/day, about 24 grams of antibody
product will be produced. Throughout the process, the temperature will be monitored and
controlled at 37°C, the pH at 7.0, and the dissolved oxygen level at 50% via PID controls.
After the culture in the first seed bioreactor is allowed to grow for 4 days, the
contents will be transferred via peristaltic pump to the 2,000L second bag seed bioreactor
containing 900L of sterilized media solution. The second seed bioreactor will have a
working volume of 1,000L. The culture will be rocked continuously to ensure proper
mixing. The culture will be allowed to grow for 4 days with a target final cell density of
6.29x105 cells/ml. Over this time, 134 grams of antibody product will be produced.
Throughout the process, the temperature will be monitored and controlled at 37°C, the
pH at 7.0, and the dissolved oxygen level at 50% via PID controls.
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5.4.2. Fluidized Bioreactor Process
At the end of the inoculum preparation, the cell cultures from 0.2L bag
bioreactors will be distributed equally (via sterile tubing) to three 200L bag seed
bioreactor with a working volume of 100L (running in parallel). This design setup was
chosen to help limit the cell growth time to 5 days but still provide enough cells to
inoculate the second seed bioreactor. Upon transfer, the bag bioreactors will already
contain 98L of prepared and sterilized media solution. The culture will be rocked
continuously to ensure proper mixing. It will be allowed to grow for four days with a
target final cell density of 2.0x106 cells/mL. Assuming a product growth rate of 90
pg/cell/day, about 51 grams of antibody product will be produced. Throughout the
process, the temperature will be maintained at 37°C, the pH at 7.0, and the dissolved
oxygen level at 50% via PID controls.
After 5 days, the culture from all three reactors is transferred into a single 2000L
seed bioreactor with a 1000L working volume. Upon transfer, the bioreactor will contain
900L of prepared and sterilized media solution will be immediately added to the seed
bioreactor. The culture will be rocked continuously to ensure proper mixing. The culture
will be allowed to grow for 5.5 days with a target final cell density of 1.5x106 cells/mL.
Over this time, 409 grams of antibody product will be produced. Throughout the process,
the temperature will be maintained at 37°C, the pH at 7.0, and the dissolved oxygen level
at 50% via PID controls.

5.5. Production Bioreactor Section
While the seed bioreactor section served to grow up the culture, the final bioreactor
serves to maximize product formation.
5.5.1. Stirred Tank Bioreactor Process
For the traditional stirred tank bioreactor process, the cell culture will be
transferred via a peristaltic pump into the 25,000L production bioreactor with a working
volume of 20,000L. Upon transfer, 19,000L of prepared and sterilized media solution will
have been immediately added to the seed bioreactor. The culture will be stirred
continuously to ensure proper mixing. The culture will be allowed to grow for 16 days
with a target final cell density of 6.11x105 cells/ml. Assuming a productivity rate of 90
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pg/cell/day, 9.3 kg of antibody product will be produced. Throughout the process, the
temperature will be maintained at 37°C, the pH at 7.0, and the dissolved oxygen level at
50% via PID controls.
5.5.2. Fluidized Bioreactor Process
The reactor must be inoculated with the cells from the previous seed bioreactor
steps, which will first have to adhere to the CytolineTM 1 beads. These cells should be in a
logarithmic growth phase and in a good nutritional state. This adherence protocol is a
continuation upon the microcarrier prep protocol (Section 5.2). The culture medium is
first removed completely from the equilibrated microcarrier-cell culture medium
mixture. The cells from the previous seed bioreactor along with 9,000L of fresh culture
medium are added to 730L CytolineTM 1 beads in the fluidized bed bioreactor. The
culture will have an initial cell density of 2.0x106 cells/mL microcarrier, as specified by
the GE Microcarrier and Cell Culture Handbook. The mixture is agitated gently every 30
minutes for a total of 5 hours. After 5 hours, culture medium is added to the final working
volume of 20,000L and incubated overnight while stirred at 100 rpm.
The fluidized bioreactor will then be operated to circulate media while spinning at
approximately 300 rpm, which corresponds to a flow rate of about 19 cm/min of media.
The culture media will circulate through the bottom of the annular fluidized bed
bioreactor. From the top, about 78% of culture media will be removed continuously and
moved to a holding tank. The remaining 27% will be circulated back through the internal
circulation loop to be enriched in the bottom of the reactor and circulated through again.
The culture will be allowed to grow for 12.8 days with a final cell target density of
1.4x108 cells/mL microcarrier. Assuming a cell productivity rate of 90 pg/cell/day, 65 kg
of antibody product will be produced. Throughout the process, temperatures will be
maintained at 37°C, pH of 7.0, and the dissolved oxygen level at 40% via PID controls.

5.6. Theoretical Model for Fluidized Bioreactor Process
The fluidized bioreactor, shown in Figure 5.1, is a unit that is fluidized with an internal
circulation system. This component is modeled as a combination of a CytopilotTM
(Vogelbusch GmbH Vienna) and a typical annular fluidized bed reactor. As with the
CytopilotTM, this fluidized bed bioreactor will have two components: an upper cylindrical

18

Monoclonal Antibody Production via Fluidized Bioreactor Technology

chamber and a lower cylindrical chamber. The lower chamber is outfitted with a doublejacket heating circuit, sampling and discharge facilities, a magnetic stirrer, and pH and
dissolved oxygen probe nozzles. The media is agitated by
the magnetic stirrer and delivered through the distributer
plate to the microcarriers in the upper chamber of the
fluidized bioreactor. The hydrodynamic pressure lifts the
settled microcarriers to form a fluidized bed, and the
chamber is tall enough such that there is an apparent
separation between the top of the fluidized microcarriers
and the top of the media volume. A portion of the media
flows down the channel that defines the internal
circulation loop, where it will be deposited back into the
lower chamber. Micro-bubbles of oxygen are sparged
into the downflow of the internal circulation tube and

Figure 5.1 Fluidized Bioroeactor

distributed homogeneously by the impeller in the lower
chamber. The working volume of the annular fluidized bed in the upper chamber was
designed to be 20,000L with an aspect ratio of height to diameter of 4:1. The bed has a
diameter of 2 meters and a height of 8.13 meters, which is reasonable for an industrial scale
bioreactor.
5.6.1. Fluidization Velocity
Practical operations of the fluidization stream in typical annular fluidized beds are
conducted at two or more multiples of the fluidization velocity. The maximum flow rate
of the bioreactor is dictated by the sedimentation rates of the CytolineTM 1 beads. If the
bed is fluidized at a velocity higher than that of the sedimentation rate, then the
microcarriers will be carried to the top of the reactor. This is known as flush out, and
usually occurs when the media is run through the bed at velocities exceeding 10 times the
minimum fluidization velocity. The sedimentation rate for the CytolineTM 1 microcarriers
is 120-220 cm/min of media, dictated by the CytolineTM 1 microcarrier product
information brochure. To avoid flush out and to achieve optimal operation, the fluidized
bed bioreactor will flow media at about 1.9 times the minimum fluidization velocity for
the average sized CytolineTM 1 bead bed, which corresponds to around 28,000L of media
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per hour or a flow rate of approximately 19 cm/min. This value was determined by
performing a sensitivity analysis upon the minimum fluidization rates for the bead size
distribution within the reactor. Calculations for the minimum fluidization velocity are
shown in Appendix A. The fluidized bed reactor will operate at the minimum fluidization
velocity of the largest particles, which is 1.9 times the minimum fluidization velocity for
an average sized CytolineTM 1 bead and about 6.2 times the minimum fluidization
velocity of the smallest CytolineTM 1 beads. The void fraction of the CytolineTM 1 bed is
estimated for an ellipsoidal packed bed as ε = 0.35, which is equivalent to near-perfect
packing for ellipsoidal particles. The CytolineTM 1 particles are ellipsoidal, and due to the
gentle agitation before fluidization in the inoculation step, it is fair to assume that the
beads will fall into the confirmation for optimal packing. Additionally, edge effects from
the sides of the fluidized bioreactor are considered to be negligible in comparison to the
size of the bed because the effective diameter of the beads is on the order of millimeters,
while the diameter of the bed is on the order of meters. More precisely, the equivalent
spherical diameter of the CytolineTM 1 particles is around 0.912 mm, while the effective
diameter of the annular fluidized bed is about 1 meter. Therefore, we can negate the
imperfections in packing due to the walls of the reactor. Perfect packing for smooth
ellipsoidal particles corresponds to a void fraction of 0.31, but because the CytolineTM 1
particles are porous, the void fraction is estimated to be slightly higher due to the uneven
surface of the particle.
5.6.2. Nutrient Transport in Fluidized Microcarrier Culture
For microcarrier culture, the normalized gradient between the concentration of
substrate in the local bulk medium and concentration of substrate at the cell surface is
given by the expression found in Appendix B. For all substrate analysis, glucose was used
as the nutrient under investigation. Glucose consumption inside the bioreactor is a good
indication of cell growth and health—when cells are healthy and the exponential growth
phase, glucose consumption is relatively simple to model. Experimentally, glucose assays
are easy and non-cost intensive perform on effluent media samples. Lastly, for the
purposes of this report, there are many well-documented mass transport parameters
published for glucose, as opposed to other media components. When typical values were
substituted for the parameters specific to glucose transport through cell culture media at
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37oC, the normalized gradient between glucose concentration at the cell surface and in the
bulk was at a value of approximately 0.01, which is far less than unity. Therefore, it is
assumed in the fluidized bioreactor model with using microcarrier culture that there exists
an adequate amount of mass transport between the microcarriers and the medium. It is
noted that when the same analysis is applied to the packed bed reactor, the normalized
gradient for glucose between the bulk and the cell surface concentrations is about 0.27,
which is less than unity but non-negligible. This corresponds to the concentration of
glucose at the cell surface to be 73% of the glucose concentration in the bulk media. All
calculations and constants are given in Appendix B. Mass transfer between the
microcarrier surface and the cell surface is generally not accounted for due to the fact that
the microcarriers are designed in a manner that minimizes mass transfer resistance.
5.6.3. Fluidized Bed versus Packed Bed—Nutrient Composition Temporal Analysis
In order to determine if fluidizing the bed was necessary, an analysis of cell growth
profiles with fresh substrate influx was conducted, with mass balance equations and
derivation shown in Appendix C. The novelty behind the fluidized bed reactor is the
ability to sustain cell concentrations that are about two orders of magnitude greater than
cell concentrations in traditional stirred tank cultures due to increased surface area and a
nutrient-replenishing fluidizing stream. In order to determine the efficacy of fluidizing
the replenishing nutrient stream, glucose consumption was examined inside the three
different reactor conformations: a fluidized bed reactor, a packed bed reactor, and a batch
reactor. It it is determined that the bed could be operated at a velocity that is smaller than
the fluidization velocity determined in section 5.6.1—which would correspond to packed
bed reactor operations—or without replenishing the nutrients in the reactor at all—
corresponding to batch reactor operations—then the fluidization of the reactor would be
unnecessary and wasteful in terms of media and energy requirements to operate the
reactor. For the fluidized bed, the nutrient replenishing stream propagates through the
reactor at the fluidization velocity dictated earlier in this section. The packed bed is
characterized by an influx of glucose that is propagating slower than the minimum
fluidization velocity for all particle sizes (chosen to be 4,430 L/hr). A batch reactor was
also considered which had neither inflow nor outflow of glucose.
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There are a few key assumptions that outline the validity of this model. The first
concerns the contents of the reactor. The media is assumed to have 8 g/L of glucose
initially and that the reactor has been charged initially with media. The cells are assumed
to be in exponential growth phase, a protocol that was suggested from the GE
microcarrier handbook. Because the bed is fluidized and the cells are on microcarriers, it
is assumed that there is no notable cell loss from the reactor. In the same vein, there is no
additional cell addition to the reactor other than the growth inside the reactor. Glucose
consumption is also assumed to be solely due to the metabolic activity of the cells and not
for product formation. Lastly, we are assuming that all reactor systems are well mixed
such that there exists no spatial dependence on cell or substrate concentration inside the
reactor at a given time point.
The results of this analysis are plotted and shown in Appendix C. The time interval
considered in this analysis was the total run time of the fluidized bioreactor, 12.8 days.
The cells were considered nutrient starved when the glucose concentration within the
reactor was below 4 g/L. The batch reactor was considered nutrient starved after less than
two days of operation. The cells in the packed bed reactor were considered nutrient
starved after about 8 days of operation. The fluidized bioreactor maintained a glucose
concentration of 4.8 g/L after the 12.8 day operating time and was therefore found to be
able to sustain the cell culture.
5.6.4. Fluidized Bed v. Packed Bed—Nutrient Consumption Spatial Analysis
The glucose consumption and cell growth profiles were modeled for a packed bed
to examine the spatial dependence of nutrient mass transfer to the cells. This analysis is
conducted in order to determine if the reactor could be operated using a packed bed
model as opposed to a fluidized bed model. Running the reactor in a packed bed
confirmation would decrease media requirements and operational energy requirements,
and would therefore be more advantageous from a financial standpoint. In the previous
section, it was assumed that the concentration of glucose in the reactor was spatially
independent with regards to the bulk concentration. While this is a good assumption for
the fluidized bed reactor, it was shown earlier in this report that the normalized gradients
between the bulk and cell surface concentrations in a packed bed bioreactor is nonnegligible at 0.27. To further explore the spatial nutrient consumption in the packed
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bioreactor, a simple model was implemented using the Transport of Diluted Species
(chds) module of the Comsol Multiphysics Software. In order to execute the model, a few
assumptions are made, like in the temporal analysis of the reactors. The media is assumed
to have 8 g/L of glucose initially, which corresponds to 44.406 mol/m3 of glucose, in the
reactor. It is also assumed the reactor is initially charged with media. The cells are
assumed to be in exponential growth phase, a protocol that was suggested from the GE
Microcarrier Handbook. Because the bed is fluidized and the cells are on microcarriers, it
is assumed that there is no notable cell loss from the reactor. Furthermore, there is no
additional cell addition to the reactor other than the growth inside the reactor. Glucose
consumption is also assumed to be solely due to the metabolic activity of the cells and not
for product formation.
Results from this analysis are plotted in Appendix D. After 60 hours of operation,
the concentration of glucose over most of the packed bed has dropped to about 20% of its
original value, creating a nutrient deprived environment in over half of the bed. After 72
hours, the cells at the bottom of the packed bed fully consume the glucose in the media
before it can get to any other cell layer in the bed, leaving the majority of the bed nutrient
deprived. After 72 hours, the cells are completely nutrient deprived over the majority of
the bed and would most certainly be dead. Time points shown were determined to show
when the reactor would be fully nutrient deprived and therefore unable to sustain cell
growth. In order to meet the monoclonal antibody production goals, the packed bed
reactor would need to operate for 306 hours, which using the model presented, would
lead to widespread cell death over the majority of the bed. Therefore, fluidization of the
microcarrier bed is necessary in order to meet the monoclonal antibody production goals.

6. Purification Process Description
After the upstream process, the extracellularly secreted product must be separated from the
media solution and purified according to FDA standards. Furthermore, each batch of downstream
purification will be quality checked to ensure quality standards are met and that the generic drug
matches the brand name formulation of Ritxan®. All following descriptions apply to both
processes unless otherwise specficied.

23

Monoclonal Antibody Production via Fluidized Bioreactor Technology

6.1. Buffer Preparation
Many downstream operations, such as the chromatography columns, will require various
buffers for each batch. Buffers will be purchased from GE Healthcare and mixed with WFI in
disposable containers. Disposable containers will help minimize cross-contamination and
eliminate any cleaning and sterilization procedures. Once prepared, the pH and conductivities
of the buffers will be checked and controlled until the buffers are used. If the buffers are
improperly prepared, they will have to be altered to reach the proper pH.

6.2. Holding Tank
For both cases, a large amount of spent media solution (20,000L or more) containing
product will be recovered at the end of the production step. However, downstream
purification must be done in smaller batches to accommodate the volume capacity of the
Protein A column.
6.2.1. Stirred Tank Bioreactor Process
For the stirred tank process, the cells will be transferred via a peristaltic pump into
a holding tank for eventual purification. Then, the approximately 20,000L solution of
cells, media, and product will proceed downstream in ten batches of 2,000L each.
6.2.2. Fluidized Bioreactor Process
Unlike the traditional stirred process, the fluidized bioreactor process will be
continuous. Therefore, spent media will be continuously collected from the top at a rate
of 19 cm/min. Approximately 5.7 million liters of spent media and product will have to
be collected in stored in fifty-eight 50,000L storage tanks. From these tanks, Protein A
purification will be conducted in two batches. The eluted product will then be processed
further downstream in two batches.

6.3. Microcarrier and Cell Disposal
As a part of downstream processes, after the media solution (containing product) has
been removed from the fluidized bioreactor, the cells and microcarriers must be disposed
appropriately. Per batch, 730L of microcarriers and cells will be heat treated to 250°C in
order to kill the cells. Then, the microcarriers and cells will be disposed according to FDA
regulations.
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6.4. Centrifugation
For the stirred tank bioreactor process, contents of the holding tank are transferred into a
centrifuge by a peristaltic pump in smaller batch sizes of 10,000L per batch. The centrifuge
helps remove the product and other components suspended in the media solution from the
solid biomass and other waste. The centrifuge will operate at a throughput rate of 10,000
L/hr. The centrifuge is operated at 25°C and has a yield of 98% product with about 2% of
desired product being discarded in the solid waste stream. Centrifugation for stirred tank
batches will require a total time of 6 hours including CIP and SIP.

6.5. Tangential Flow Filtration
For the fluidized bioreactor process, the media will not have to be separated from the
cells due to the nature of the setup. Therefore, tangential flow filtration offers a more
efficient and cost-effective method to perform a primary purification step. TFF helps filter
large molecular weight aggregates, large proteins, and any remaining cells. The feed (media
containing product and other particles) is passed tangentially over a membrane in order to
prevent filter caking. This will be a continuous process but six TFF filters will be used in
parallel to help reduce the individual operational time of the unit. The feed will be filtered at
a speed of 5 L/min/m2 and each filter membrane will have a cross sectional area of 1.8m2. In
the case of the fluidized bioreactor process, the filtration step will require 58 TFF units with a
cross sectional area of 3.0m2 and about 4.5 days to process the media output of the bioreactor
and have a 98% yield.

6.6. Protein A Chromatography
Protein A Chromatography is the first chromatography column in the downstream
process. It acts as the first main isolation step for product and isolates the monoclonal
antibody via affinity chromatography. Therefore, the column is useful in eliminating host cell
DNA, media components and endogenous viral particles.
After centrifugation (for the stirred tank bioreactor process) or after tangential flow
filtration (for the fluidized bioreactor process), the supernatant pH is equilibrated to 7.0 using
H3PO4. Then, the solution is directly transferred to the Protein A column via a peristaltic
pump. Before the first batch, the column must be loaded with resin. Then, at the beginning of
each batch, the column must be equilibrated with 2-3 bed volumes of equilibration buffer
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(20mM sodium phosphate at pH 7.0). The supernatant from the centrifugation step is then
directly applied to the column. Then, an intermediate wash step is used with wash buffer
(containing 0.25M TMAC or 0.25M TEAC) at a pH of 6. Finally, the monoclonal antibody
product is eluted from the column by washing with elution buffer (25mM sodium citrate) at a
pH of 2.8. The low pH allowed for the removal of the product from the resin so it could be
collected in the elution stream. The elution stream will be transferred into a storage tank.
Finally, the column is then regenerated with 2-3 bed volumes of regeneration buffer. The
maximum linear flow rate for the column will be about 400 cm/hr. The Protein A column is
expected to have about 98% product yield. For the stirred tank process, it will require a total
of 1.5 days to process all input (each input refers to a batch of 2000L of solution). For the
fluidized bioreactor process, a linear flow rate of 40 cm/min will be used and require 4.5 days
to process all media input (where each input refers to half of the media output of the fluidized
bioreactor). These times also account for the sterilization required in between each batch.

6.7. Cation Exchange Chromatography
Cation exchange chromatography is used to reduce high molecular weight aggregates,
charge variants, residual DNA and host cell proteins. Cation exchange uses positively
charged resin to bind to negatively charged particles (including the product) while positive
and neutral particles pass through the column.
Before the first batch, the column must be loaded with resin. Then, before each batch,
the column must be equilibrated with a buffer (60nM NaCl) at a pH of 5.5 and conductivity
of 6.5 mS/cm. Then, about 2000L from the holding tank after the Protein A step will be
transferred into the column from both processes. The first wash buffer is salt free and has a
pH between 7.0 and 7.8 and conductivity between 0.2 and 2 mS/cm. A second buffer wash is
performed at pH 5.5 and conductivity between 0.5 and 3.0 mS/cm. Finally, the column is
eluted to remove the desired product from the resin using elution buffer (160-175mM NaCl)
at pH 5.5 and a conductivity of 12-20 mS/cm. The eluted stream is transferred to a storage
tank. Finally, the column is regenerated using regeneration buffer .The maximum linear flow
rate for the column will be about 400 cm/hr. The column is expected to have about 98%
product yield. Including sterilization in between batches, it will require about 1-1.5 days to
process the input into the columns for both processes.
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6.8. Anion Exchange Chromatography
Anion exchange chromatography is also used to reduce high molecular weight
aggregates, charge variants, residual DNA and host cell proteins. Anion exchange uses
negatively charged resin to bind to positively charged particles while negative particles (such
as the product) pass through the column. Before each batch, the column must be equilibrated
with equilibration buffer (20-100mM NaCl) at pH 8.0. The media solution is applied to the
column in batch sizes of 2000L for both processes. Then, the column is washed with buffer.
The product is removed in the wash step and stored in a storage tank. Finally, the column is
washed with elution buffer (1M NaCl) at pH 8.0. Then, the column is regenerated using
regeneration buffer. The maximum linear flow rate for the column will be about 400 cm/hr.
The column is expected to have about 98% product yield. Including sterlization in between
batches, it will require about 1-1.5 days to process all batches for both processes.

6.9. Viral Nanofiltration
Viral nanofilration will be used after the anion exchange chromatography step to filter
the viruses. Viral nanofiltration is a size-based membrane separation in which proteins can
easily pass through the hollow fiber walls of the membrane while viruses are captured within
the pores. This type of filtration is dependent upon pressure, flow rate, protein concentration,
and the ratio of product volume to membrane surface area. First, the filters and unit must be
flushed thoroughly with WFI. Then, the unit must be equilibrated with equilibration buffer.
Finally, the sample (in sizes of 2000L for each process) can be loaded and the permeate will
be collected for further purification. Its recovery rate of monoclonal IgG at 20mg/ml product
concentration is about 99%. With six units running in parallel, this process will require about
6 hours for both processes.

6.10. Ultrafiltration
After viral inactivation, size-based ultrafiltration is used to remove small viral and
foreign particles. A filter with a 100kD MWCO will be used to keep the desire product in the
retentate but allow for smaller particles to be removed. This step will also help concentrate
the product to a final concentration of about 10 mg/mL. To help decrease the process time for
the filtration step, six filters will be run in parallel. The process will require about 6 hours
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where each batch size equals 2000 L for both processes. Its recovery rate of monoclonal
antibody will be about 96%.

6.11. Sterile Filtration
Sterile filtration serves as the last purification step to help remove any final endotoxins
and also to help concentrate the product to the appropriate concentration. To help decrease
the process time for the filtration step, six filters will be run in parallel. The process will
require about 6 hours to process all input (where the input for each process is about 2000L).
The recovery rate is expected to be about 96%.

7. Major Unit Operation Specifications
7.1. Common Units
7.1.1. Pumps
A peristaltic pump is used to transfer fluid from throughout the process as
depicted by the pump icon in the process flow diagrams. The pump can be purchased
from Watson Marlow and is the 825 Peristaltic Pump. In both the stirred tank and
fluidized bioreactor processes, the power of the pump ranges from 1.5-5.0 hp. The pumps
operate at room temperature and a 50 psi (3.5 bar) pressure drop with maximum flow rate
of 33.3 L/min. The pump will be sterilized and are purchased from Watson Marlow for
the cost of $13,000 per pump. The same company also offers a variety of pumps with
maximum flow rates of ~300L/min which will be used for the fluidized bioreactor
process. Watson Marlow Bioprene sterile tubing is used to transfer the fluid through the
variety of processes.
7.1.2. Media Sterilization Filters
The 0.2 micron filter is used to purify the media by removing any impurities and
toxins before introduction to the bioreactors. The filter is 30 inches in size and the
filtration area is 1.8m2 (18ft2). The membrane filter material is Polyethersulfone (PES)
and operates at room temperature with a max differential pressure of 0.5 bar. The filters
require a type of housing for security that requires a one-time purchase from Sartorius
Stedim Biotech for the cost of $2,000. The filters are disposable and replaced after every
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batch. They are purchased from Sartorious Stedim Bioteach under the model name
Sartopore 2 for the cost of $650/unit. The filters are disposable so no CIP or SIP will be
required, but SIP is required for the housing unit.
7.1.3. Digital Control Unit
This system is used to control agitation speeds, temperature at 37°C, pH between
7.0-7.2 and dissolved oxygen at a specified level for all bioreactors in both processes.
The control units are $300 per unit and are purchased from Vernier Software and
Technology. Each unit will control one parameter. A total of 24 control units will be
needed for all the bioreactors.

7.2. Inoculum Prep
7.2.1. Bag Bioreactor (PFD 01/P-02)
The WAVETM Bioreactor created by GE Life Sciences will be used for the bag
bioreactors. The WAVETM Bioreactor 2/10EH – electric rocker base comes equipped
with integrated temperature control and aeration pump. It is an efficient and costeffective method for expansion of CHO cells in suspension. The rocking action of the
base provides continual mixing and oxygen transfer. For each batch, a new pre-sterilized
cell bag can be used. The system requires no cleaning or sterilization and helps eliminate
cross-contamination between batches. Each bioreactor unit for this stage of the process is
able to hold one 200mL bag. The unit is purchased from GE Healthcare for $16,480. The
bags are plastic pre-sterilized, single use chambers for non-invasive mixing of fluids
using the WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2,
and 50% DO. The process time for this unit is 3.5 days. The 20 disposable bags have
sensors and ports for oxygen and media and are purchased from GE Healthcare for
$202.00 per bag.

7.3. Seed Bioreactor Section (Stirred Tank Process)
7.3.1. Storage/Mixing Tank (PFD 01/P-03)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the first seed bioreactor. The tank
will be manufactured from Stainless Steel 316L, has a volume of 150L and a working
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capacity of 70%. It stands 0.9m tall and is 0.4m in diameter. For sterilization, CIP and
SIP will be conducted after each batch. The tank operates at room temperature and at 1
bar. The tank is manufactured by Sharpsville Container and costs $110,000.
7.3.2. Seed Bioreactor 1 (PFD 01/P-07)
The first seed bioreactor is the disposable WAVETM 500/1000 bioreactor
purchased from GE Healthcare. The unit consists of a permanent base used for rocking
along with disposable cell culture bags. It is stainless steel with dimensions of
201x124x160 cm. Each bioreactor unit for this stage of the process is able to hold one
200 L bag. The unit is the GE WAVETM Bioreactor purchased from GE Healthcare for
$404,500. The bag has a 200L volume with 50% working volume. The 200L bags are
plastic pre-sterilized, single use chambers for non-invasive mixing of fluids using the
WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50%
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The
process time for this unit is 4 days. The plastic disposable bags have sensors and ports for
oxygen and media and are purchased from GE Healthcare for $1,200 per bag.
7.3.3. Storage/Mixing Tank (PFD 01/P-09)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the second seed bioreactor. The
tank will be manufactured from Stainless Steel 316L, has a volume of 1,500L and a
working capacity of 70%. Its height is 2.3m and its diameter 0.9m. For sterilization, CIP
and SIP will be conducted after each batch. The tank operates at room temperature and at
1 bar. The tank is manufactured by Sharpsville Container and costs $120,000.
7.3.4. Seed Bioreactor 2 (PFD 01/P-13)
The second seed bioreactor is another disposable bag bioreactor from GE
Healthcare. The unit is the XDR-50 to 2000 Single Use Bioreactor and provides use with
working culture volume up to 2,000L. The unit consists of a permanent base used for
rocking along with disposable cell culture bags. Each bioreactor unit for this stage of the
process is able to hold one 2,000L bag. The unit is purchased from GE Healthcare for
$600,000. The bag has a 2,000L volume with 50% working volume. The 2000 L bags are
plastic pre-sterilized, single use chambers for non-invasive mixing of fluids using the

30

Monoclonal Antibody Production via Fluidized Bioreactor Technology

WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50%
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The
process time for this unit is 4 days. The plastic disposable bags have sensors and ports for
oxygen and media and are purchased from GE Healthcare for $1,800 per bag.

7.4. Seed Bioreactor Section (Fluidized Process)
7.4.1. Storage/Mixing Tank (PFD-03/P-03)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the first seed bioreactor. The tank
will be manufactured from Stainless Steel 316L, has a volume of 150L and a working
capacity of 70%. It stands 0.9m tall and is 0.4m in diameter. For sterilization, CIP and
SIP will be conducted after each batch. The tank operates at room temperature and at 1
bar. The tank is manufactured by Sharpsville Container and costs $110,000. The outflow
from the tank will be split into three equal streams into three seed bioreactors running in
parallel.
7.4.2. Seed Bioreactors in Parallel (PFD 03/P-07)
The first set of seed bioreactors involves three disposable bag bioreactors in
parallel. Each has a 70L bag volume with a 33.3L working volume. The bioreactors are
the disposable WAVETM 500/1000 bioreactor purchased from GE Healthcare. The unit
consists of a permanent base used for rocking along with disposable cell culture bags. It
is stainless steel with dimensions of 201x124x160 cm. Each bioreactor unit for this stage
of the process is able to hold one 70L bag. The unit is the GE WAVETM Bioreactor
purchased from GE Healthcare for $404,500. The bag has a 70L volume with 50%
working volume. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50%
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The
process time for this unit is 5 days. The plastic disposable bags have sensors and ports for
oxygen and media and are purchased from GE Healthcare for $1,000 per bag.
7.4.3. Storage/Mixing Tank (PFD 03/P-09)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the second seed bioreactor. The
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tank will be manufactured from Stainless Steel 316L, has a volume of 1,500L and a
working capacity of 70%. Its height is 2.3m and its diameter 0.9m. For sterilization, CIP
and SIP will be conducted after each batch. The tank operates at room temperature and at
1 bar. The tank is manufactured by Sharpsville Container and costs $120,000.
7.4.4. Second Seed Bioreactor (PFD 03/ P-13)
The second seed bioreactor is another disposable bag bioreactor from GE
Healthcare. The unit is the XDR-50 to 2000 Single Use Bioreactor and provides use with
working culture volume up to 2,000L. The unit consists of a permanent base used for
rocking along with disposable cell culture bags. Each bioreactor unit for this stage of the
process is able to hold one 2,000L bag. The unit is purchased from GE Healthcare for
$600,000. The bag has a 2,000L volume with 50% working volume. The 2000L bags are
plastic, pre-sterilized, single use chambers for non-invasive mixing of fluids using the
WAVETM rocker. The unit is kept at 37°C, 1 bar, a pH ranging from 7.0-7.2, and 50%
DO. The pH, temperature, and oxygen levels will be controlled with PID controls. The
process time for this unit is 5.5 days. The plastic disposable bags have sensors and ports
for oxygen and media and are purchased from GE Healthcare for $1,800 per bag.

7.5. Production Section
7.5.1. Storage/Mixing Tank (PFD 01/ P-15 & P-19)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the third tank bioreactor. The tank
will be manufactured from Stainless Steel 316L, has a volume of 10,000L and a working
capacity of 70%. Its height is 3.5m and its diameter is 2.0m. For sterilization, CIP and
SIP will be conducted after each batch. The tank operates at room temperature and at 1
bar. The tank is manufactured by Sharpsville Container and costs $130,000. There are
two of these media storage tanks for a total of 20,000L.
7.5.2. Stirred Tank Bioreactor (PFD 01/ P-23)
The production stirred tank bioreactor is a stainless steel jacketed bioreactor
purchased from Techniserv Inc (SCAL-TECH Products). It has a 25,000L volume with a
height of 5.0m and a diameter of 2.5m. Following each batch, CIP and SIP is used to
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sterilize the unit. The pH, temperature and oxygen levels will be controlled with PID
controls and will run for 16 days. The bioreactor operates at 37°C and about 1.5-2 bar.
The bioreactor will be bought for $900,000.
7.5.3. Storage/Mixing Tank (for fluidized bioreactor) (PFD 03/ P-15 & P-19)
This tank is used to store and mix powder serum-free media with water for
injection before being filtered and then transferred into the last holding tank. As soon as
media is mixed, it will be filtered and fed to the following storage tank before a new
batch of media is mixed. This process will continue in order to meet the media
requirement for the fluidized bioreactor. The tank will be manufactured from Stainless
Steel 316L, has a volume of 10,000L and a working capacity of 70%. Its height is 3.5m
and its diameter is 2.0m. For sterilization, CIP and SIP will be conducted after each
batch. The tank operates at room temperature and at 1 bar. The tank is manufactured by
Sharpsville Container and costs $130,000.
(Note: There are two of these media storage tanks for a total of 20,000L.)
7.5.4. Media Storage Tank (for fluidized bioreactor) (PFD 03/ P-23)
This tank is used to store the media before it enters the fluidized bioreactor. This
unit has a volume of 50,000L, with a height of 6.0m and a diameter of 3.25m. Media
from the mixing tanks (PFD 03/ P-15 & P-19) is fed to this storage tank and the fed to the
fluidized bioreactor. As media is being transferred from the storage tank to the bioreactor,
media from the mixing tanks is also being transferred to the storage tank. As previously
stated, this continuous media transfer process is used in order to meet the total media
requirement of 5.7 million liters for the fluidized bioreactor. For sterilization, CIP and
SIP will be conducted after each batch. It will be purchased from Sharpsville Container
for a cost of $165,000.
7.5.5. Fluidized Bioreactor (PFD 03/P-25)
The fluidized bioreactor is the GE Healthcare CytopilotTM Production Bioreactor.
It has a 25,000L volume and annular shape. Following each batch, CIP and SIP is used to
sterilize the unit. The pH, temperature and oxygen levels will be controlled with PID
controls and will run for 13 days. The bioreactor operates at 37°C, about 1 bar, and DO
of 30%. The bioreactor will be bought for $1,500,000.
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7.6. Downstream Purification
7.6.1. Holding Tank (Stirred Tank Process) (PFD-03/P-25)
The holding tank is used to store the output from the production process so that
smaller batches can be sent downstream for purification. The unit has a volume of
25,000L with 80% capacity. It has a height of 5.0m and a diameter of 2.5m. For
sterilization, CIP and SIP will be conducted after each batch. It will be purchased from
Sharpsville Container for a cost of $145,000.
7.6.2. Holding Tank (Fluidized Process) (PFD-04/P-27)
The holding tank is used to store the output for the production process so that
smaller batches can be sent downstream for purification. It has a volume of 50,000L with
80% capacity. The tank has height of 6.0m and a diameter of 3.25m. The material is
Stainless Steel 316L with an electro-polished finish. It will be purchased from Sharpsville
Container and costs $165,000.
7.6.3. Tangential Flow Filtration Unit (PFD 04/ P-29)
In the fluidized bioreactor process, the contents of the production bioreactor must
be separated and the TFF unit allows the product or feed to flow directly tangentially
along the surface of the membrane. The unit is purchased from Pall Corporation and each
unit costs $500,000. The model is the Cadence Single Pass TFF System and is Stainless
Steel 316L with an electro-polished finish. It operates between 4-40°C, from 4-6 bar and
pH between 2-13. The flow range is between 6-1000 L/h.
7.6.4. TFF Holding Tank (PFD 04/ P-31)
The holding tank is used to store the output from the TFF unit so that batches can
be sent downstream for purification. The unit has a height of 6.0m, a diameter of 3.25m,
and a volume of 50,000L with 80% capacity. It will be purchased for $165,000 from
Sharpsville Container.
7.6.5. Centrifuge (PFD 02/P-27)
In the stirred tank bioreactor process, the contents of the production bioreactor
must be separated into a solid waste stream and liquid stream containing the desired
product. A hermetic disc-stack centrifuge produced by Alfa Laval is used. The
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Culturefuge 400 model, constructed with Stainless Steel 316L, can be purchased from
Alfa Laval for $480,000. The centrifuge’s throughput flow rate is 10,000 L/h. The unit
operates at 25°C. CIP and SIP is used to sterilize the unit after each batch.
7.6.6. Centrifuge Holding Tank (PFD 02/P-29)
The centrifuge holding tank is used to store the output from the centrifuge unit so
that batches can be sent downstream for purification. The unit has a height of 5.0m, a
diameter of 2.5m, and a volume of 25,000L with 80% capacity. For sterilization, CIP and
SIP will be conducted after each batch. It will be purchased from Sharpsville Container
for a cost of $145,000.
7.6.7. Protein A Chromatography Column (PFD 02 & 04/P-31 & P-33)
The Protein A affinity chromatography column is used to further purify the
mainstream fluid to help isolate the product. The Chromaflow 2000/100-300 column will
be purchased from GE Healthcare for $200,000. The column is made of Stainless Steel
316L. The column is packed with nProtein A Sepharose 4 Fast Flow resin (distributed by
GE Healthcare). The bed (portion of column occupied by resin) will be sized at a bed
height of 0.5m and diameter of 2.54m. The bed volume is 2000L. The resin has a binding
capacity of 50 mg/ml. The resin has a working velocity of 30-400 cm/h. The resin will
flow through the column at 40 cm/min for the fluidized bed. The column is operated at
4°C, at 1 bar. The cost of the column is $200,000 and the resin is $8,000 per liter.
7.6.8. Protein A Holding Tank (PFD 02 & 04 / P-33 & P-35)
The Protein A holding tank is used to store the output from the Protein A column.
The unit has a height of 3.0m, a diameter of 1.5m, and a volume of 5,000L with 80%
capacity. For sterilization, CIP and SIP will be conducted after each batch. It will be
purchased from Sharpsville Container for a cost of $122,000.
7.6.9. Cation Exchange Chromatography Column (PFD 02 & 04/ P-35 & P-37)
The cation exchange chromatography column is used to further purify the
mainstream fluid to help isolate the product. The Chromaflow 1000 column will be
purchased from GE Healthcare for $250,000. The column is made of Stainless Steel
316L. The column is packed with Eshmuno S resin (distributed by EMD Millipore). The
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bed (portion of column occupied by resin) will be sized at a height of 0.5m and diameter
of 2.54m. The resin has a binding capacity of greater than 60 mg antibody/mL media and
a working velocity of up to 800 cm/hr. The column is operated at 25°C, at 1 bar. The cost
of the column is $250,000 and the resin is $1,500 per liter.
7.6.10. Cation Exchange Holding Tank (PFD 02 & 04 / P-37 & P-39)
The cation exchange holding tank is used to hold and mix product from cation
exchange chromatography with buffer solutions in preparation for anion exchange
chromatography. The unit has a height of 3.0m, a diameter of 1.5m, and a volume of
5,000L with 80% capacity. For sterilization, CIP and SIP will be conducted after each
batch. It will be purchased from Sharpsville Container for a cost of $122,000.
7.6.11. Anion Exchange Chromatography Column (PFD 02 & 04/ P-39 & P-41)
The anion exchange chromatography column is used to further purify the
mainstream fluid to help isolate the product. The Chromaflow 1000 column will be
purchased from GE Healthcare. The column is made of Stainless Steel 316L
electroporated. The column is packed with Capto Q resin (GE Healthcare). The bed
(portion of column occupied by resin) will be sized at a height of 0.5m and diameter of
2.54m. The bed volume is 2,000L. The resin has a binding capacity of greater than 100
mg antibody/mL medium and a working velocity of 700 cm/hr. The column is operated at
25°C, at 1 bar. The cost of the column is $250,000 and the resin is $1,800 per liter.
7.6.12. Anion Exchange Holding Tank (PFD 02 & 04/ P-41 & P-43)
The anion exchange holding tank is used to collect the product from the anion
exchange column. The unit has a height of 5.0m, a diameter of 2.5m, and a volume of
25,000L with 80% capacity. For sterilization, CIP and SIP will be conducted after each
batch. It will be purchased from Sharpsville Container for a cost of $145,000.
7.6.13. Viral Nanofiltration Unit (PFD 02 & 04/ P-43& P-45)
The viral filtration unit will be purchased from AsahiKasei Bioprocess. The
Planova BioEX membrane is effective against enveloped and non-enveloped viruses as
small as 18nm while allowing proteins as large as 200kD to pass through without
denaturing. This membrane is ideal for our 145kD product. The unit consists of a
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permanent virus filtration controller along with disposable filters. The unit can handle up
to 5000L of volume at for each batch run. The MW cutoff for this filter is 200kD and the
protein throughput is 6.5 kg/m2 per 3 hours. The filter effective surface area is 1.8m2 and
the suggested operating pressure is less than 343 kPa. The filter housing can be purchased
from AsahiKasei Bioprocess for $15,000 and will be SIP sterilized. The membrane filters
are disposable and cost $2,000 per filter.
7.6.14. Ultrafiltration Unit (PFD 02 & 04/ P-45 & P-47)
The ultrafiltration unit will be purchased from Pall Corporation. The membrane
has a MW cutoff of 100kD. The unit consists of a permanent base along with disposable
filters. The material of the disc filters is Omega Polyethersulfone and the filter has an
effective surface area of 1.8m2. The housing unit will be sterilized through SIP. The filter
housing and membranes are purchased from Pall Corporation and cost 12,000 per
housing unit and $1,000 per filter membrane.
7.6.15. Final Sterile Filtration Unit (PFD 02 & 04/ P-47 & P-49)
The final sterile filtration unit will be purchased from Sartorious Biotech. The
Sartopore 2 membrane has a pore size of 0.2 micron and the filter material is
Polyethersulfone. The filtration area is 1.8m2 and the max differential pressure is 5 bar at
20°C. The unit consists of a permanent base along with disposable filters. The hosing
membrane unit sterilization is SIP and the membranes are disposable. The housing unit
costs $2,000 and the filter membranes cost $650/unit.

7.7. Additional Downstream Separation (Fluidized Bioreactor Process)
7.7.1. High Temperature Inactivation (PFD 05/ P-52)
An industrial size autoclave can be purchased from WSF Industries Inc. This unit
serves to kill the cells attached to the microcarriers in order to allow for safe disposal.
The unit is made of Stainless Steel 316L with an electro-polished finish. For sterilization,
CIP and SIP will be conducted after each batch. The autoclave will operate at 25°C. The
cost of this unit is $500,000.
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8. Additional Equipment Description
Additional costs will need to be considered for equipment not depicted in the process flow
diagrams. These items help maintain good manufacturing practices. Since we are working at a
refurbished green site, the site is equipped with many of these individual operations and
processes so some of the equipment expenses are added to the annual expenses. Individual prices
for the equipment are not needed because it does not have to be bought. Some equipment will
have to be bought and the price will be included. A summary of these costs can be found in
Section 10.

8.1. Biosafety Cabinet
Three biosafety cabinets will be required to provide a sterile environment to handle and
transfer the vial of cells into the bag bioreactors in the inoculum prep section. The biosafety
cabinet is manufactured by Thermo ScientificTM. The biosafety cabinets will already be in the
plant and the costs will be included in the annual expenses.

8.2. Cell Bank
Though out of scope of this project, a cell bank will be required to provide the initial
inoculum for the inoculum prep sections. The cell bank will store optimized recombinant
CHO cells designed to produce rituximab and be created in a clean lab. These cells will be
cultured and grown to a final cell density of 1x108 cells/mL and aliquoted into 2mL vials.
Before either facility begins operation, a cell bank will be created to sustain the inoculum
requirements with more cells being added to the cell bank as needed.

8.3. Air Generator (HVAC Equipment)
Purified air will be the source of oxygen throughout the process and will be provided by
an HVAC system. The system will supply clean air to bioreactors, clean rooms, and other
process equipment. The air generator will be in the plant and the costs will be included in the
annual expenses.

8.4. Clean Steam Generator
The clean steam generator is used to produce steam from WFI for SIP procedures. The
clean steam generator will already be in the plant and the costs will be included in the annual
expenses.
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8.5. CIP Skids
Clean-In-Place (CIP) is a technique used to clean equipment. A CIP skid is portable and
contains the cleanings solutions and equipment necessary. In order to clean all the unit
operations and storage tanks, ten CIP skids will be needed for this process. They will be
manufactured by Sani-matic and each will cost about $100,000.

8.6. Buffer Transfer Bags
Buffer transfer bags are used to transfer media or buffer to appropriate unit operations.
These disposable bags and bag holders are manufactured by HyClone and will cost
approximately $70,000 a year.

8.7. Filter Integrity Tester
Though disposable filters are used throughout the process, they must be tested before
each use to assure they are not clogged, torn or general unusable. The filter integrity tester
from Millipore and is in the plant so the costs will be included in the annual expenses.

8.8. Tube Fuser and Sealer
At various times in the process, a tube fuser will be necessary to connect tubing between
disposable and permanent process equipment such as buffer transfer steps or filtration steps.
A tube sealer is also necessary to seal any plastic tubing to prevent leaks in bags during
transport. The Sartorius Stedim Biotech’s Sterile Tube Fuser is a fully automatic device that
cuts and fuses tube ends together to ensure sterility. The tube fuser and sealer are in the plant
and the costs will be included in the annual expenses.

8.9. Water Treatment Package
Though WFI will be used for most of the water requirements in the process, U.S.
Pharmacopeia (USP) grade water is needed for temperature control needs in the bioreactor
process. This water will not be in contact with the cell culture suspension, but inserted into
the stainless steel bioreactor jackets for cooling. The cost for the water treatment package is
included in the annual expenses.
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8.10. WFI Still
The WFI still is used to purify water produced for the water treatment package for use
with cell culture. WFI is used to ensure sterility of not only the product but also of the
process equipment to help eliminate cross-contamination issues. The still is manufactured by
the Paul Mueller Co. The WFI still will already be in the plant and the costs will be included
in the annual expenses.

8.11. Biowaste and Neutralization Tanks
All biowaste produced in the process will have to be treated appropriately before
disposal. All waste potentially containing live culture is sent to the biowaste tank. All other
waste, such as used buffers, is sent directly to a neutralization tank. Approximately 178L of
cells are coming out of the tank bioreactor process. The neutralization tank will need to be
about 125,000L so five 25,000L tanks will be used. The tanks can be bought from
Sharpsville Container for $145,000 each.
A facility will be contracted out to help dispose of the non-liquid waste. This nonliquid waste includes the disposable WAVETM bags and other disposable products. The
disposable bags and all their parts are mainly made from plastics that are derived from
petroleum. Current recycling concepts are focused on incineration in outsourced power plants
to recover the energy from the petroleum. The costs of the outsourcing will also be added to
the annual expenses.

8.12. Biowaste Inactivation System
This system is needed to kill any live mass remaining in the biowaste tank. This
includes all CIP and SIP washes, from the main bioreactors and primary recovery. The
biowaste inactivation system is in the plant and costs will be included in the annual expenses.

8.13. Waste Neutralization System
The waste neutralization system is needed to adjust the pH of cell-free waste to 7.0.
Then, the waste can be disposed directly into the sewer line. This allows the wastes to be sent
to the sewer. The waste neutralization system is in the plant and the costs will be included in
the annual expenses.
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8.14. Quality Control Lab
A quality control lab will review the quality of all factors involved in production. In
the quality control lob, a set of procedures will be performed to ensure that the manufactured
product adheres to a defined set of quality criteria. The costs of this lab will be included in
the annual expenses.

8.15. Laboratory Information Management System (LIMS)
The Laboratory Information Management system (LIMS) is software that is used to
manage a laboratory. It manages samples, users, instruments, and many laboratory functions.
The LIMS unit will already be in the plant and the costs will be included in the annual
expenses.

8.16. Portable Pump on Cart
In the case of pump malfunction, three extra pumps will be stored on portable carts as
a replacement. An extra Watson-Marlow 825 pump and a cart will cost $13,000 each.

8.17. Refrigeration
Freezing of the monoclonal antibody is necessary to keep the product stable for as
long as possible. Effective temperatures for long term storage range from -20°C to - 80°C.
The freezing is done using an ultra cold freezer, which can reach temperatures up to - 85°C.
The freezer can hold up to 1050L (or 21 bags). Manufactured by Thermo ScientificTM, the
two freezers are a part of the plant and the costs are included in the annual expenses.

8.18. Final Packaging
The final output of the purification process will not have ready-to-administer product.
The product will be shipped out to a facility that can add the proper fillers for storage and
stability and ship the product to the necessary destinations. Final packaging, including both
shipping and lyophilization, and will be performed by Quality BioResources, Inc. This
process costs $280,000 per batch.
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9. Unit Specification Sheets
9.1. Stirred Tank Bioreactor Process
Bag Bioreactor (PFD 01/P-02)

Description and Function

To prepare the inoculum for seed bioreactor. An electric rocker base,
with integral temperature control, weight controllers for perfusion
culture, aeration pump, pH probe, and various rocking speeds is used
along with 200mL Cellbag bioreactor chambers. The bags are plastic
pre-sterilized, single-use chambers for non-invasive mixing of fluids
using the WAVETM rocker.

Vendor

GE Healthcare

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product
Model:
Construction:
Bag Bioreactor:
Sterilization:
Temp:
Pressure:
pH:
DO:
Duration:

Input (kg/Batch)
Output (kg/Batch)
0.00524
0.0262
0.002
0
0.098
0.098
0
0
0
0
GE Healthcare WAVETM Base 2/10EH
High quality stainless steel and aluminum
Cellbag 200mL Bioreactor Chamber
Plastic Disposable Bags
37 ̊ C
1 bar
7.0 – 7.2
50%
3.5 days

Rocker and Control Unit:
$ 16,480
200 mL Cellbag Bioreactor Chamber: $ 202.00 per bag (need 20)
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 01/P-03)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #01

Operation

Batch
Input

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Dry Powder Media
Water

Quantity
(L)
0.2
97.8

Output
Media Solution

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polish finish
150L
0.9m
0.4m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Quantity
(L)
98.00

Storage Tank:
$ 110,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Seed Bioreactor (PFD 01/P-07)

Description and Function

Bioreactor used for continued cell growth and production of
monoclonal antibodies. The WAVETM Bioreactor 500/1000 is a selfcontained system with integral temperature control, aeration pump,
and rocking controller for use with working culture volumes between
50L and 500L. The 200L bags are plastic pre-sterilized, single-use
chambers for non-invasive mixing of fluids using the WAVETM
bioreactor.

Vendor

GE Healthcare

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Cells
Media
Water
Endotoxin
Product

Characteristics

Model:
Construction:
Finish:
Dimensions:
Bag Bioreactor:
Sterilization:

Operations Conditions

Temp:
Pressure:
pH:
DO:
Duration:

Purchase Cost

Input (kg/Batch)
Output (kg/Batch)
0.52
3.04
2
0
98
98
0
0.81
0
0.02
GE Healthcare WAVETM Bioreactor 500/1000
Stainless Steel 316L
Electro-polished
201x124x160cm
Cellbag 200L Bioreactor Chamber
Plastic Disposable Bags
37 ̊ C
1 bar
7.0 – 7.2
50%
4 days

WAVETM Bioreactor system:
$ 404,500
200 L Cellbag Bioreactor Chamber:
$ 1,200 per bag
PI control for Temp, pH, DO, Flow Rate, and Volume:
$ 2,500/control = $10,000
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Media Prep (PFD 01/P-09)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Input
Dry Media
Powder
Water

Quantity (L)
18.00

Output
Media
Solution

Quantity (L)
900.0

882.0

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
1500L
2.3m
0.9m
SIP/CIP

Operations Conditions

Temp:
Pressure:

25°C
1 bar

Purchase Cost

Storage Tank:
$ 120,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500

Characteristics
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Seed Bioreactor (PFD 01/P-13)

Description and Function

Bioreactor used for continued cell growth and production of
monoclonal antibodies. The XDR 2000 Single-Use Bioreactor offers
a smooth transfer from development to manufacturing scale. It has
robust industrial automation with an aeration pump. It provides
exacting temperature control for use with working culture volumes
up to 2000L. The 2000L bags are plastic pre-sterilized, single-use
chambers for non-invasive mixing of fluids using the XDR
bioreactor.

Vendor

GE Healthcare

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product

Model:
Construction:
Bag Bioreactor:
Sterilization:

Temp:
Pressure:
pH:
DO:
Duration:

Input (kg/Batch)
Output (kg/Batch)
3.04
15.21
20
0
980
980
0.81
4.06
0.02
0.16

XDR-2000 Single-Use Bioreactor
Jacketed stainless steel vessel
Cellbag 2000 L Bioreactor Chamber
Plastic Disposable Bags

37 ̊ C
1 bar
7.0 – 7.2
50%
4 days

WAVETM Bioreactor system:
$ 600,000
2000 L Cellbag Bioreactor Chamber:
$1,800 per bag
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 01/P-15)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
190.0

Output
Media
Solution

Quantity (L)
9500.0

9310.0

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
10,000L
3.5m
2.0m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tank:
$ 130,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 01/P-19)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
190.0

Output
Media
Solution

Quantity (L)
9500.0

9310.0

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
10,000L
3.5m
2.0m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tanks:
$ 130,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Production Bioreactor (PFD 01/P-23)

Description and Function

Vendor

Bioreactor used for continued cell growth and production of
monoclonal antibodies. The final bioreactor serves to maximize
product formation. Utilizes state-of-the-art bus technologies and
supports process analytical technology (PAT).
Techniserv, Inc (SCAL-TECH Products)

PFD Reference

PFD #01

Operation

Batch

Materials Handled

Characteristics

Cells
Media
Water
Endotoxin
Product
Model:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Input (kg/Batch)
Output (kg/Batch)
6.73
356.32
400
0
19600
19600
4.056
36.34
0.16
9.41
SCAL-TECH Pro Suites Bioreactor
Electro-polished
25,000L
5.0m
2.5m
SIP/CIP

Operations Conditions

Temp:
Pressure:
pH:
DO:
Duration:

37 ̊ C
1 bar
7.0 – 7.2
50%
16 days

Purchase Cost

Bioreactor:
$900,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep Sterile Filtration (PFD 01/P-05, P-11, P-17, P-21)

Description and Function

0.2 µm dead end filter to remove bacteria and other impurities from
the serum free media prior to feeding the cultivators and production
bioreactor. The sanitary stainless steel filter housings are designed
for filtration applications. The filter capsules membranes are
disposable ready-to-use filter or depth filter capsules.

Vendor

Sartorious Stedim Biotech

PFD Reference

PFD #01

Operation

Batch

Characteristics

Model:
Membrane Filter Material:
Size:
Filtration Area:
Max. Differential Pressure:
Membrane Unit Sterilization:
Membrane Sterilization:

Sartopore 2 0.2 µm
Polyethersulfone (PES)
30”
1.8m2 (18ft2)
5 bar (75 psi) at 20 °C
SIP
Disposable

Operations Conditions

Temp:
Pressure:

25°C
0.5 bar (7.5 psi)

Purchase Cost

Filter Housing:
$ 2,000
Filter Membrane: $ 650/unit
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Pump (PFD 01 & 02/P-04, P-06, P-08, P-10, P-12, P-14, P-16, P-18, P-20, P-22, P-24, P-26,
P-28, P-30, P-32, P-34, P-36, P-38, P-40, P-14, P-42, P-44, P-46, P-48)
Description and Function

Pump to transfer fluid. High-flow hygienic pumps that are designed
for low-shear sanitary pumping. They are ideal for viscous or shear
sensitive products.

Vendor

Watson-Marlow

PFD Reference

PFD #01 and #02

Operation

Batch

Model:
Material Construction:
Flow Rate:
Max Pressure:
Tubing:
Sterilization

825 Peristaltic Pump
304 Stainless Steel
33.3 L/min
3.5 bar
Sterilized Bioprene, 40mm

Operations Conditions

Temp:
Pressure Change:
Power:

25°C
50 psi (3.5 bar)
1.5 – 5.0 hp

Purchase Cost

825 Peristaltic Pump:

Characteristics

$13,000
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Storage Tank (PFD 02/P-25)
Description and Function

To store output from production bioreactor before being centrifuged.

Vendor

Sharpsville Container

PFD Reference

PFD #02

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
25,000 L
5.0m
2.5m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tank:
$ 145,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Centrifuge (PFD 02/P-27)
Description and Function
Vendor

To remove cells from the stream containing the monoclonal antibody
product.
Alfa – Laval

PFD Reference

PFD #02

Operation

Batch

Materials Handled

Characteristics

Cells
Media
Water
Endotoxin
Product

Input (kg/Batch)
Output (kg/Batch)
356.32
0
0
0
19600
19208
36.34
33.44
9.41
9.22

Model:
Centrifuge Type:
Material of Construction:
Finished:
Capacity Range:
Sterilization:

Operations Conditions

Temp:
Throughput:

Purchase Cost

$ 480,000

Culturefuge 400
Hermetic Disk Stack
Stainless Steel 316L
Electro-polished product
5,000 to 20,000 L/hr
SIP/CIP

25°C
10,000 L/h
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Centrifugation Pool Tank (PFD 02/P-29)
Description and Function

To store sterilized supernatant from the centrifugation process.

Vendor

Sharpsville Container

PFD Reference

PFD #02

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
25,000L
5.0m
2.5m
SIP/CIP

25°C
1 bar

Storage Tank:
$ 145,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Protein A Chromatography Column (PFD 02/P-31)

Description and Function

To purify the antibody Fab fragments. It acts as the first main
isolation step for product and isolates the monoclonal antibody via
affinity chromatography. Therefore, the column is useful in
eliminating host cell DNA, media components, and endogenous viral
particles.

Vendor

GE Healthcare

PFD Reference

PFD #02

Operation

Batch
Input (kg/Batch)

Materials Handled

Cells
Media
Water Streams:
Centrifuge effluent
Equilibration buffer
Wash buffer
Elution buffer
Regeneration buffer
Protein A waste
Endotoxin
Product

Output (kg/Batch)
0
0

19208
2000
2000
4000
6000
33.44
9.22

0
0

4000
29208
20.06
9.04

Model :
Column Diameter:
Bed Height:
Material of Construction:
Bed Volume:
Resin
Binding Capacity:
Working Flow Velocity:
Temperature Stability:

Chromaflow 2000/100-300
2.54m
0.4m
Stainless Steel 316L
2,000L
n-Protein A Sepharose 4
50 mg antibody / ml media
30-400 cm/h
4-40°C

Operations Conditions

Temp:
Pressure:

4°C
1.01 bar

Purchase Cost

Column:
Resin:

Characteristics

$ 200,000
$ 8,000/ liters (need 2,000L)
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Protein A Pool Tank (PFD 02/P-33)
Description and Function

To collect product from anion exchange column.

Vendor

Sharpsville Container

PFD Reference

PFD #02

Operation

Batch

Characteristics

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Operations Conditions

Purchase Cost

Temp :
Operating Pressure:

Stainless Steel 316L
Electro-polished
5,000L
3.0m
1.5m
SIP/CIP
25°C
1 bar

Storage Tank:
$ 122,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Cation Exchange Chromatography Column (PFD 02/P-35)
Description and Function

To purify and isolate antigen binding fragments from impurities.

Vendor

GE Healthcare

PFD Reference

PFD #02

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Cells
Media
Water Streams:
Prot A effluent
Cat wash 1 buffer
Cat wash 2 buffer
Elution buffer
Regeneration buffer
Cat ex waste
Endotoxin
Product
Model:
Material of Construction:
Finish:
Bed Volume:
Column Diameter:
Bed Height:
Resin:
Binding Capacity:
Working Flow Velocity:

Output (kg/Batch)
0
0

2000
2000
2000
2000
6000
20.06
9.04

0
0

2000
12000
10.03
8.77

Chromaflow 1000
Stainless Steel 316L
Electro-polished
2,000L
2.54m
0.5m
Eshmuno S (EMD Millipore)
> 60 mg antibody/ ml media
800 cm/hr

Operations Conditions

Temp:
Pressure:

25°C
1 bar

Purchase Cost

Column:
Resin:

$ 250,000
$ 15,000/10 Liters (need 200 of these)
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Cation Exchange Pool Tank (PFD 02/P-37)
Description and Function

To hold and mix product from cation exchange chromatography
with buffer solutions in preparation for anion exchange
chromatography.

Vendor

Sharpsville Container

PFD Reference

PFD #02

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Total Volume:
Height:
Diameter:
Sterilization:
Temp :
Operating Pressure:

Stainless Steel 316L
Electro-polished
5,000L
3.0m
1.5m
SIP/CIP
25°C
1 bar

Storage Tank:
$ 122,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Anion Exchange Chromatography Column (PFD 02/P-39)
Description and Function

To remove impurities and purify antigen binding fragments.

Vendor

GE Healthcare

PFD Reference

PFD #02

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Cells
Media
Water Streams:
Cat ex effluent
Cat wash 1
Cat wash 2
Elution buffer
Regeneration buffer
Anion ex waste
Endotoxin
Product
Model:
Material of Construction:
Finish:
Bed Volume:
Column Diameter:
Bed Height:
Resin:
Binding Capacity:
Working Flow Velocity:

Operations Conditions

Temp:
Pressure:

Purchase Cost

Column:
Resin:

Output (kg/Batch)
0
0

2000
2000
2000
2000
6000
10.03
8.77

0
0

2000
12000
5.02
8.50

Chromaflow 1000
Stainless Steel 316L
Electro-polished
2,000L
2.54m
0.5m
Capto Q (GE Healthcare)
> 100 mg antibody/mL media
700 cm/hr
25°C
1 bar

$ 250,000
$ 109.00/60 liters (need 40 of these)
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Anion Exchange Pool Tank (PFD 02/P-41)
Description and Function

To collect product from anion exchange column.

Vendor

Sharpsville Container

PFD Reference

PFD #02

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Total Volume:
Height:
Diameter:
Sterilization:
Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
25,000L
5.0m
2.5m
SIP/CIP
25°C
1 bar

Storage Tank:
$ 145,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Nanofiltration Unit (PFD 02/P-43)
Description and Function

To remove viruses. It is a size based membrane separation in which
the product flows through while viruses are captured within the
pores.

Vendor

Asahi Kasei Bioprocess

PFD Reference

PFD #02

Operation

Batch
Input (kg/Batch)

Materials Handled

Cells
Media
Water
Endotoxin
Product

Characteristics

Model:
MW Cutoff:
Protein Throughput:
Filtration pressure:
Filter effective surface area:
Sterilization:
Membrane:

Operations Conditions

Temp:
Suggested Operating Pressure:
Operating pH:

Purchase Cost

Filter Housing: $ 15,000
Membrane Filter: $ 2,000

Output (kg/Batch)

0
0
2000
5.02
8.50
Planova BioEx
200 kD
6.5 kg/m2 per 3 hours
294 kPa (42.6 psi)
1.8m2
SIP (autoclave)
Disposable
25°C
< 343 kPa
2-9

0
0
2000
2.51
8.42

61

Monoclonal Antibody Production via Fluidized Bioreactor Technology

Ultrafiltration (PFD 02/P-45)
Description and Function

To remove small viral and foreign particles. The desired product will
stay in the retentate but smaller particles will be removed.

Vendor

Pall Corporation

PFD Reference

PFD #02

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product

0
0
2000
2.51
8.42

Model:
Disc Filters:
MW Cutoff:
Filter effective surface area:
Sterilization:
Membrane Treatment:

0
0
2000
1.25
8.08

Membrane Unit
Omega polyethersulfone membrane
100 kD
1.8m2
SIP (autoclave)
Sterilized, washed, and reused

Temp:
Operating Pressure:
Filter Housing:
Filter Membrane:

Output (kg/Batch)

0 - 40°C
1 bar
$ 12,000
$ 1,000
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Final Sterile Filtration (PFD 02/P-47)

Description and Function

.2 µm dead end filter to remove bacteria and other impurities from
the serum free media prior to feeding the cultivators and production
bioreactor. The sanitary stainless steel filter housings are designed
for filtration applications. The filter capsules membranes are
disposable ready-to-use filter or depth filter capsules.

Vendor

Sartorious Biotech

PFD Reference

PFD #02

Operation

Batch

Input (kg/Batch)
Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product

Output (kg/Batch)

0
0
2000
1.25
8.08

Model:
Membrane Filter Material:
Size:
Filtration Area:
Max. Differential Pressure:
Membrane Unit Sterilization:
Membrane Sterilization:

Sartopore 2 0.2 µm
Polyethersulfone (PES)
30 inches
1.8m2 (18ft2)
5 bar (75 psi) at 20 °C
SIP
Disposable

Temp :
Pressure :

25°C
0.5 bar (7.5 psi)

Filter Housing:
Filter Membrane:

$ 2,000
$ 650/unit

0
0
2000
0
7.76
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9.2. Fluidized Bed Bioreactor Process
Bag Bioreactor (PFD 03/P-02)

Description and Function

To prepare the inoculum for seed bioreactor. An electric rocker base,
with integral temperature control, weight controllers for perfusion
culture, aeration pump, pH probe, and various rocking speeds is
used along with 200mL Cellbag bioreactor chambers. The bags are
plastic pre-sterilized, single-use chambers for non-invasive mixing
of fluids using the WAVETM rocker.

Vendor

GE Healthcare

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product
Model :
Construction:
Bag Bioreactor :
Sterilization:

Temp :
Pressure :
pH :
DO :
Duration:

Input (kg/Batch)
Output (kg/Batch)
0.00524
0.0262
0.002
0
0.098
0.098
0
0
0
0
GE Healthcare WAVETM Base 2/10EH
High quality stainless steel and aluminum
Cellbag 200mL Bioreactor Chamber
Plastic Disposable Bags
SIP for rocker
37 ̊ C
1 bar
7.0 – 7.2
50%
3.5 days

Rocker and Control Unit:
$16,480
200 mL Cellbag Bioreactor Chamber: $202.00 per bag (need 30)
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 03/P-03)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #03

Operation

Batch
Input

Materials Handled

Dry Powder Media
Water

Quantity
(L)
0.2
97.8

Output
Media Solution

Quantity
(L)
98.00

Material of Construction:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
150L
0.9m
0.4m
SIP/CIP

Operations Conditions

Temp:
Pressure:

25°C
1 bar

Purchase Cost

Storage Tank:
$ 110,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500

Characteristics
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Seed Bioreactor (PFD 03/P-07)

Description and Function

Bioreactor used for continued cell growth and production of
monoclonal antibodies. The WAVETM Bioreactor 500/1000 is a selfcontained system with integral temperature control, aeration pump,
and rocking controller for use with working culture volumes
between 50L and 500L. The 70L bags are plastic pre-sterilized,
single-use chambers for non-invasive mixing of fluids using the
WAVETM bioreactor.

Vendor

GE Healthcare

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product
Model:
Construction:
Dimensions:
Bag Bioreactor:
Sterilization:
Temp:
Pressure:
pH:
DO:
Duration:

Input (kg/Batch)
Output (kg/Batch)
0.26
1.75
2
0
98
98
0
0.47
0
0.02
WAVETM Bioreactor 500/1000
Stainless Steel
201x124x160 cm
Cellbag 70L Bioreactor Chamber
Plastic Disposable Bags
37 ̊ C
1 bar
7.0 – 7.2
50%
5 days

WAVETM Bioreactor system:
$ 404,500 (3x)
70L Cellbag Bioreactor Chamber:
$ 1,000 per bag
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 03/P-09)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
18.00

Output
Media
Solution

Quantity (L)
900.0

882.0

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
1500L
2.3m
0.9m
SIP/CIP

Temp :
Pressure :

25°C
1 bar

Storage Tank:
$ 120,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Seed Bioreactor (PFD 03/P-13)

Description and Function

Bioreactor used for continued cell growth and production of
monoclonal antibodies. The XDR-2000 Single-Use Bioreactor offers
a smooth transfer from development to manufacturing scale. It has
robust industrial automation with an aeration pump. It provides
exacting temperature control for use with working culture volumes
up to 2000L. The 2000L bags are plastic pre-sterilized, single-use
chambers for non-invasive mixing of fluids using the XDR
bioreactor.

Vendor

GE Healthcare

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product
Model:
Construction:
Bag Bioreactor:
Sterilization:
Temp:
Pressure:
pH:
DO:
Duration:

Input (kg/Batch)
Output (kg/Batch)
5.24
38.25
20
0
980
980
1.40
10.20
0.05
0.46
XDR-2000 Single-Use Bioreactor
Jacketed stainless steel vessel
Cellbag 2000L Bioreactor Chamber
Plastic Disposable Bags
37 ̊ C
1 bar
7.0 – 7.2
50%
5.5 days

WAVETM Bioreactor system:
$ 600,000
125L Cellbag Bioreactor Chamber: $ 1,800 per bag
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 03/P-15)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
8.6E+05

Output
Media
Solution

Quantity (L)
4.29E+06

4.21E+06

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
10,000L
3.5m
2.0m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tank:
$ 130,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Prep (PFD 03/P-19)
Description and Function

Tank used to store and mix powdered serum free media with water
for injection prior to being pumped through a sterile filter.

Vendor

Sharpsville Container

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
8.6E+05

Output
Media
Solution

Quantity (L)
4.29E+06

4.21E+06

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished finish
10,000L
3.5m
2.0m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tank:
$ 130,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Media Storage (PFD 03/P-23)
Description and Function

To store media before entering the production fluidized bioreactor.

Vendor

Sharpsville Container

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Input
Dry Media
Powder
Water

Quantity (L)
1.72E+05

Output
Media
Solution

Quantity (L)
8.60E+06

8.42E+06

Model:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
50,000L
6.0m
3.25m
SIP/CIP

Temp:
Pressure:

25°C
1 bar

Storage Tank:
$ 165,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Production Bioreactor (PFD 03/P-25)
Description and Function

Fluidized Bioreactor with internal circulation used for continued cell
growth and production of monoclonal antibodies. The final
bioreactor serves to maximize product formation.

Vendor

GE Healthcare

PFD Reference

PFD #03

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product
Model:
Material:
Finish:
Sterilization:
Temp:
Pressure:
pH:
DO:
Duration:

Input (kg/Batch)
Output (kg/Batch)
38.25
2672.4
1.72E+05
1.17E+05
8.42E+06
5.90E+06
10.20
272.58
0.46
65.75
25,000L CytopilotTM Production Bioreactor
Stainless Steel 316L
Electro-polished
SIP/CIP
37 ̊ C
1 bar
7.0 – 7.2
40%
13 days

Bioreactor:
$1,500,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$2,500/control = $12,500

72

Monoclonal Antibody Production via Fluidized Bioreactor Technology

Sterile Filtration (PFD 03/P-05, P-11, P-17, P-21)

Description and Function

.2 µm dead end filter to remove bacteria and other impurities from
the serum free media prior to feeding the cultivators and production
bioreactor. The sanitary stainless steel filter housings are designed
for filtration applications. The filter capsules membranes are
disposable ready-to-use filter or depth filter capsules.

Vendor

Sartorious Biotech

PFD Reference

PFD #03

Operation

Batch

Characteristics

Model:
Membrane Filter Material:
Size:
Filtration Area:
Max. Differential Pressure:
Membrane Unit Sterilization:
Membrane Sterilization:

Sartopore 2 0.2 µm
Polyethersulfone (PES)
30”
1.8m2 (18ft2)
5 bar (75 psi) at 20 °C
SIP
Disposable

Operations Conditions

Temp:
Pressure:

25°C
0.5 bar (7.5 psi)

Purchase Cost

Filter Housing:
Filter Membrane:

$ 2,000
$ 650/unit
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Pump (PFD 03 & 04/ P-04, P-06, P-08, P-10, P-12, P-14, P-16, P-18, P-20, P-22, P-24, P-26,
P-28, P-30, P-32, P-34, P-36, P-38, P-40, P-14, P-42, P-44, P-46, P-48, P-50, P-51)
Description and Function

Pump to transfer fluid. High-flow hygienic pumps that are designed
for low-shear sanitary pumping. They are ideal for viscous or shear
sensitive products.

Vendor

Watson-Marlow

PFD Reference

PFD #03 and #04

Operation

Batch

Characteristics

Model:
Material Construction:
Flow Rate:
Max Pressure :
Tubing:

825 Peristaltic Pump
304 Stainless Steel
33.3 L/min
3.5 bar
Bioprene, 25mm

Operations Conditions

Temp:
Pressure Change:
Power:

25°C
50 psi
1.5 – 5.0 hp

Purchase Cost

$13,000
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Storage Tank (PFD 04/P-27)
Description and Function

To store output of production bioreactor before tangential flow
filtration.

Vendor

Sharpsville Container

PFD Reference

PFD #04

Operation

Batch

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Stainless Steel 316L
Electro-polished
50,000L
6.0m
3.25m
SIP/CIP

Operations Conditions

Temp:
Pressure:

25°C
1 bar

Purchase Cost

Storage Tank:
$165,000 (x58)
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$2,500/control = $12,500 (x58)

Characteristics
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Tangential Flow Filtration (PFD 04/P-29)
Description and Function

To remove cells, viruses, and bacteria from the stream containing
the monoclonal antibody product. It a process by which the product
or feed is directed tangentially along the surface of the membrane.

Vendor

Pall Corporation

PFD Reference

PFD #04

Operation

Batch

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product

Input (kg/Batch)
Output (kg/Batch)
2672.4
0
1.17E+05
0
5.90E+06
5.84E+06
272.58
250.78
65.75
64.43

Model:
Material:
Finished:
Sterilization:

Cadence Single Pass TFF System
Stainless Steel 316L
Electro-polished
SIP/CIP

Temp:
Flow Range:
Pressure Range:
pH Range:

4-40°C
6-1,000 L/h
4-6 bar
2-13

$500,000 (x50)
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TFF Pool Tank (PFD 04/P-31)
Description and Function

To store sterilized supernatant from the tangential flow filtration
process.

Vendor

Sharpsville Container

PFD Reference

PFD #04

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:
Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
50,000 L
6m
3.25 m
SIP/CIP
25 ° C
1 bar

Storage Tank:
$145,000 (x58)
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500 (x58)
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Protein A Chromatography Column (PFD 04/P-33)

Description and Function

To purify the antibody Fab fragments. It acts as the first main
isolation step for product and isolates the monoclonal antibody via
affinity chromatography. Therefore, the column is useful in
eliminating host cell DNA, media components, and endogenous viral
particles.

Vendor

GE Healthcare

PFD Reference

PFD #04

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Operations Conditions
Purchase Cost

Cells
Media
Water Streams:
Centrifuge
effluent
Equilibration buffer
Wash buffer
Elution buffer
Regeneration
buffer
Protein A waste
Endotoxin
Product

0
0

0
0

5.84E+06
2000
2000
4000

4000

6000
250.78
64.43

Model:
Column Diameter:
Bed Height:
Material of Construction:
Bed Volume:
Resin
Binding Capacity:
Working Flow Velocity:
Temperature Stability:
Temp:
Pressure:
Column:
Resin:

Output (kg/Batch)

5.85E+06
130.40
63.14

Chromaflow 2000/ 100-300
2.54m
0.4m
Stainless Steel 316L
2000L
n-Protein A Sepharose 4
50 mg antibody / ml media
40 cm/min
4-40 °C
4 °C
1.01 bar

$ 200,000
$ 8,000/ liters (need 2,000 L)
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Protein A Pool Tank (PFD 04/P-35)
Description and Function

To collect product from anion exchange column.

Vendor

Sharpsville Container

PFD Reference

PFD #04

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Total Volume:
Height:
Diameter:
Sterilization:
Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
5,000.0 L
3.0 m
1.5 m
SIP/CIP
25 ° C
1 bar

Storage Tank:
$ 122,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Cation Exchange Chromatography Column (PFD 04/P-37)
Description and Function

To purify and isolate antigen binding fragments from impurities.

Vendor

GE Healthcare

PFD Reference

PFD #04

Operation

Batch
Input (kg/Batch)

Materials Handled

Cells
Media
Water Streams:
Prot A effluent
Cat wash 1 buffer
Cat wash 2 buffer
Elution buffer
Regeneration buffer
Cat ex waste
Endotoxin
Product

Output (kg/Batch)
0
0

2000
2000
2000
2000
6000
130.40
63.14

2000
12000
50.16
61.25

Model:
Material of Construction:
Finish:
Bed Volume:
Column Diameter:
Bed Height:
Resin:
Binding Capacity:
Working Flow Velocity:

Chromaflow 1000
Stainless Steel 316L
Electro-polished
2,000.0 L
2.54 m
0.5 m
Eshmuno S (EMD Millipore)
> 60 mg antibody/ ml media
800 cm/hr

Operations Conditions

Temp :
Pressure:

25 ° C
1 bar

Purchase Cost

Column: $ 250,000
Resin: $ 15,000/10 Liters (need 200 of these)

Characteristics
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Cation Exchange Pool Tank (PFD 04/P-39)
Description and Function

To hold and mix product from cation exchange chromatography
with buffer solutions in preparation for anion exchange
chromatography.

Vendor

Sharpsville Container

PFD Reference

PFD #04

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Volume:
Height:
Diameter:
Sterilization:

Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
5,000.0 L
3.0 m
1.5 m
SIP/CIP

25 ° C
1 bar

Storage Tank:
$ 122,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Anion Exchange Chromatography Column (PFD 04/P-41)
Description and Function

To remove impurities and purify antigen binding fragments

Vendor

GE Healthcare

PFD Reference

PFD #04

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water Streams:
Cat ex effluent
Anion wash 1
buffer
Anion wash 2
buffer
Elution buffer
Regeneration buffer
Anion ex waste
Endotoxin
Product

0
0
2000
2000
2000
2000
6000
50.16
61.25

Model:
Material of Construction:
Finish:
Bed Volume:
Column Diameter:
Bed Height:
Resin :
Binding Capacity:
Working Flow Velocity:
Temp:
Pressure:
Column:
Resin:

Output (kg/Batch)

2000
12000
30.09
59.41

Chromaflow 1000
Stainless Steel 316L
Electro-polished
2,000.0 L
2.54 m
0.5 m
Capto Q (GE Healthcare)
> 100 mg antibody/ ml media
700 cm/hr
25 °C
1 bar

$ 250,000
$ 109.00/60 Liters (need 40 of these)

82

Monoclonal Antibody Production via Fluidized Bioreactor Technology

Anion Exchange Pool Tank (PFD 04/P-43)
Description and Function

To collect product from anion exchange column.

Vendor

Sharpsville Container

PFD Reference

PFD #04

Operation

Batch

Characteristics

Operations Conditions

Purchase Cost

Material of Construction:
Finish:
Total Volume:
Height:
Diameter:
Sterilization:
Temp:
Operating Pressure:

Stainless Steel 316L
Electro-polished
25,000.0 L
5.0 m
2.5 m
SIP/CIP
25 ° C
1 bar

Storage Tank:
$ 145,000
PI control for pH, Temp, DO, Flow Rate, Volume, and Pressure:
$ 2,500/control = $12,500
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Viral Nanofiltration Unit (PFD 04/P-45)
Description and Function

To remove viruses. It is a size based membrane separation in which
the product flows through and the viruses are captured within the
pores.

Vendor

Asahi Kasei Bioprocess

PFD Reference

PFD #04

Operation

Batch
Input (kg/Batch)

Materials Handled

Cells
Media
Water
Endotoxin
Product

Output (kg/Batch)

0
0
2000
30.09
59.41

0
0
2000
10.03
58.82

Characteristics

Model:
MW Cutoff:
Protein Throughput:
Filtration pressure:
Filter effective surface area:
Sterilization:
Membrane:

Planova BioEx (EX1-0000)
200 kD
6.5 kg/m2 per 3 hours
294 kPa (42.6 psi)
1.8 m2
SIP (autoclave)
Disposable

Operations Conditions

Temp:
Suggested Operating Pressure:
Operating pH:

25 ° C
<343 kPa
2-9

Purchase Cost

Filter Housing:
Membrane Filter:

$ 15,000 (x6)
$ 2,000
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Ultrafiltration (PFD 04/P-47)
Description and Function

To remove small viral and foreign particles. The desired product
will stay in the retentate but smaller particles will be removed.

Vendor

Pall Corporation

PFD Reference

PFD #04

Operation

Batch
Input (kg/Batch)

Materials Handled

Characteristics

Cells
Media
Water
Endotoxin
Product
Model:
Disc Filters:
MW Cutoff:
Filter effective surface area:
Sterilization:
Membrane Treatment:

Operations Conditions

Temp:
Operating Pressure:

Purchase Cost

Filter Housing:
Filter Membrane:

0
0
2000
10.03
58.82

Output (kg/Batch)
0
0
2000
3.34
56.47

Membrane Unit
Omega polyethersulfone membrane
100 kD
1.8 m2
SIP (autoclave)
Sterilized, washed, and reused
0 - 40°C
1 bar
$ 12,000 (x6)
$ 1,000
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Sterile Filtration (PFD 04/P-49)

Description and Function

.2 µm dead end filter to remove bacteria and other impurities from
the serum free media prior to feeding the cultivators and production
bioreactor. The sanitary stainless steel filter housings are designed
for filtration applications. The filter capsules membranes are
disposable ready-to-use filter or depth filter capsules.

Vendor

Sartorious Biotech

PFD Reference

PFD #04

Operation

Batch

Input (kg/Batch)
Materials Handled

Characteristics

Operations Conditions

Purchase Cost

Cells
Media
Water
Endotoxin
Product

Output (kg/Batch)

0
0
2000
3.34
56.47

Model:
Membrane Filter Material:
Size:
Filtration Area:
Max. Differential Pressure:
Membrane Unit Sterilization:
Membrane Sterilization:

Sartopore 2 0.2 µm
Polyethersulfone (PES)
30”
1.8 m2 (18 ft2)
5 bar (75 psi) at 20 °C
SIP
Disposable

Temp:
Pressure:

25 °C
0.5 bar (7.5 psi)

Filter Housing:
Filter Membrane:

$ 2,000
$ 650/unit

0
0
2 00
0
54.21
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High Temperature Inactivation (PFD 05/P-52)
Description and Function

An industrial size autoclave sterilizer that serves to kill the cells
attached to the microcarriers in order to allow for safe disposal.

Vendor

WSF Industries Inc.

PFD Reference

PFD #05

Operation

Batch

Characteristics

Material of Construction:
Finished:
Volume:
Sterilization:

Operations Conditions

Temp:
Pressure:

Purchase Cost

$ 500,000

Stainless Steel 316L
Electro-polished
5,000L
SIP/CIP
250°C
20-30 psi
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10. Overall Process Cost for Stirred Tank Bioreactor Process
10.1. Utility Costs
The major utility needs of the plant consists of electricity and process water.
Electricity is the most expensive and costs approximately $38,250 per batch. This calculation
is based off a $0.085 per kWh rate obtained from a Philadelphia energy provider. 450,000
kWh of energy are used per batch for the tank process. These energy requirements are due to
operation of process machinery, the production bioreactor, the pumps, the WFI still, the clean
steam generators, and other various units.
Process water is the other major utility that will be used to produce monoclonal
antibodies. The plant will require about 108,000 kg/batch, which is approximately
2,052,000kg per year. This water will be used to generate WFI and steam for buffers and SIP
in addition to the water needed for the powder media. At a rate of $0.00473/kg, a rate
obtained from a Philadelphia water company, the costs of process water will be about $9,700
per year.

10.2. Material Resource Costs
The costs of media and buffers can be found in this section. Ex-Cell® ACF CHO dry
powder media can be purchased from Sigma-AldrichTM for $35.20 per kilogram.
Approximately 10,000kg of dry media are needed for each batch when using the tank
process. All of the buffers for the Protein A, Cation Exchange, and Anion Exchange columns
can be purchased from GE Healthcare at a price of $1.24 per kilogram. Approximately
460,000kg of buffers are need per batch for the tank process.
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10.3. Major Unit Operation Costs
Innoculum Prep - Bioreaction
Number

Type

Units

P-02

Bioreactor Rocker
Bag

1
20

200mL

P-03

Mixing Tank

1

150L

P-04
P-05

1
1
1
1

1
1

200L

P-08

Pump
Sterile Filter
Filter Membrane
Pump
TM
WAVE Bioreactor
System
Bag
Pump

P-09

Mixing Tank

1

1,500L

P-10
P-11

P-14

Pump
Sterile Filter
Filter Membrane
Pump
Bioreactor System
Bag
Pump

1
1
1
1
1
1
1

P-15

Mixing Tank

1

P-16
P-17
P-18

Pump
Sterile Filter
Filter Membrane
Pump

1
1
1
1

P-19

Mixing Tank

1

P-20
P-21

Pump
Sterile Filter
Filter Membrane
Pump
Production
Bioreactor

1
1
1
1

P-06
P-07

P-12
P-13

P-22
P-23

Size

2

1.8m

1

1

2

1.8m

2,000L
10,000L
2

1.8m

10,000L
2

1.8m

25,000L

Vendor
GE Healthcare
GE Healthcare
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow

Purchase Cost
($/unit)
$16,480.00
$202.00
$110.00
$13,000.00
$2,000.00
$650.00
$13,000.00

GE Healthcare

$404,500.00

GE Healthcare
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow
GE Healthcare
GE Healthcare
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow

$1,200.00
$13,000.00

Techniserv, Inc

$1200.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$600,000.00
$1,800.00
$13,000.00
$130,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$130,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$900,000.00
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Primary Recovery
Number

Type

Units

P-24

Pump

1

P-25

Storage Tank

1

P-26
P-27
P-28

Pump
Centrifuge
Pump
Centrifugation Pool
Tank

1
1
1

10,000 L/hr

1

25,000L

P-29

Size

25,000L

Vendor
Watson Marlow
Sharpsville
Container
Watson Marlow
Alfa-Laval
Watson Marlow
Sharpsville
Container

Purchase Cost
($/unit)
$13,000.00
$145,000.00
$13,000.00
$480,000.00
$13,000.00
$145,000.00

Protein A Chromatography
Size

Vendor

1
1

2,000L

Watson Marlow
GE Healthcare

Purchase Cost
($/unit)
$13,000.00
$200,000.00

2,000

1L

GE Healthcare

$8,000.00

Watson Marlow
Sharpsville
Container

$13,000.00

Number

Type

Units

P-30
P-31

P-32

Pump
Protein A Column
n-Protein A Sepharose
4 Resin
Pump

P-33

Protein A Pool Tank

1
1

5,000L

$122,000.00

Cation Exchange Chromatography
Number

Type

Units

P-34

Pump
Cation Exchange
Column
Eshmuno S Resin
Pump
Cation Exchange Pool
Tank

1

P-35
P-36
P-37

Size

Watson Marlow

Purchase Cost
($/unit)
$13,000.00

Vendor

1

2,000L

GE Healthcare

$250,000.00

200
1

10L

$15,000.00
$13,000.00

1

5,000L

EMD Millipore
Watson Marlow
Sharpsville
Container

$122,000.00

Anion Exchange Chromatography
Number

Type

Units

P-38

Pump
Anion Exchange
Column
Capto Q Resin
Pump
Anion Exchange Pool
Tank

1

P-39
P-40
P-41

Size

Watson Marlow

Purchase Cost
($/unit)
$13,000.00

Vendor

1

2,000L

GE Healthcare

$250,000.00

40
1

60L

$109,000
$13,000.00

1

25,000L

GE Healthcare
Watson Marlow
Sharpsville
Container

$145,000.00
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Viral Nanofiltration
Number

Type

Units

P-42

Pump
Nanofiltration Housing
Unit

1

Filters

1

P-43

Size

Vendor
Watson Marlow
Asahi Kasei
Bioprocess
Asahi Kasei
Bioprocess

6
1.8m2

Purchase Cost
($/unit)
$13,000.00
$15,000.00
$2,000.00

Final Filtration
Number

Type

Units

P-44
P-45
P-46

Pump
Ultrafiltration Unit
Filters
Pump

1
6
1
1

P-47

Sterile Filter

1

Filter Membrane

1

Pump

1

P-48

Size
2

1.8m

1.8m2

Vendor
Watson Marlow
Pall Corporation
Pall Corporation
Watson Marlow
Sartorious
Biotech
Sartorious
Biotech
Watson Marlow

Purchase Cost
($/unit)
$13,000.00
$12,000.00
$1,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00

10.4. Additional Equipment Costs
Additional Equipment
Purchase Cost
($/Unit)
$15,000.00
$100,000.00

Type

Units

Vendor

Incubators
CIP Skids

2
3

Buffer Transfer Bags

80

Portable Pump
Biowaste and Neutralization
Tanks

3

Thermo Scientific
Sani-matic
HyClone – (Thermo
Scientific)
Watson Marlow

5

Sharpsville Container

$145,000.00

Final Packaging

1

Quality BioResources,
Inc.

$280,000.00

80,000/year
$13,000.00
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Additional Equipment Included in Annual Expenses
Type
Units
Vendor
Biosafety Cabinet
3
Thermo Scientific
Air Generator (HVAC Equipment)
1
Clean Steam Generator
1
Filter Integrity Tester
1
Millipore
Sartorius Stedim
Tube Fuser and Sealer
1
Biotech
Water Treatment Package
1
WFI Still
1
Paul Mueller Co
Biowaste Inactivation System
1
Waste Neutralization System
1
Laboratory Information Management System
1
Refrigeration
2
Thermo Scientific

11. Overall Process Cost for Fluidized Bioreactor Process
11.1. Utility Costs
The major utility needs of the plant consists of electricity and process water.
Electricity is the most expensive and costs approximately $59,500 per batch. This calculation
is based off a $0.085 per kWh rate obtained from a Philadelphia energy provider.
700,000kWh of energy are used per batch for the stirred tank process. These electricity
requirements are higher than the stirred tank process due to the increased number of pumps
and the increased amount of water. Again, electricity is required for operation of process
machinery, the production bioreactor, the pumps, the WFI still, the clean steam generators,
and other various units.
Process water is the other major utility that will be used to produce monoclonal
antibodies. The plant will require about 8,500,000kg/batch, which is approximately 100
million kg per year. This large amount of increased water is due to the increased amount of
media for the fluidized bed process. Again, this water will be used to generate WFI and
steam for buffers and SIP in addition to the water needed to mix with the media. At a rate of
$0.00473/kg, a rate obtained from a Philadelphia water company, the costs of process water
will be about $40,205 per batch.
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11.2. Material Resource Costs
The costs of media, buffers, and microcarriers can be found in this section. Ex-Cell®
ACF CHO dry powder media can be purchased from Sigma-AldrichTM for $35.20 per
kilogram. Approximately 2 million kg of dry media are needed for each batch when using the
fluidized bed system. All of the buffers for the Protein A, Cation Exchange, and Anion
Exchange columns can be purchased from GE Healthcare at a price of $1.24 per kilogram.
Approximately 400,000kg of buffers are need per batch for the fluidized bed process. Lastly,
the CytolineTM 1 microcarriers can be purchased from GE Healthcare at a cost of $4,488 per
kilogram. Approximately 12,000kg of microcarriers are needed for the production bioreactor
for each batch.
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11.3. Major Unit Operation Costs
Innoculum Prep - Bioreaction
Number

Type

Units

P-02

Bioreactor Rocker
Bag

1
30

200mL

P-03

Mixing Tank

1

150L

P-04
P-05

1
1
1
1

1
1

70L

P-08

Pump
Sterile Filter
Filter Membrane
Pump
WAVETM Bioreactor
System
Bag
Pump

P-09

Mixing Tank

1

1,500L

P-10
P-11

P-14

Pump
Sterile Filter
Filter Membrane
Pump
Bioreactor System
Bag
Pump

1
1
1
1
1
1
1

P-15

Mixing Tank

1

P-16
P-17
P-18

Pump
Sterile Filter
Filter Membrane
Pump

1
1
1
1

P-19

Mixing Tank

1

P-20
P-21
P-22

Pump
Sterile Filter
Filter Membrane
Pump

1
1
1
1

P-23

Media Storage Tank

1

P-24
P-25

Pump
Production Bioreactor

1
1

P-06
P-07

P-12
P-13

Size

Vendor

2

1.8m

3

2

1.8m

2,000L
10,000L
2

1.8m

10,000L
2

1.8 m

50,000L
25,000L

GE Healthcare
GE Healthcare
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow

Purchase Cost
($/unit)
$16,480.00
$202.00
$110.00
$13,000.00
$2,000.00
$650.00
$13,000.00

GE Healthcare

$404,500.00

GE Healthcare
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow
GE Healthcare
GE Healthcare
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow
Sharpsville
Container
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow
Sharpsville
Container
Watson Marlow
GE Healthcare

$1,000.00
$13,000.00
$120.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$600,000.00
$1,800.00
$13,000.00
$130,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$130,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00
$165,000.00
$13,000.00
$1,500,000.00
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Primary Recovery
Number

Type

Units

P-26

Pump

1

P-27

Storage Tank

58

P-28

P-30

Pump
Tangential Flow
Filtration
Pump

P-31

TFF Pool Tank

58

P-29

Purchase
Cost ($/unit)
$13,000.00

Size

Vendor

50,000L

58

Watson Marlow
Sharpsville
Container
Watson Marlow

50

Pall Corporation

$500,000.00

50

Watson Marlow
Sharpsville
Container

$13,000.00

50,000L

$165,000.00
$13,000.00

$165,000.00

Protein A Chromatography
Size

Vendor

58
1

2,000L

Watson Marlow
GE Healthcare

Purchase
Cost ($/unit)
$13,000.00
$200,000.00

5

1L

GE Healthcare

$8,000.00

Watson Marlow
Sharpsville
Container

$13,000.00

Number

Type

Units

P-32
P-33

P-34

Pump
Protein A Column
n-Protein A Sepharose
4 Resin
Pump

P-35

Protein A Pool Tank

1

1
5,000L

$122,000.00

Cation Exchange Chromatography
Number

Type

Units

P-36

Pump
Cation Exchange
Column
Eshmuno S Resin
Pump
Cation Exchange Pool
Tank

1

P-37
P-38
P-39

Size

Watson Marlow

Purchase
Cost ($/unit)
$13,000.00

Vendor

1

2,000L

GE Healthcare

$250,000.00

1
1

10L

$15,000.00
$13,000.00

1

5,000L

EMD Millipore
Watson Marlow
Sharpsville
Container

$122,000.00
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Anion Exchange Chromatography
Number

Type

Units

P-40

Pump
Anion Exchange
Column
Capto Q Resin
Pump
Anion Exchange Pool
Tank

1

P-41
P-42
P-43

Size

Watson Marlow

Purchase
Cost ($/unit)
$13,000.00

Vendor

1

2,000L

GE Healthcare

$250,000.00

40
1

60L

$109,000
$13,000.00

1

25,000L

GE Healthcare
Watson Marlow
Sharpsville
Container

$145,000.00

Viral Nanofiltration
Number

Type

Units

P-44

Pump
Nanofiltration Housing
Unit

1

Filters

1

P-45

Size

Vendor

6
1.8m2

Watson Marlow
Asahi Kasei
Bioprocess
Asahi Kasei
Bioprocess

Purchase
Cost ($/unit)
$13,000.00
$15,000.00
$2,000.00

Final Filtration
Number

Type

Units

P-46
P-47

Pump
Ultrafiltration Unit
Filters
Pump
Sterile Filter
Filter Membrane
Pump

1
6
1
1
1
1
1

P-48
P-49
P-50

Size

Vendor
2

1.8 m

1.8m2

Watson Marlow
Pall Corporation
Pall Corporation
Watson Marlow
Sartorious Biotech
Sartorious Biotech
Watson Marlow

Purchase
Cost ($/unit)
$13,000.00
$12,000.00
$1,000.00
$13,000.00
$2,000.00
$650.00
$13,000.00
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Microcarrier Handling
Number

Type

Units

P-51
P-52

Pump
Autoclave Sterilizer

1
1

Size

Vendor

5,000L

Watson Marlow
WSF Industries Inc

Purchase
Cost ($/unit)
$13,000.00
$500,000.00

11.4. Additional Equipment Costs
Additional Equipment
Purchase Cost
($/Unit)
$15,000.00
$100,000.00

Type

Units

Vendor

Incubators
CIP Skids

2
3

Buffer Transfer Bags

80

Portable Pump
Biowaste and Neutralization
Tanks

3

Thermo Scientific
Sani-matic
HyClone (Thermo
Scientific)
Watson Marlow

5

Sharpsville Container

$145,000.00

Final Packaging

1

Quality BioResources,
Inc.

$280,000.00

80,000/year
$13,000.00

Additional Equipment Included in Annual Expenses
Type
Units
Vendor
Biosafety Cabinet
3
Thermo Scientific
Air Generator (HVAC Equipment)
1
Clean Steam Generator
1
Filter Integrity Tester
1
Millipore
Sartorius Stedim
Tube Fuser and Sealer
1
Biotech
Water Treatment Package
1
WFI Still
1
Paul Mueller Co
Biowaste Inactivation System
1
Waste Neutralization System
Laboratory Information Management System
1
Refrigeration
2
Thermo Scientific
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12. Scheduling
Scheduling is an important aspect to consider when building biopharmaceutical plants.
Each process will be operated for about 330 days per year, allowing for about 35 days for
maintenance and any contingency time needed in case of plant shutdown during operation. A
Gantt chart can be used to easily visualize the occupation times of each piece of equipment in a
given process to help identify any bottlenecks or inefficient design strategies. A two-batch Gantt
chart for each process is included below. Only major units are shown and operation time includes
transfer in and out times, loading times, and CIP and SIP times.

12.1. Gantt Chart
12.1.1. Stirred Tank Bioreactor Process
The Gantt chart for the stirred tank bioreactor process is shown in Figure 12.1.
Though this chart only shows two batches (the first batch in green and the second in
purple), 16 total batches can be run every year in about 330 days. The first batch will
require about 33 days and each incremental batch will require an additional 16 days.
12.1.2. Fluidized Bioreactor Process
Figure 12.2 shows the Gantt chart for the fluidized bioreactor process. For this
process, 24 batches can be run every year in about 330 days. The first batch requires
about 32 days and each incremental batch will require an additional 13 days.
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Figure 12.1

Figure 12.2

99

Monoclonal Antibody Production via Fluidized Bioreactor Technology

13. Economic Analysis
The fluidized bioreactor process offers the advantage of a lower batch time, fewer required
batches per year, and a significant increase in product formation. However, it also requires
investment in additional equipment, increases the sizes of various upstream and downstream
unites such as storage tanks or tangential filtration units. A profitability analysis can more
accurately compare the fluidized bioreactor process to the traditional tank process to help
determine which is the most fiscally conservative option.

13.1. Market Analysis
In the European Union (EU), Rituxan®’s patent will expire in 2014 and in 2018 in
the United States (US). This creates an incredible opportunity for generic competition.
With various blockbuster drugs also approaching a “patent cliff,” the biotechnology
market, particularly the generic monoclonal antibody market, will be booming. In 2013,
560kg and 370kg of Rituxan® was sold in the US and EU respectively. Table 13.1 below
shows the projected fractional market share of generic rituximab. It is projected that in
the first year of a patent expiration, a generic is able to capture 50% of the market and
that the market share increases every year until reaching a steady rate of 70%. Assuming
that by 2021, 70% of the international and domestic market will be controlled by
generics, the facility will be designed to produce 650kg of rituximab after accounting for
downstream production losses.
Table 13.1: Expected market share projections for the European Union and United States markets. The expected market share
will determine the amount of generic rituximab sold to customers.

Year
2015
2016
2017
2018
2019
2020
2021

Fractional EU
Market Share
0.50
0.60
0.70
0.70
0.70
0.70
0.70

Fractional US
Market Share

0.50
0.60
0.70

Total Kg Sold
by Facility
279
335
391
391
576
613
650
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13.2. Profitability Analysis
For the profitability analysis, it is assumed that the plant’s effective tax rate will be
22%, which reflects the sector average tax rate, and that the cost of capital for the plant will
be 18%. A higher cost of capital was assumed due to the riskiness of the project and is also a
reflection of the sector average.
The economic analysis shows that the stirred tank process has a net present value (at
18% and a life of 12 years) of about $3.8 billion. It has a return on investment (ROI) of 249%
and an internal rate of return (IRR) of 243%. The fluidized bioreactor process has a net
present value of about $17 billion, an ROI of about 229% and IRR of 226%. The IRR and
ROI values for biotechnology projects are incredibly high due to the high market price of the
product. Furthermore, drug companies rarely see a drug as successful as Rituxan®. The
success of one drug helps pay for the failures of 10,000 others. A high ROI and IRR are to be
expected in processes such as these due to the relatively low investment compared to the
generated earnings. Furthermore, the cost of development is out-of-scope of this project and
therefore not included in the economic analysis. However, each successful drug costs a
company several millions of dollars and therefore the realized ROI or IRR of a
biopharmaceutical process is much less than 500-600%.
13.2.1. Stirred Tank Process

Profitability Measures
The Internal Rate of Return (IRR) for this project is
The Net Present Value (NPV) of this project in 2015 is
ROI Analysis (Third Production Year)
Annual Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

1,611,764,957
(253,790,021)
(1,734,736)
(302,441,565)
1,053,798,635
423,677,306
248.73%

243.03%
$ 3,807,362,600
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13.2.2. Fluidized Bioreactor Process

Profitability Measures
The Internal Rate of Return (IRR) for this project is
The Net Present Value (NPV) of this project in 2015 is

224.53%
$16,625,953,100

ROI Analysis (Third Production Year)
Annual Sales
Annual Costs
Depreciation
Income Tax
Net Earnings
Total Capital Investment
ROI

7,104,371,792
(1,155,142,234)
(20,597,570)
(1,304,299,037)
4,624,332,951
2,020,253,396
228.90%

13.2.3. Price of Generic Rituximab
Currently, pricing information for Rituxan® is available for the United States
market alone. Each unit of Rituxan® (assuming a unit refers to 100mg of product) is sold
for about $1450 per 100mg. The generic version can be marketed for 30% lower prices
than the brand-name drug. Normally, most generic small molecule drugs are marketed at
70% lower prices. However, due to the high cost of production and the high market price
of therapeutic proteins, even a 30% decrease offers a great discount to consumers.
Therefore, generic rituximab will be marketed at about $10.3 million per kg.
13.2.4. Plant Life
The new facility is expected to have a life of about 10 years. Most of the capital
investment (main production units and machinery) normally has a longer lifespan, but the
marketing life of the drug can be assumed to be about 10 years for a preliminary analysis.
In the unfortunate case that the plant ahs to be shut down in as little as five years due to
inability to sell generic rituximab or due to other innovations in the field, the plant will
have some finite salvage value. However, for the purposes of the economic calculations,
it is assumed the plant will operate for 10 years and allow two additional years for design
and construction.
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13.2.5. Input and Cost Summaries
13.2.5.1.
General Information
Process Title:
Product:
Plant Site Location:
Site Factor:
Operating Hours per Year:
Operating Days Per Year:
Operating Factor:

Stirred Tank Process
Monoclonal Antibody Production via Fluidized Bed Bioreactor
Rituximab
Philadelphia, PA
1.00
7920
330
0.9041

Product Information
This Process will Yield
0 kg of Rituximab per hour
0 kg of Rituximab per day
152 kg of Rituximab per year
Price

$10,262,244.00 /kg

Chronology
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Action
Design
Construction
Production
Production
Production
Production
Production
Production
Production
Production
Production
Production

Distribution of
Permanent Investment
100%
0%
0%
0%

Production
Capacity
0.0%
0.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

Depreciation
7 year MACRS

14.29%
24.49%
17.49%
12.49%
8.93%
8.92%
8.93%
4.46%

Product Price

$10,262,244.00
$10,426,439.90
$10,593,262.94
$10,762,755.15
$10,934,959.23
$11,109,918.58
$11,287,677.28
$11,468,280.11
$11,651,772.60
$11,838,200.96
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Variable Cost Summary
Variable Costs at 100% Capacity:
General Expenses
Selling / Transfer Expenses:
Direct Research:
Allocated Research:
Administrative Expense:
Management Incentive Compensation:
Total General Expenses
Raw Materials

$ 15,614,004
$ 156,140,042
$ 7,807,002
$ 31,228,008
$ 19,517,505
$ 230,306,563

$21,364.976000 per kg of Rituximab

$3,250,681

$0.000000 per kg of Rituximab

$0

$7,533.844106 per kg of Rituximab

$1,146,274

Byproducts
Utilities
Total Variable Costs

$ 234,703,518

Fixed Cost Summary

Operations
Direct Wages and Benefits
Direct Salaries and Benefits
Operating Supplies and Services
Technical Assistance to Manufacturing
Control Laboratory

$
$
$
$
$

5,241,600
786,240
314,496
-

Total Operations

$

6,342,336

Wages and Benefits
Salaries and Benefits
Materials and Services
Maintenance Overhead

$
$
$
$

871,240
217,810
871,240
43,562

Total Maintenance

$

2,003,852

General Plant Overhead:
Mechanical Department Services:
Employee Relations Department:
Business Services:

$
$
$
$

505,299
170,805
419,897
526,650

Total Operating Overhead

$

1,622,651

$

387,218

Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$
$
$

800,000

Total Other Annual Expenses

$

800,000

Maintenance

Operating Overhead

Property Taxes and Insurance
Property Taxes and Insurance:
Other Annual Expenses

Total Fixed Costs

$ 11,156,057
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Investment Summary
Bare Module Costs
Fabricated Equipment
Process Machinery
Spares
Storage
Other Equipment
Catalysts
Computers, Software, Etc.

$
$ 14,915,939
$
$
$
$
$
-

Total Bare Module Costs:

$ 14,915,939

Direct Permanent Investment
Cost of Site Preparations:
Cost of Service Facilities:
Allocated Costs for utility plants and related facilities:

$
$
$

745,797
745,797
-

Direct Permanent Investment

$ 16,407,533

Total Depreciable Capital
Cost of Contingencies & Contractor Fees

$

2,953,356

Total Depreciable Capital

$ 19,360,889

Total Permanent Investment
Cost of Land:
Cost of Royalties:
Cost of Plant Start-Up:

$
$
$

387,218
1,936,089

Total Permanent Investment - Unadjusted
Site Factor
Total Permanent Investment

$ 21,684,196
1.00
$ 21,684,196

Working Capital

Total Capital Investment

2016
385,002,844
945,397
(1,084,181)
17,111,238
17,812
401,993,110

Accounts Receivable
Cash Reserves
Accounts Payable
Rituximab Inventory
Raw Materials
Total

$
$
$
$
$
$

Present Value at 18%

$ 340,672,127
$ 362,356,323
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13.2.5.2.

Fluidized Bioreactor Process

General Information
Process Title:
Product:
Plant Site Location:
Site Factor:
Operating Hours per Year:
Operating Days Per Year:
Operating Factor:

Monoclonal Antibody Production via Fluidized Bed Bioreactor
Rituximab
Philadelphia, PA
1.00
7920
330
0.9041

Product Information
This Process will Yield
0 kg of Rituximab per hour
2 kg of Rituximab per day
671 kg of Rituximab per year
Price

$10,262,244.00 /kg

Chronology
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Action
Design
Construction
Production
Production
Production
Production
Production
Production
Production
Production
Production
Production

Distribution of
Permanent Investment
100%
0%
0%
0%

Production
Capacity
0.0%
0.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

Depreciation
7 year MACRS
14.29%
24.49%
17.49%
12.49%
8.93%
8.92%
8.93%
4.46%

Product Price

$10,262,244.00
$10,426,439.90
$10,593,262.94
$10,762,755.15
$10,934,959.23
$11,109,918.58
$11,287,677.28
$11,468,280.11
$11,651,772.60
$11,838,200.96
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Variable Cost Summary
Variable Costs at 100% Capacity:
General Expenses
Selling / Transfer Expenses:
Direct Research:
Allocated Research:
Administrative Expense:
Management Incentive Compensation:
Total General Expenses
Raw Materials

$ 68,823,739
$ 688,237,394
$ 34,411,870
$ 137,647,479
$ 86,029,674
$1,015,150,156

$81,786.793414 per kg of Rituximab

$54,850,313

$0.000000 per kg of Rituximab

$0

$2,569.985019 per kg of Rituximab

$1,723,560

Byproducts
Utilities
Total Variable Costs

$ 1,071,724,029

Fixed Cost Summary

Operations
Direct Wages and Benefits
Direct Salaries and Benefits
Operating Supplies and Services
Technical Assistance to Manufacturing
Control Laboratory

$
$
$
$
$

10,483,200
1,572,480
628,992
-

Total Operations

$

12,684,672

Wages and Benefits
Salaries and Benefits
Materials and Services
Maintenance Overhead

$
$
$
$

10,344,762
2,586,190
10,344,762
517,238

Total Maintenance

$

23,792,952

General Plant Overhead:
Mechanical Department Services:
Employee Relations Department:
Business Services:

$
$
$
$

1,774,051
599,679
1,474,211
1,849,011

Total Operating Overhead

$

5,696,952

$

4,597,672

Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$
$
$

550,000

Total Other Annual Expenses

$

550,000

$

47,322,248

Maintenance

Operating Overhead

Property Taxes and Insurance
Property Taxes and Insurance:
Other Annual Expenses

Total Fixed Costs
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Investment Summary
Bare Module Costs
Fabricated Equipment
Process Machinery
Spares
Storage
Other Equipment
Catalysts
Computers, Software, Etc.

$
$ 177,106,004
$
$
$
$
$
-

Total Bare Module Costs:

$ 177,106,004

Direct Permanent Investment
Cost of Site Preparations:
Cost of Service Facilities:
Allocated Costs for utility plants and related facilities:

$
$
$

8,855,300
8,855,300
-

Direct Permanent Investment

$ 194,816,605

Total Depreciable Capital
Cost of Contingencies & Contractor Fees

$

35,066,989

Total Depreciable Capital

$ 229,883,593

Total Permanent Investment
Cost of Land:
Cost of Royalties:
Cost of Plant Start-Up:

$
$
$

4,597,672
22,988,359

Total Permanent Investment - Unadjusted
Site Factor
Total Permanent Investment

$ 257,469,625
1.00
$ 257,469,625

Working Capital

Total Capital Investment

Accounts Receivable
Cash Reserves
Accounts Payable
Rituximab Inventory
Raw Materials
Total

2016
$ 1,697,023,711
$
3,985,957
$ (13,949,722)
$ 75,423,276
$
300,550
$ 1,762,783,771

Present Value at 18%

$ 1,493,884,552
$ 1,751,354,176
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13.2.6. Fixed Costs
For both designs, the plant will run for 24 hours and require 3 total shifts. Each
shift for the stirred tank process will have 20 operators and each shift for the fluidized
bed reactor will have 40 operators. Because this is a brownfield site, annual expenses
were estimated to include the cost of using the site’s existing equipment such as quality
control labs, waste treatment systems, and WFI stills. The operators will have direct
wages and benefits totaling $42.00/hr. Engineers and scientists will be placed throughout
the facility for the production of monoclonal antibody. They will work with the seed
train, production, and purification process and will operate all the machinery. There will
also be people working in the culture labs and managing the material, for example
measuring media, buffer, etc. For the fluidized bed process, many more workers are
needed per shift in order to manage all of the media and buffer prep solutions. There
needs to be maintenance and utility personnel, IT and auto control personnel, and people
to manage quality control, CIP & SIP procedures, and waste management. Again,
additional workers are needed to manage the fluidized bed facility because it is larger in
surface area due to the increased number of storage tanks and pumps. For the facilities,
regulatory personnel are also needed. Lastly, management positions will be needed to
manage the engineering, financial, and human resources related issues.
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13.2.6.1.

Stirred Tank Process

Fixed Costs
Operations
Operators per Shift:
Direct Wages and Benefits:
Direct Salaries and Benefits:
Operating Supplies and Services:
Technical Assistance to Manufacturing:
Control Laboratory:

20
$42
15%
6%
$0.00
$0.00

(assuming
3 shifts)
/operator hour
of Direct Wages and Benefits
of Direct Wages and Benefits
per year, for each Operator per Shift
per year, for each Operator per Shift

4.50%
25.00%
100.00%
5.00%

of Total Depreciable Capital
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits

Maintenance
Wages and Benefits:
Salaries and Benefits:
Materials and Services:
Maintenance Overhead:
Operating Overhead
General Plant Overhead:
Mechanical Department Services:
Employee Relations Department
Business Services
Property Taxes and Insurance
Property Taxes and Insurance:

7.10%
2.40%
5.90%
7.40%

of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits

2.00% of Total Depreciable Capital

Straight Line Depreciation
Direct Plant:
8.00% of Total Depreciable Capital, less

1.18 times the Allocated Costs
for Utility Plants and Related Facilities
1.18 times the Allocated Costs for Utility Plants and Related Facilities

Allocated Plant:
6.00% of
Other Annual Expenses
Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$0
$0
$800,000

Depletion Allowance
Annual Depletion Allowance:

$0
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13.2.6.2.

Fluidized Bioreactor Process

Fixed Costs
Operations
Operators per Shift:
Direct Wages and Benefits:
Direct Salaries and Benefits:
Operating Supplies and Services:
Technical Assistance to Manufacturing:
Control Laboratory:

40
$42
15%
6%
$0.00
$0.00

(assuming
3 shifts)
/operator hour
of Direct Wages and Benefits
of Direct Wages and Benefits
per year, for each Operator per Shift
per year, for each Operator per Shift

4.50%
25.00%
100.00%
5.00%

of Total Depreciable Capital
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits
of Maintenance Wages and Benefits

Maintenance
Wages and Benefits:
Salaries and Benefits:
Materials and Services:
Maintenance Overhead:
Operating Overhead
General Plant Overhead:
Mechanical Department Services:
Employee Relations Department
Business Services

7.10%
2.40%
5.90%
7.40%

Property Taxes and Insurance
Property Taxes and Insurance:

of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits
of Maintenance and Operations Wages and Benefits

2.00% of Total Depreciable Capital

Straight Line Depreciation
Direct Plant:
8.00% of Total Depreciable Capital, less

1.18 times the Allocated Costs
for Utility Plants and Related Facilities
1.18 times the Allocated Costs for Utility Plants and Related Facilities

Allocated Plant:
6.00% of
Other Annual Expenses
Rental Fees (Office and Laboratory Space):
Licensing Fees:
Miscellaneous:

$0
$0
$550,000

Depletion Allowance
Annual Depletion Allowance:

$0

13.2.7. Raw Materials and Equipment Costs
Equipment costs were combined for similar units. The bare module cost was
assumed to be 3.21 for all equipment.

Bare Module Factor Calculator:
Cost of Installation Materials:
Cost of Installation Labor:
Cost for Freight, Insurances, and Taxes:
Cost of Construction Overhead:
Cost of Contractor Engineering Expenses:
Total Derived Bare Module Factor:

71%
54%
9%
57%
30%

of Equipment Purchase Cost
of Equipment Purchase Cost
of Equipment Purchase Cost
of Equipment Purchase Cost
of Equipment Purchase Cost

3.21 of Equipment Purchase Cost
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13.2.7.1.
Raw Materials
Raw Material:
1 Resin
2 Media
3 Rituximab
4 Buffer
5 Microcarriers
6
7
8
9
10
Total Weighted Average:

Stirred Tank Process
Unit:
L
kg
kg
kg
kg

Required Ratio:
3.947
52.755
1
3000
0

L per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab

Cost of Raw Material:
$4000.000 per L
$35.200 per kg
$0.000E+00 per kg
$1.240 per kg
$4488.000 per kg

$21364.976 per kg of Rituximab

Equipment Costs
Equipment Description
Name
PID Controls
Bioreactor Rocker
Pump
Mixing Tank
Sterile Filter
Ultrafiltration Unit
Production Bioreactor
Centrifuge
Storage Tank
Protein A Column
Cation Ex Column
Anion Ex Column
Nanofiltration Unit

13.2.7.2.
Raw Materials
Raw Material:
1 Resin
2 Media
3 Rituximab
4 Buffer
5 Microcarriers
6
7
8
9
10
Total Weighted Average:

Type
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery

Purchase Cost Bare Module Cost
$162,500
$1,020,980
$299,000
$260,230
$10,000
$120,000
$900,000
$480,000
$679,000
$200,000
$250,000
$250,000
$15,000

$521,625
$3,277,346
$959,790
$835,338
$32,100
$385,200
$2,889,000
$1,540,800
$2,179,590
$642,000
$802,500
$802,500
$48,150

Fluidized Bioreactor Process
Unit:
L
kg
kg
kg
kg

Required Ratio:
0.895
3080.597
1
517.91
17.2585

L per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab
kg per kg of Rituximab

Cost of Raw Material:
$4000.000 per L
$0.035 per kg
$0.000E+00 per kg
$1.240 per kg
$4488.000 per kg

$81786.793 per kg of Rituximab
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Equipment Costs
Equipment Description
Name
PID Controls
Bioreactor Rocker
Pump
Mixing Tank
Sterile Filter
Ultrafiltration Unit
Fluidized Bioreactor
Tangential Flow Filtration
Storage Tanks
Protein A Column
Cation Ex Column
Anion Ex Column
Nanofiltration Unit
Autoclave Sterilizer

Type

Purchase Cost Bare Module Cost

Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery
Process Machinery

$1,620,000
$3,329,980
$2,444,000
$405,230
$10,000
$72,000
$1,500,000
$25,000,000
$19,529,000
$200,000
$250,000
$250,000
$15,000
$500,000

$5,200,200
$10,689,236
$7,845,240
$1,300,788
$32,100
$385,200
$4,815,000
$80,250,000
$62,688,090
$642,000
$802,500
$802,500
$48,150
$1,605,000

13.2.8. Other Variable Costs and Working Capital
For the purposes of working capital, it was assumed that about one percent of
sales would be spent on selling/transfer costs paid to a sister facility. Ten percent of sales
would be recycled back into research and development. Furthermore, the accounts
payable and receivable periods were extended to 90 days.
13.2.8.1.

Stirred Tank Process

Other Variable Costs
General Expenses
Selling / Transfer Expenses:
Direct Research:
Allocated Research:
Administrative Expense:
Management Incentive Compensation:

1.00%
10.00%
0.50%
2.00%
1.25%

of Sales
of Sales
of Sales
of Sales
of Sales

Working Capital
Accounts Receivable
Cash Reserves (excluding Raw Materials)
Accounts Payable
Rituximab Inventory
Raw Materials

!
!
!
!
!

90
30
90
4
2

Days
Days
Days
Days
Days
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13.2.8.2.

Fluidized Bioreactor Process

Other Variable Costs
General Expenses
Selling / Transfer Expenses:
Direct Research:
Allocated Research:
Administrative Expense:
Management Incentive Compensation:

1.00%
10.00%
0.50%
2.00%
1.25%

of Sales
of Sales
of Sales
of Sales
of Sales

Working Capital
Accounts Receivable
Cash Reserves (excluding Raw Materials)
Accounts Payable
Rituximab Inventory
Raw Materials

!
!
!
!
!

90
30
90
4
2

Days
Days
Days
Days
Days

13.2.9. Utilities
As described in the previous section 10, large amounts of process water and
electricity will be required for both processes.
13.2.9.1.
Utilities
Utility:
1 High Pressure Steam
2 Low Pressure Steam
3 Process Water
4 Cooling Water
5 Electricity
6
7
8
9
10
Total Weighted Average:

13.2.9.2.
Utilities
Utility:
1 High Pressure Steam
2 Low Pressure Steam
3 Process Water
4 Cooling Water
5 Electricity
6
7
8
9
10
Total Weighted Average:

Stirred Tank Process
Unit:
lb
lb
kg
lb
kWh

Required Ratio
0
0
20368.73275
0
8.75E+04

Utility Cost
lb per kg of Rituximab
lb per kg of Rituximab
kg per kg of Rituximab
lb per kg of Rituximab
kWh per kg of Rituximab

per lb
$0.000E+00 per lb
$4.730E-03 per kg
per lb
$0.085 per kWh

$7533.844 per kg of Rituximab

Fluidized Bioreactor Process
Unit:
lb
lb
kg
lb
kWh

Required Ratio
0
0
157107.69
0
2.15E+04

Utility Cost
lb per kg of Rituximab
lb per kg of Rituximab
kg per kg of Rituximab
lb per kg of Rituximab
kWh per kg of Rituximab

per lb
$0.000E+00 per lb
$4.730E-03 per kg
per lb
$0.085 per kWh

$2569.985 per kg of Rituximab
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13.3. Sensitivity Analysis
A sensitivity analysis must be conducted to determine the effect of key variables on
the profitability of a plant. Furthermore, a sensitivity analysis will help determine which
process design is superior.
13.3.1. Variable Cost
In the base cases for both designs, the variable costs for the stirred tank process
are about $235 million and about $1 billion for the fluidized bioreactor. There is a
significant difference between the two cases because variable costs were calculated as a
percentage of products produced. In terms of variable costs per kg, the stirred tank costs
$1.5 million per kg while the fluidized bioreactor costs $1.6 million per kg. The fluidized
bioreactor process does have a higher variable cost to produce the same amount of
product. However, other factors such as total permanent investment, product price, and
ultimately the cash flow from revenue can affect the profitability of a project.
Furthermore, changes in product price and variable costs, which may positively or
negatively impact revenue, can drastically change the internal rate of return for the
processes. For both processes, the internal rates of return are extremely high, but can
yield negative IRR values for low variable costs and low product prices.
Table 13.2: The effect of variable costs and product prices on the internal rate of return of the stirred tank process.
Sensitivity Analyses

Product Price
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$102,622
$2,134,547
$4,166,471
$6,198,395
$8,230,320
$10,262,244
$12,294,168
$14,326,093
$16,358,017
$18,389,941
$20,421,866

$2,347,035
0.08%
205.86%
249.20%
268.17%
278.82%
285.64%
290.38%
293.86%
296.53%
298.65%
300.36%

$48,818,332
Negative IRR
175.45%
230.68%
254.86%
268.43%
277.12%
283.16%
287.60%
291.00%
293.69%
295.87%

$95,289,628
Negative IRR
145.05%
212.16%
241.55%
258.04%
268.60%
275.93%
281.33%
285.47%
288.73%
291.38%

$141,760,925
Negative IRR
114.63%
193.64%
228.23%
247.65%
260.07%
268.71%
275.06%
279.93%
283.78%
286.90%

$188,232,222
Negative IRR
84.16%
175.13%
214.92%
237.26%
251.55%
261.49%
268.80%
274.40%
278.82%
282.41%

Variable Costs
$234,703,518
Negative IRR
53.53%
156.61%
201.61%
226.86%
243.03%
254.27%
262.53%
268.86%
273.87%
277.93%

$281,174,815
Negative IRR
22.12%
138.09%
188.30%
216.47%
234.51%
247.04%
256.26%
263.33%
268.91%
273.44%

$327,646,111
Negative IRR
-12.92%
119.56%
174.98%
206.08%
225.98%
239.82%
249.99%
257.79%
263.96%
268.95%

$374,117,408
Negative IRR
Negative IRR
101.03%
161.67%
195.69%
217.46%
232.60%
243.73%
252.26%
259.00%
264.47%

$420,588,704
Negative IRR
Negative IRR
82.47%
148.35%
185.29%
208.94%
225.37%
237.46%
246.72%
254.04%
259.98%

$467,060,001
Negative IRR
Negative IRR
63.87%
135.04%
174.90%
200.42%
218.15%
231.19%
241.19%
249.09%
255.49%
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Table 13.3: The effect of variable costs and product prices on the internal rate of return of the fluidized bioreactor
process.
Sensitivity Analyses

Product Price
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$102,622
$2,134,547
$4,166,471
$6,198,395
$8,230,320
$10,262,244
$12,294,168
$14,326,093
$16,358,017
$18,389,941
$20,421,866

$10,717,240
-5.73%
161.27%
213.27%
239.35%
255.03%
265.49%
272.97%
278.58%
282.95%
286.44%
289.30%

$222,918,598
Negative IRR
136.79%
196.92%
227.08%
245.20%
257.30%
265.94%
272.43%
277.48%
281.52%
284.83%

$435,119,956
Negative IRR
112.28%
180.57%
214.80%
235.37%
249.11%
258.92%
266.28%
272.01%
276.60%
280.35%

$647,321,314
Negative IRR
87.73%
164.22%
202.53%
225.55%
240.91%
251.90%
260.14%
266.55%
271.68%
275.88%

$859,522,672
Negative IRR
63.04%
147.86%
190.25%
215.72%
232.72%
244.87%
253.99%
261.08%
266.76%
271.41%

Variable Costs
$1,071,724,029 $1,283,925,387 $1,496,126,745 $1,708,328,103 $1,920,529,461 $2,132,730,819
Negative IRR
Negative IRR
Negative IRR
Negative IRR
Negative IRR
Negative IRR
37.87%
10.87%
Negative IRR
Negative IRR
Negative IRR
Negative IRR
131.51%
115.14%
98.76%
82.36%
65.90%
49.31%
177.97%
165.70%
153.42%
141.14%
128.86%
116.58%
205.90%
196.07%
186.24%
176.41%
166.59%
156.76%
224.53%
216.34%
208.14%
199.95%
191.76%
183.57%
237.85%
230.82%
223.80%
216.77%
209.75%
202.73%
247.84%
241.69%
235.55%
229.40%
223.25%
217.10%
255.62%
250.15%
244.69%
239.22%
233.76%
228.29%
261.84%
256.92%
252.00%
247.08%
242.16%
237.24%
266.94%
262.46%
257.99%
253.52%
249.04%
244.57%

13.3.2. Overall Product Yield
In the base case, it is assumed that 85% of the product will be recovered after
downstream purification. However, technical errors or errors in process design may often
lower the yield of a process. Assuming only the yield changes but all other costs remain
constant, product yield can dramatically change the profitability of a project. For the
stirred tank process, in the lower limit of only 5% yield, the NPV is about $175 million,
the IRR and ROI are about 115%. In the upper limit of complete product recovery, the
ROI and IRR are approximately 250% and the NPV is about $4.5 billion. On the other
hand, the range of 5% to 100% product yield for the fluidized bioreactor process yields
an NPV range of $654 million to $19.6 billion and IRR and ROI ranges of 65% to 230%.
For all product yields, the fluidized bioreactor process is the fiscally superior process.
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Figure 13.1: The impact of product yield on net present value of project, the internal rate of return, and the
return on investment for the stirred tank process.
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Figure 13.2: The impact of product yield on net present value of project, the internal rate of return, and the
return on investment for the fluidized bioreactor process.
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13.3.3. Product Price
In the base case, it is assumed that the product will be sold for about
$10.3MM/kg. Due to the unpredictability of pharmaceutical markets, the product’s
selling price may change due to an increase in process costs or a decrease in the demand
for the drug. For the stirred tank process, given the range of product price to be
$100,000/kg to $20.5MM/kg, the NPV ranges from -$26MM to $7.6 billion and the IRR
and ROI values range from negative values to 255%. For the fluidized bioreactor process,
the NPV ranges from -$340MM to $34 billion and the IRR and ROI values range from
negative values to 245%. In the case that the product price is greater than $105,000/kg,
the fluidized bioreactor process is more favorable.
13.3.3.1.

Stirred Tank Process
NPV (18%, 12 years)!
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Figure 13.3: The impact of product price on net present value of project, the internal rate of return, and the
return on investment for stirred tank process.
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13.3.3.2.

Fluidized Bioreactor Process
NPV (18%, 12 years)!

IRR!

ROI!

$40.00 !

250%!

$35.00 !
200%!
$30.00 !
$25.00 !

150%!

$20.00 !

Percent!

NPV in Billions (USD)!

118

100%!

$15.00 !
$10.00 !

50%!
$5.00 !
$- !
$- !

0%!
$5.00 !

$10.00 !

$15.00 !

$20.00 !

Product Price in Millions ($/kg)!
Figure 13.4: The impact of product price on net present value of project, the internal rate of return, and the return on
investment for the fluidized bioreactor process.

13.3.4. Plant Life
In the base case, it is assumed the plant has an operational life of 10 years. For
both processes, if as the life span increases, the NPV also increases but then levels out to
an approximately constant value. Regardless of plant life, the fluidized bioreactor process
has a significantly larger NPV.
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Figure 13.5: The impact of plant life on the net present value of the project for both processes.

13.3.5. Cost of Capital
The cost of capital determines the riskiness of a project and gives a minimum
value of return required for a project to be acceptable. The cost of capital of the project is
assumed to be 18% for the base case. However, as the cost of capital increases, the NPV
of the project will decrease. Regardless of the cost of capital, the fluidized bioreactor
consistently has a significantly higher NPV of the project.

Stirred Tank NPV

$30.00

FB NPV

$25.00
NPV (USD in billions)
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Figure 13.6: The impact of cost of capital on the net present value of the project for both processes.
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13.3.6. Differential Present Worth Analysis
To ultimately determine which process is preferable the after-tax cash flows
have to be analyzed for both projects. The after-tax cash flow includes capital costs,
working capital, variable and fixed costs, depreciation, and taxes.
Table 13.4: The after-tax cash flow for the stirred tank process.
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Sales
1,561,400,400
1,586,382,800
1,611,765,000
1,637,553,200
1,663,754,000
1,690,374,100
1,717,420,100
1,744,898,800
1,772,817,200
1,801,182,300

Capital Costs Working Capital
(21,684,196)
(401,993,100)
401,993,100

Var Costs
Fixed Costs Depreciation Taxible Income
(234,703,518) (11,156,057) (2,766,700)
1,312,774,200
(238,458,774) (11,334,554) (4,741,500)
1,331,848,000
(242,274,115) (11,515,906) (3,386,200)
1,354,588,700
(246,150,501) (11,700,161) (2,418,200)
1,377,284,400
(250,088,909) (11,887,364) (1,728,900)
1,400,048,800
(254,090,331) (12,077,561) (1,727,000)
1,422,479,200
(258,155,776) (12,270,802) (1,728,900)
1,445,264,600
(262,286,269) (12,467,135)
(863,500)
1,469,281,900
(266,482,849) (12,666,609)
1,493,667,700
(270,746,575) (12,869,275)
1,517,566,400

Taxes
(292,748,642)
(297,002,109)
(302,073,284)
(307,134,412)
(312,210,893)
(317,212,868)
(322,294,004)
(327,649,868)
(333,087,906)
(338,417,313)

Cash Flow
(423,677,306)
1,022,792,208
1,039,587,395
1,055,901,652
1,072,568,122
1,089,566,882
1,106,993,351
1,124,699,515
1,142,495,547
1,160,579,835
1,581,142,223

Table 13.5: The after-tax cash flow for the stirred tank process.
Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Sales
6,882,373,900
6,992,491,900
7,104,371,800
7,218,041,700
7,333,530,400
7,450,866,900
7,570,080,800
7,691,202,100
7,814,261,300
7,939,289,500

Capital Costs Working Capital
(257,469,625) (1,762,783,800)
1,762,783,800

Var Costs
(1,071,724,029)
(1,088,871,614)
(1,106,293,560)
(1,123,994,257)
(1,141,978,165)
(1,160,249,815)
(1,178,813,812)
(1,197,674,833)
(1,216,837,631)
(1,236,307,033)

Fixed Costs
(47,322,248)
(48,079,404)
(48,848,674)
(49,630,253)
(50,424,337)
(51,231,127)
(52,050,825)
(52,883,638)
(53,729,776)
(54,589,452)

Depreciation Taxible Income
(32,850,400)
5,730,477,300
(56,298,500)
5,799,242,400
(40,206,600)
5,909,022,900
(28,712,500)
6,015,704,800
(20,528,600)
6,120,599,300
(20,505,600)
6,218,880,300
(20,528,600)
6,318,687,500
(10,252,800)
6,430,390,800
6,543,693,900
6,648,393,000

Taxes
(1,260,705,005)
(1,275,833,331)
(1,299,985,042)
(1,323,455,050)
(1,346,531,846)
(1,368,153,674)
(1,390,111,255)
(1,414,685,971)
(1,439,612,655)
(1,462,646,457)

Cash Flow
(2,020,253,396)
4,502,622,656
4,579,707,573
4,649,244,516
4,720,962,182
4,794,596,061
4,871,232,279
4,949,104,873
5,025,957,616
5,104,081,230
6,948,530,301

Next, the stirred tank process is chosen as the “base case” because it has the
lowest initial investment. The fluidized bioreactor process is chosen as the “alternative.”
For the years 2015 to 2026, the cash flow of the stirred tank process was subtracted from
the cash flow for the fluidized bioreactor process.
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Table 13.6: The after-tax cash flow for the stirred tank process.

Year
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

(FB-Tank) Cash Flows
$
$
(1,596,576,090)
$
3,479,830,448
$
3,540,120,179
$
3,593,342,865
$
3,648,394,060
$
3,705,029,179
$
3,764,238,928
$
3,824,405,359
$
3,883,462,068
$
3,943,501,394
$
5,367,388,078

Then, the net present value of the differential cash flow amounts is calculated to
determine which process is more favorable. The NPV was calculated for costs of capital
ranging from 5% to 30%. For all values, the differential NPV was extremely positive
indicating the fluidized bioreactor is the more favorable process.

Differential NPV
Differential NPV in Billions
(USD)
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Figure 13.7: Differential net present value of the difference in cash flows between the two processes for
varying costs of capital.
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14.

Additional Consideration
Along with creating a cost-effective design to produce rituximab, FDA
regulations and good manufacturing practices (GMP) must always be followed.
Furthermore, plants of this caliber will have significant waste requirements and all
disposal must also abide by the rules instated by the Environmental Protection Agency.

14.1. Environmental Concerns
The monoclonal antibody production process creates biological and non-biological
waste. First, several disposable units are used throughout the process which must be
sterilized and disposed properly. Second, a variety of buffers are also used throughout
downstream purification. Third, a significant amount of biowaste is generated. Any streams
containing living cells and viruses are considered class II biohazarads and must be treated by
the biowaste inactivation package. This package will heat the waste to 80°C for one minute
and inactivate the CHO cells. After inactivation, the waste is combined with non-biological
waste in the waste neutralization tank (which neutralizes content pH to 7.0). This waste can
then be safely disposed into the sewage system.
All disposable bags and filter membranes must be autoclaved or sterilized (if
autoclaving is not possible for a certain unit) to thoroughly kill all cells and toxins. A
contract waste disposal facility will be responsible for handling all landfill waste.
Unfortunately, recycling services still do not exist for disposable bag bioreactors, which
results in a significant carbon footprint for the plant.

14.2. Current Good Manufacturing Practices
Following good manufacturing practices, as set forth by the United States Food and
Drug Administration (FDA), quality materials and units must be used, a strictly regulated and
well-trained staff must be on the floor at all times to monitor plant and product safety, and
the plant layout must be approved. To help ensure that product from every batch is
consistently safe, operators will monitor various quality checkpoints throughout the process.
These checkpoints are usually placed strategically throughout the process, especially at key
decisions points. For example, there will be in-process quality checks after each
chromatography column as well as a check at the end of the production process. Several
other quality checks will also be routinely performed. A final quality check will be
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performed at the end of the purification process before the drug is shipped to a contract
facility for final packaging and shipping.
All quality checks involve removing small samples from transfer streams and testing
the samples in a quality control lab. Every check is documented and follows a validation
protocol; these documents are stored to provide reference for the manufacturer and the FDA
(refer to FDA’s Code of Federal Regulations Title 21, Subchapter C). Furthermore, sterility
throughout the process is maintained by using standard CIP and SIP techniques (see
Appendix G). As discussed before, disposable units such as the bag bioreactors help
eliminate cross contamination and increase the sterility of the process.
It is also important to note that changes in facility design or innovative facility ideas
such as the fluidized bioreactor design require FDA approval before operating. In general,
the FDA will analyze new designs and facilities on the basis of maintain product integrity. As
long as sufficient trials can prove the consistency and safety of a design and as long as the
process can produce the desired drug at the mandated purity level, a new design can receive
FDA approval.

14.3. Plant Layout
Designing a plant is equally as important as designing the process. In a
biopharmaceutical plant, all rooms must comply with stringent quality standards in order to
avoid cross contamination during operation. Figure 14.1 shows a sample plant layout. The
manufacturing and purification chambers are completely separated. A separate room is used
for the cell bank and preparatory areas. Finally, quality control has been placed at the far side
of the plant to ensure ample testing space and to decrease the any possibility of sample
contamination. Similarly, the autoclave and waste area rooms are located further away from
the main process area. In general, the plant will be equipped with air locks where needed,
include air purification filters in each room, and include a closed layout so that each room
can be completely isolated from the remainder of the plant in case of emergencies or spillage.
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Figure 14.1: Sample facility design.
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15.

Conclusions and Recommendations
Ultimately, it is recommended that the fluidized bioreactor process be
implemented for the new facility. However, before the process is implemented, pilotscale studies should be conducted to verify that the calculations and assumptions made in
the project are applicable on a larger scale. Assuming an 85% yield for the overall
process and capturing 70% of the domestic and European markets, the overall production
goal is 650 kg of rituximab. The fluidized bioreactor process requires only one process
running for 212 days per year while the traditional stirred tank process requires 4 parallel
processes running for 325 days to reach the production goal. Furthermore, the overall
product yield per day for the fluidized bioreactor process is about 7-fold greater. An
incremental analysis between the two processes at an assumed MARR of 18% gives a
differential present worth of about $13 billion indicating that it is a favorable project. The
fluidized bioreactor process has a higher total permanent investment but ultimately offers
a more profitable payout.
The fluidized bioreactor process is also superior to the stirred tank process for
significant changes in plant life, variable cost, overall product yield, product price, and
cost of capital. It is an extremely innovative process that requires deviation from the
traditional stirred tank structure, but ultimately offers the solution to a key industry
problem. It allows cells to grow to a higher cell density by two orders of magnitude,
which ultimately allows for increased product formation. Despite disadvantages including
increased media requirements and a heavier load on downstream purification, the
fluidized bioreactor process is superior to the traditional stirred tank process.
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Appendix A: Minimum Fluidization Velocity Calculations
Particle Volume Calculation
! = 4!"#$
Where a = major axis radius, b = minor axis radius, and c = vertical axis radius.
Particle Surface Area Calculation
!" = 4!(

!"

!.!

+ !" !.! + !"
3

Effective Spherical Diameter
! =!

!.!

)!/!.!

6∗!
!"

Three values were calculated for D; Dmax = 1.31E-03 m, Davg = 9.12E-04 m, and Dmin = 4.98E-04 m.
Minimum fluidization velocities were calculated for each of the three diameter sizes
using the Ergun equation coupled with the bed mass balance:
! !! − ! !! = !

150!! (1 − !! )
1.75!! 1 !
!!" + ! !
!
! !!"
!
!
!! !!
!! !! !!
!!

Values
ρs = 1320 kg/m3; ρf = 992.9 kg/m3; µf = 6.73E-4 kgm-1s-1; Φs = 0.99; εM = 0.35.
Solving for
Dmax, VoM = 0.003158 m/s
Davg, VoM = 0.001643 m/s
Dmin, VoM = 0.000507 m/s
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Appendix B: Nutrient Transport in a Fluidized Bed Reactor
Cell-liquid mass transport. For Glucose, in microcarrier culture
[S]b defined as the concentration of species S, glucose, in the bulk
[S]s defined as the concentration of species S, glucose, at the surface of the cell
Y defined as the cell surface coverage on the microcarrier
RS is defined as the uptake rate per cell of species S.
ShS is the Sherwood Number, given by the relation below.
DS is the diffusion coefficient for glucose in media at 37oC.
!

!/!

!ℎ! = 2 + !0.552!" ! !"!
Where Sc is the Schmidt Number which is the ratio of the viscous diffusion rate
to the molecular mass diffusion rate.
!!
!"!! = !
!! !!
And Re is the Reynold’s Number, given by the correlation for flow in an annular
channel
!(!! − !! )!!
!" = !
!!
The Sherwood number for the packed bed bioreactor, ShS,pb = 16;
The Sherwood number for the fluidized bioreactor, ShS,fb = 338.3.
The normalized concentration gradient of Glucose between the bulk medium and
at the cell surface is given by the expression:
[!]! − [!]!
!!! !!
=!
[!]!
!! [!]! !ℎ!
Using values of Y = 3.53E+08 cell/m2; RS = 4.03E-02 mol cell-1day-1; DS =
0.0000864 m2day-1; de = 0.000911795 m; [S]b = 44.406 mol/m3; and the
Sherwood Relations given above,
[!]! ![!]!

= 0.01 for the fluidized bed bioreactor

[!]!
[!]! ![!]!
[!]!

= 0.27 for the packed bed bioreactor
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Appendix C: Fluidized Bed versus Packed Bed—Nutrient
Composition Temporal Analysis
Assumptions:
1) Media has 8 g/L of glucose initially and the reactor has been charged initially with media.
2) Cells in exponential growth phase (µnet = µg)
3) No notable cell loss from the reactor, nor notable gain from the incoming stream.
4) Glucose consumption is solely due to metabolic consumption of glucose by the cell. No
glucose consumption is attributed directly to product formation.
5) All reactor systems are well mixed, such that there exists no spatial dependence on cell or
substrate concentrations inside the reactor at a given time point.
Cell Growth
X is defined as cell concentration within the reactor
µnet is defined as the specific growth rate of the cell culture
!"
= ! !!"# !
!"
Solving for µnet:
!
ln
= ! !!"# !
!!
t = 12.8 days; µnet = 0.3325 day-1
Substrate Consumption
Glucose mass balance is given by the equation below:
!"
!! !!"#
!!
= !! !!! − !(!) − !
!(!)!
!"
!!
!

Where
VR is the Volume of the Reactor (L);
F is the flow rate of the nutrient rich stream through the reactor (L/day);
So is the concentration of glucose at time zero (g Glucose/L);
S is concentration of glucose in the reactor at time t (g Glucose/L);
µnet is the specific growth rate calculated above (day-1);
YX/S is the yield coefficient of cells on glucose (g cell/g glucose);
X(t) is the concentration of cells in the reactor at time t (g cell/L).
This equation was solved as follows:
!"
!! !!"#
!!
= !! !!! − !(!) − !
!(!)!
!"
!!
!

!"
!
!!"#
=!
!!! − !(!) − !
!(!)!
!"
!!
!!
!

!"
!
!
!!"#
+ ! ! = ! !! − !
!(!)!
!"
!!
!!
!!
!
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Which leads to the final result that:
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With values of YX/S = 0.411 g cell/g glucose; Xo = 1.9 g cell/L; VR = 20000 L;
µnet = 0.3325 day-1;
So = 8 g/L.
For Batch reactor, F = 0 L/day; for the Packed Bed Bioreactor, F = 106262.2 L/day; for the
Fluidized Bioreactor, F = 671152 L/day. These values were substituted into the equation and
plotted for each bioreactor confirmation over the entire growth time of 12.8 days. The results are
plotted below:
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Figure 1: The Glucose concentration plotted over the total growth time in different reactor confirmations. The blue
line corresponds to batch operation, the red line corresponds to packed bed operation, and the green line corresponds
to a fluidized bioreactor operation. In the packed bed and batch operation, the reactor will become nutrient deprived
(<4g/L of glucose) before the end of the growth period. The fluidized bed bioreactor will be able to sustain cell
growth and culture throughout the entirety of the growth period, having 4.78 g/L of glucose by the end of the 12.8
day growth period.
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Appendix D: Fluidized Bed versus Packed Bed—Nutrient
Composition Spatial Analysis
Assumptions:
1) Media has 8 g/L of glucose initially and the reactor has been charged initially with media.
2) Cells in exponential growth phase (µnet = µg)
3) No notable cell loss from the reactor, nor notable gain from the incoming stream.
4) Glucose consumption is solely due to metabolic consumption of glucose by the cell. No
glucose consumption is attributed directly to product formation.
With spatial gradients, the diffusion equation becomes
!"
+ ! ∇ −!! ∇! + !∇! = !!
!"
Where
!! = !

!!"#
!(!)
!!
!

u = 0.0005 m/s in the + y direction;
DS = DS = 0.0000864 m2day-1
These numbers were programmed into the Comsol Multiphysics 2D Transport of Diluted Species
module. The results are seen in Figure 2 below.
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Figure D1: Comsol Multiphysics surface plots of Glucose Concentration Gradients in a Packed Bed Reactor.
Surface concentration gradients are shown when the reactor was initially charged (A), after running for 60 hours (B),
and after running for 72 hours (c). Initially, the concentration is uniform at 44.406 mol/m3 in A. By 60 hours (B),
the majority of the packed bed will only have 9.27 mol/m3 (1.93 g/L) of glucose. After 72 hours, the majority of the
bed will have 0 g/L of glucose. The reactor will be nutrient deprived after 60 hours, and have no glucose
propagating through by 72 hours.
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A

B
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Figure D2: Comsol Multiphysics surface plots of Glucose Concentration Gradients in a Packed Bed Reactor.
Surface concentration gradients are shown when the reactor was initially charged (A), after running for 60 hours (B),
and after running for 72 hours (c). Initially, the concentration is uniform at 44.406 mol/m3 in A. By 60 hours (B),
the majority of the packed bed will only have 9.27 mol/m3 (1.93 g/L) of glucose. After 72 hours, the majority of the
bed will have 0 g/L of glucose. The reactor will be nutrient deprived after 60 hours, and have no glucose
propagating through by 72 hours.
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Appendix E: Design Calculations for Fluidized Bioreactor
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Appendix F: Process Design Calculations
Stirred Tank Process
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Fluidized Bed
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Appendix G: CIP and SIP Procedures
Clean-in-place and steam in place (CIP and SIP) procedures are used in biological processes to
sterilize permanent equipment between each batch. These procedures are critical to preventing
cross contamination2.
The following CIP procedure will be used for the process where required:
Each vessel will be washed with an amount of sterile water equal to half its
volume for 10 minutes.
Next, a cleaning solution of caustic (NaOH 0.5 M) equal to half the vessel’s
volume will be sprayed into the tank.
Sterile water will then be used as in step 1 to wash away the cleaning solution for
10 minutes.
Next, a cleaning solution of acid (H3PO4 5% w/w) equal to half the vessel’s
volume will be sprayed into the tank.
Sterile water will then be used as in step 1 to wash away the cleaning solution.
Lastly, another half volume of sterile water will be used to wash the vessel once
more before the next batch. This washing regime will use approximately 2 vessel
volumes of water. This includes the water to be used to make the sterile wash solution.
For certain units, the CIP procedure may be determined by the manufacturer protocol.

Steam-in-place procedures are required for large, sturdy pieces of equipment such as stainless
steel bioreactors.
The following SIP procedure will be used for the process where required:
Each reactor will be washed with an amount of sterile water equal to half its
volume.
Next, a cleaning solution of caustic (NaOH 0.5 M) equal to half the vessel’s
volume will be sprayed into the vessel.
Sterile water will then be used as in step 1 to wash away the cleaning solution.
2

Stewart, J.m Seiberling, D., “The Secret’s Out: Clean in Place” Chemical Engineering, 1996
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Next, a cleaning solution of acid (H3PO4 5% w/w) equal to half the vessel’s
volume will be sprayed into the tank.
Sterile water will then be used as in step 1 to wash away the cleaning solution.
Five lb/hr of pure steam per cubic foot of vessel volume will be pumped into the
vessel to heat it up to the temperature of the steam, 130°C. Note: The steam used in this
procedure will be generated by a sterile steam generator at 130°C and 2 bars.
Once the 130°C has been reached in the vessel, the steam flow rate will be
reduced to one lb/hr of pure steam per cubic foot of vessel volume and held at the flow
rate.
Lastly, after thirty minutes, the flow rate of steam will be stopped and a half
volume of sterile water will then be sprayed into the tank to wash it and cool it down to
room temperature.
For certain units, the SIP procedure may be determined by the manufacturer
protocol.

149

Monoclonal Antibody Production via Fluidized Bioreactor Technology

Appendix H: Vendor Sheets

Downstream 28

Cytopilot Mini reactor
– low volume,
high productivity

M

aterial for the production of
biopharmaceuticals for
therapeutics and diagnostics is
often produced using different cell culture
techniques. One technique is to use
microcarriers for cell culture.
Microcarriers help improve yield, lower
serum and media costs and provide a low
physical and chemical stress environment
for anchorage dependent cells.
Cytopilot™ Mini is a laboratory-scale
reactor that achieves high productivity
from a small reactor volume. It is
designed for maximum ease of use, with
easy filling and discharging, simple
cleaning-in-place (CIP) routines and
reliable operation. Cytopilot Mini
achieves very high cell densities of
immobilised cells which, due to its novel
method of oxygen and nutrient transfer, it
can sustain in a continuous perfusion
production system. Such high cell
densities often require volumes of culture
medium per day in the order of 25 times
the bed matrix volume, depending on the
optimisation of culture.

High productivity
The reactor is easy to use and highly
productive. As an indication of its
productivity, Cytopilot Mini together with
Cytoline™ microcarriers can give a
volumetric productivity of 400 mg
antibodies/litre microcarriers per day, with
a titre of up to 100–200 mg/l (data
supplied by customer) from a hybridoma
culture. Furthermore, processes run on
Cytopilot Mini are easy to scale up,
reactors at 100 litre scale are already in
operation.

Figure 1. Cytopilot Mini fluidised bed reactor
has a total volume of 2 litres with a working
volume of 100-500 ml microcarriers. It has a
novel internal circulation loop through which
oxygen microbubbles circulate, ensuring a
high level of dissolved oxygen throughout the
fluidised bed.

Cytopilot Mini is a laboratory-scale
reactor which enables cell culture on
porous Cytoline microcarriers in a low
shear stress environment. Cytopilot
Mini provides controlled, fluidised bed,
perfusion culture for the evaluation of
parameters for engineering and
feasibility studies, for product testing,
or as a production tool for diagnostic
purposes. Cytopilot Mini is now
available world-wide.
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Easy change to serum-free
media
Continuous supply of nutrients to cells in
a fluidised bed constitutes the perfusion
culture. A perfusion culture system like
Cytopilot Mini gives very stable culture
conditions and facilitates changing from
serum-containing to serum-free media, or
switching from growth to production
media.

Downstream 28

How does it work?
Figure 2 describes the principle of
operation. Cytopilot Mini consists of two
chambers separated by the distribution
plate. The novel internal recycling loop
runs through both chambers. Liquid
agitated by the magnetic stirrer in the
bottom chamber is conveyed via the
distribution plate into the upper chamber.
Settled microcarriers are then lifted by
hydrodynamic pressure to form a
fluidised bed. The degree of expansion of
the fluidised bed is dependent on the
stirrer speed. When the bed is fluidised, a
clear zone forms between the top of the
suspended microcarriers and the top of
the culture medium. Culture medium
circulates back in through the upper
sieve/filter and down through the internal
recycling loop to the stirrer in the lower
chamber.

Microsparger

Exhaust air
Headspace

Oxygen bubbles
Cytoline microcarrier
(blue)

Distribution plate

pH, TI, pO 2

Figure 2. Principle of oxygenation in
Cytopilot fluidised bed reactors. Oxygen
microbubbles are sparged into the culture
medium as it is drawn down through the
central recycling loop.

Magnetic stirrer

Near-perfect oxygen transfer
Oxygen bubbles are sparged into the
culture medium in the upper microcarrierfree zone. Coalescent bubbles immediately
rise to the surface and only the liquid
saturated with microbubbles flows down
through the recycling loop to the
magnetic stirrer. The gas bearing capacity
of these microbubbles provides the system
with an oxygen reserve. The microcarriers
are freely suspended in the medium, and
statistically, all microcarriers obtain the
same amount of oxygen and nutrients.
This near-perfect oxygen transfer
minimises the formation of gradients in
the culture medium and makes scale up
very simple. Furthermore, excess C02 can
be drawn off via the headspace. The
benefit gained from this type of aeration
system and cells immobilised inside the
porous matrix of Cytoline, is the dramatic
reduction in cell damage.

Cytoline, its favoured partner
Optimal fluidisation of the microcarriers
is achieved by selecting the microcarrier
with optimum features, i.e. specific
density, size, rigidity, non-abrasive, simple
to use, sterilisable. Cytopilot Mini
fluidised bed reactor is designed

specifically to exploit the potential of
Cytoline microcarriers. These are
macroporous microcarriers weighted with
silica designed for culture of CHO cells,
hybridoma and other stress sensitive cells.
Cytopilot Mini together with Cytoline
provides a controlled fluidised bed,
perfusion environment.

Cell cultures and areas of use
Cytopilot Mini is useful for evaluating
fluidised bed cell culture at laboratoryscale, feasibility studies for large-scale cell
culture and for producing enough
material for product testing or diagnostic
purposes. It is ideal for use with the
following cell cultures:

• Adherent cell lines with strong
anchorage properties, for example
fibroblast cells in combination with
heavy microcarriers such as Cytoline 1
with a high sedimentation rate.
• Semi-adherent cells in combination with
heavy or light microcarriers such as
Cytoline 1 and 2, respectively.
• Suspension cell lines in combination
with light macroporous carriers
(Cytoline 2) for very sensitive cells or
heavy microcarriers (Cytoline 1) for
more rigid cells.

For more information, ask for the following Data Files:
Cytopilot Mini

Code no. 18-1060-74

Cytoline 1 and Cytoline 2
macroporous microcarriers

Code no. 18-1060-65

Other microcarrier products:
Cytodex™ microcarriers for cell culture

Code no. 18-1060-61

Cytopore macroporous microcarriers

Code no. 18-1132-68

™
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Thermo Scientific Precision Incubators
Performance, Quality and Value for Your Incubation Needs
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Global Leader in

Quality and Reliability
For more than 50 years, Thermo Scientific products have been
trusted by the world’s leading biotechnology, pharmaceutical,
academic, industrial and clinical laboratories. Our solutions deliver
the performance, quality and reliability required by researchers
and clinicians worldwide.
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Thermo Scientific
Precision
Incubators

Our new Thermo Scientific Precision incubator series
delivers excellent temperature uniformity, performance
and value for a wide range of microbiological incubation
applications – from everyday needs to demanding
incubation and storage tasks.
Precision® High-Performance Incubators
> Superior Temperature Uniformity

pg. 3-6

Precision Standard Incubators
> For Everyday Incubation Applications

pg. 7

Precision Compact Incubators
> Space-Saving Design for Basic Applications

pg. 8

Precision Refrigerated Incubators
> For Various Applications at Temperatures

pg. 9-10

Below and Above Ambient

APPLICATIONS

Precision
High-Performance
Incubators

Bacterial Research

Precision
Standard
Incubators

Precision
Compact
Incubators

Precision
Refrigerated
Incubators

•

•

•
•
•

Biochemical Oxygen Demand (BOD)
Chemical Storage

•

Chick Embryo Studies
Coliform Determinations
Crystallization Studies
Drying And Staining Procedures

•
•
•

•
•
•
•
•

•
•

•

•
•

•
•
•
•
•

Entomological Studies
Enzyme Digestion Studies
Hematological Testing
Microbiological Determinations
Paraffin Embedding
Pharmaceutical Stability Testing
Sample Storage
Tissue Culturing
Plant Growth Studies

•
•
•
•
•
•
•
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•
•
•
•
•

•

•
•
•

Thermo Scientific Precision High-Performance Incubators
Mechanical or
Gravity Convection

Featuring advanced microprocessor controls, our Precision
high-performance incubators are available with mechanical
or gravity convection for your most important applications that
require excellent temperature distribution or gentle sample
incubation and handling between 5°C above ambient to 75°C.

Choice of Mechanical or
Gravity Convection
• Mechanical convection provides
uniform heating and precise
temperature control. A blower
circulates heated air in a horizontal
airflow pattern for efficient heat
distribution with tight temperature
tolerances of up to ±0.3°C
• Gravity convection offers safe
incubation with reduced air changes,
minimizing drying-out of samples
while providing a stable environment
Advanced Microprocessor
Controls
• Sophisticated microprocessor
controls feature easy-to-view digital
LED readout and reliable temperature
control
• Fixed setpoints on control panel
eliminate the need for tuning and offset feature enables easy calibration
• Temperature is displayed on large,
three-character screen and can be
easily set from 5°C above ambient
to 75°C in 0.1°C increments using
touch-sensitive arrow keys

Built-In Safety
• Built-in safety back-up maintains
control at 3°C above setpoint if
primary heater control fails
• Visual alarm indicates when
temperature exceeds 3°C setpoint
• Silicone gasket on outer door
and 3” thick fiberglass insulation
prevents heat loss and ensures
excellent temperature uniformity
• Circuit breaker protects against
power surges.
Simplicity and Flexibility
• Inner glass door permits viewing
of samples without disturbing the
chamber environment
• Internal electrical outlet allows
operation of a shaker, stirrer or
other lab apparatus
Durable and Robust
• Cabinet has durable, enamel-coated
steel exterior. Interior chamber
features easy-to-clean stainless steel
• Low-watt density heater elements
are designed for long life and energy
efficiency

Mechanical Convention Models
• Stackable, table-top units
• Outer door opens to 180˚ for unhindered access
• Double door unit and large capacity units also available
• Choice of 120V and 240V versions
• Internal electrical outlet in all models

-4743

High-Performance Mechanical Convection

Double Doors

Large Capacity

Chamber Volume

2.2 cu. ft./62 L

3.4 cu. ft./96 L

4.5 cu. ft. /127 L

11.2 cu. ft./317 L

30 cu. ft./850 L

Temperature Control

Microprocessor PID

Microprocessor PID

Microprocessor PID

Hydraulic Thermostat

Hydraulic Thermostat

Temperature Display

LED

LED

LED

LED

Thermometer

Temperature Range

ambient +5° to 75°C

ambient +5° to 75°C

ambient +5° to 75°C

ambient +5° to 65°C

ambient +5° to 70°C

Uniformity @37˚C

±0.5°C

±0.5°C

±0.5°C

± 0.6°C

±0.5°C

18 x 12.5 x 18 in.

18 x 19 x 18 in.

18 x 25.5 x 18 in.

37 x 25 x 21 in.

30 x 72 x 24.25 in.

(46 x 32 x 46 cm)

(46 x 48 x 46 cm)

(46 x 65 x 46 cm)

(94 x 64 x 53 cm)

(72.2 x 182.9 x 61.6 cm)

25 x 26 x 23.5 in.

25 x 33 x 23.5 in.

25 x 39 x 23.5 in.

39.8 x 34.5 x 25 in.

36 x 88.5 x 31.5 in.

(64 x 66 x 60 cm)

(64 x 84 x 60 cm)

(64 x 99 x 60 cm)

(101 x 88 x 64 cm)

(91.4 x 224.5 x 74.3 cm)

120 V (60Hz)

330 watts/8.3 amps

330 watts/8.3 amps

410 watts /8.9 amps

520 watts/4.3 amps

450 watts/12.1 amps

240 V (50/60Hz)

330 watts/6.6 amps

330 watts/6.6 amps

410 watts/7.0 amps

520 watts/2.2 amps

—

Shelves

1 supplied, 3 max

1 supplied, 6 max

2 supplied, 10 max

6 supplied, 36 max*

6 supplied, 30 max

120 V

PR205045M

PR205055M

PR205065M

PR205075M

3971, solid door
3973, glass door

240 V

PR205040M

PR205050M

PR205060M

PR205070M

Shipping Weight

150 lb/68 kg

165 lb/74.5 kg

190 lb/86.2 kg

215 lb/98 kg

Dimensions (W x H x D)
Chamber

Exterior

Electrical Specs

Catalog Number

685 lb/310.7 kg

*18 shelves per door opening
Additional shelf kits for table top units: Catalog Number 13247S
Additional shelf kits for double door units: Catalog Number AY2076X1
Additional shelf kits for large capacity units: Catalog Number 3166190
All 120V table top units are UL/cUL listed.
12 month warranty (parts and labor)
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Gravity Convection Models
• Three stackable, table-top units
• Outer door opens to 180° for unhindered access
• Choice of 120 V and 240 V versions
• Electrical outlet in all models

-4765

GE Healthcare
Life Sciences
Data file 18-1060-65 AE

Cell culture & processing

Cytoline™ 1 macroporous
microcarriers
Cytoline™ microcarriers are designed for use in packed,
fluidized bed reactors for the culture of CHO and suspension
cells intended for the production of recombinant proteins
for therapeutic use. Cytoline microcarriers are macroporous
and consist of a matrix based on polyethylene weighted with
silica. The microcarriers yield high cell concentrations that
can be sustained over long periods of time.
• Macroporous microcarriers
• High density cell culture
• Designed for fluidized bed cultures

Macroporous microcarriers
Cells gain easy access to the interior of Cytoline due to
the macroporous structure of the microcarriers (Figure 1).
Inside Cytoline, cells are protected from both physical and
environmental stresses, and are able to create their own
micro-environment. This micro-environment increases
metabolic communication between the cells and permits
protein-free perfusion, which in turn decreases media costs,
particularly in long-term continuous processes.

Fig 1. Scanning electron micrograph of Cytoline 1.

The polyethylene base matrix causes the microcarriers to be
hydrophobic while the silica content gives Cytoline a slight
negative charge. Cytoline is further primed by an NaOH wash
during preparation to optimize performance, the effects of
which are particularly noticeable in protein-free media.

High density culture
Cytoline microcarriers offer both an external surface and an
interior space that can be populated by anchoragedependent cells or cells grown in suspension. Cell retention during
perfusion is improved due to metabolic communication. As
a result, cell density per reactor volume is high in contrast to
when conventional microcarriers are used (Figure 2).

imagination at work

Fig 2. Close-up reveals the tight clustering of CHO cells on Cytoline 1.

Designed for fluidized bed culture
Cytoline 1 is optimized for the culture of CHO cells in fluidized
beds. CHO cells attach well to Cytoline 1 and final cell densities
are very high. These high densities are possible because of the
high sedimentation rate of Cytoline 1, 120 to 220 cm/min.
A high sedimentation rate enables the use of a high circulation
rate, which ensures an adequate supply of oxygen to the
reactor in order to maintain the high cell concentration.

Good adhesion during long periods
of culture
When culturing recombinant CHO cells using Cytodex™
microcarriers, the cells occasionally have a tendency to peel
off the microcarriers after about 10 days in culture. When
using Cytoline to culture CHO cells, there is no sign of cell
detachment even after more than 60 days in culture.

Characteristics of Cytoline microcarriers
• Steam sterilizable (in situ) 121 °C, 1 bar
• Alkali and acid resistant
• Lot-to-lot consistency
• No material of biological origin is used
• Suitable for immobilization and growth of adherent
and non-adherent cell types
• Suitable for bioreactor systems that are in use in
industrial environments, such as stirred tanks, airlift
culture systems and fluidized beds
• Increases culture surface area when used in routine
laboratory culture techniques, such as roller, spinner
culture, or shaker flasks
• Lens-shape is advantageous for nutrient /oxygen
supply diffusion
• Storage in the dark gives optimal shelf-life
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Specifications of Cytoline
Cytoline 1
Sedimentation velocity (cm/min)

120–220

Length (mm)

1.7–2.5

Thickness (mm)

0.4–1.1

Density (g/cm3)

1.32

Pore size (µm)

10–400

Surface area (m /g)

>0.3
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Ordering information
Product

Quantity

Code Number

Cytoline 1

50 mL

17-1268-01

Cytoline 1

500 mL

17-1268-02

Cytoline 1

5L

17-1268-03

S

S

High-flow
Hygienic Pumps
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Put Watson-Marlow to work
on your pumping problems
■ Watson-Marlow peristaltic pumps are problem
solving pumps, best applied where other pump
types fail or frustrate.Watson-Marlow works only
through trained engineers, and, wherever you are,
they will work with you, using the experience of
meeting and solving literally thousands of pumping
problems.

Watson-Marlow leads the world in
solving fluid handling problems with
peristaltic pumping technology. The
company is accredited for design and
manufacture to ISO9001, and
provides its customers with nothing
less than the best products, service and
knowledge. Watson-Marlow conducts
its business ethically, and stands by
its word, its recommendations and
its products.

■ As the largest peristaltic pump
manufacturer, with a range of pumps
and tubing for flow rates from
microlitres per hour to thousands of
litres per hour, we stand every
chance of helping you, but if we
cannot we will tell you.

PERISTALTIC PUMPS

ARE IDEAL FOR

■ Abrasive and aggressive fluids
■ Beverage dispensing
■ Cell culture

■ If we can help, we will do whatever
is necessary to prove to you that it will
do the job. Any product we
recommend, we will stand by
completely, and if it fails to meet the
agreed need, then that will be our
problem and not yours.

■ Fermentation
■ Filtration and separation
■ Food processing
■ Industrial chemicals
■ Inks and pigments
■ Pharmaceuticals

The benefits of peristaltic pumping

■ Photographic solutions

Compared to lobe pumps, diaphragm

■ Water treatment

pumps, gear pumps and piston pumps,
and every other type of pump, these
are the advantages of Watson-Marlow
pumps:
1 No contamination of the fluid.
2 No contamination of the pump.
3 Ideal for shear-sensitive and aggressive
fluids.
4 Self-priming, dry-running.
5 No valves, seals or glands.
6 Automatic check valve action prevents
backflow.
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Standards
CE Conforms to all relevant Directives
IEC 335-1 is the International Electrotechnical
Commission standard dealing with the
“Safety of household and similar appliances,
general requirements”. Equivalents are
BS3456: Part 101 and DIN VDE 0700: Part 1).

Purchasers in the EU please note
825 and 840 pumpheads are specially designed
for connection by the user to gearboxes of the
users choice and they do not carry the CE mark.
These pumpheads are supplied with
“Declarations of Incorporation” as required by
the EU Machinery Directive.
The B/RA and the RA bare shaft pumps carry
the CE mark, but the complete motorised pump
assembly must also carry the assembler's CE
mark in addition to the Watson-Marlow CE
mark.
Customers in EU member States must note that
self assembly of machines carries with it the
responsibility to ensure that the final working
assembly complies with all the relevant EU
safety directives and the assembler’s CE mark
is affixed on completion.

EN60529 is the European Norm standard
dealing with the “Classification of degrees of
protection provided by enclosures for
rotating machines. Equivalents are BS 4999:
Part 105, IEN 60034: Part 5, and DIN VDE
0530: Part 5. IP numbers (such as IP34, IP42,
IP55) indicate the degree of ingress
protection of the product, with the first digit
indicating protection against the ingress of
objects, and the second digit indicating the
degree of protection against the ingress of
water.
EN60204-1 is the European Norm covering
“The Safety of Machines - Electrical
Equipment of Machines”.
EN61010-1 is the European Norm covering
“Safety requirements for electrical
equipment for measurement, control and
laboratory use”.
EN50081-1 is the European Norm covering
“Electromagnetic compatibility - Generic
Emission standard - Residential, commercial
and light industry”.
EN50082 - 1 is the European Norm covering
“Electromagnetic compatibility - Generic
Immunity standard - Residential, commercial
and light industry”.

Spare parts availability
Watson-Marlow’s policy is to provide spare
parts for all products for a minimum of eight
years from discontinuation. For major
products, this period is extended to twelve
years. The ability to implement this policy is
not entirely within Watson-Marlow’s control
and cannot be guaranteed, but every effort
will be made to honour this policy.

Common conversions
To go from
bar
inches
deg C
gal (IMP)
gal (US)
gal (IMP)
gpm (US)
gpm (IMP)
inches Hg
inches Hg
kg/cm2
kW
kPa
N/m2
Pa
litre
kgcm

Multiply by
14.50377
25.4
(1.8 x C) + 32
4.5460
3.7854
1.20095
0.22712
0.27276
1.1329
0.4912
14.22334
1.341
0.14504
1.0
0.00001
0.0001
0.098

To get to
psi
mm
deg F
litres
litres
gal (US)
m3/hr
m3/hr
ft H2O
psi
psi
hp
psi
Pa
bar
m3
Nm
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800 SERIES

25mm High-flow, hygienic pump
Standards
BS800, IEC 335-1,
EN60529 (IP55) CE

Provides 2000 litre/hr
(0.33 litre/rev)
Twin stainless steel rollers
Hinged door with only two
captive bolts makes
changing tube extremely
simple and safe
Use USP Class VI Bioprene
tubing for 2 bar (29 psi) and
3.5 bar (51 psi) operation

825R or B/R Motor power/tube life
hp kW
1.1 1.6

Tube elements complete
with hygienic connectors
Tubing in extended element
lengths for fitting customers
own connectors

0.75 1.0
0.55 0.75

Bareshaft pumpheads to
take a range of footmounted motors with
flexible couplings

0.37 0.5

Pumpheads to accept IEC B5
output flange-mounted gear
motors

0

0

0
0

10

20

30

400

40

50
RPM

800

60
1200

70

80

90

1600

100
2000

L/h

Ordering information
Pumps
825B/R

Baseplate mounted bareshaft pumphead

080.2500.000

825RA

Pumphead with bareshaft adaptor (no baseplate)

083.2510.000

Bioprene tubing for 825 pumps
Tube bore

25mm

1”

2 bar TM tube element

770mm length

088.0250.E0M

25mm

1”

3.5 bar TH tube element

770mm length

088.0250.E0H

25mm

1”

2 bar TM tube element

2.3m length

088.0250.00M

25mm

1”

3.5 bar TH tube element

2.3m length

088.0250.00H

Connectors for 825 pumps
825CT

Triclamp hygienic connector

825CS

SMS hygienic connector

825CI

IDF/ISS hygienic connector

825CQ

Quick coupling (MIL-C-2748F)

825CR

Quick RJT (BS1864) connector

1”

089.0250.00T
089.0250.00S
089.0250.00R

1”

089.0250.00Q
089.0250.00R

Tube lubricant
400g

Translucent food machinery grease (USDA-H1) approved
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098.0005.000

800 SERIES

Drive options
A number of motor/gearbox
options and control options are
available for these pumps
including fixed and variable speed
with mechanical variatiors. The
options include inverter control
enabling 4-20mA and 0-10V
process control, remote stop/start
and reverse, and frequency output.

Explosion-proof pumps
All pumps are available fitted with Exd IIB T4
specification explosion-proof motors that
meet all EU explosion-proof standards.
Specially selected combinations of explosionproof motors and electronic inverters are
available. These inverters are not fitted with
explosion-proof casework and therefore must
be sited outside the hazardous area.

Configurations
All 800 series pumps are available
from Watson-Marlow as complete,
ready to run, motorised pumps
with a two year warranty.
Each pump supplied by WatsonMarlow is a fully assembled,
ready-to-run unit, or a B/RA or an
RA bare shaft, ready-to-drive
pumphead, which complies with
all relevant EU (European Union)
safety directives and carries the
relevant CE mark or declaration of
incorporation.

Fixed speed pumps
825 and 840 pumps can be supplied as a
complete speed units fitted with an IP55 motor
and gearbox in 4 different speeds.
825FB/R pump speeds are 22, 38, 68 and 98
rpm. 840FB/R pump speeds are 22, 39, 62 and
100 rpm.

Variable speed inverter controlled pumps
We supply complete electronically variable
speed pumps with two maximum speeds with a
5:1 reduction ratio. The minimum flow rate will
be approximately 20% of the maximum
achievable.
Watson-Marlow have selected as standard
accessories, single phase input/three phase
output inverters for use with the 800 series
pumps (maximum power requirement 1.5KW,
for use with the 825 pumps and 2.2KW for use
with 840 pumps).
All Watson-Marlow pumps are available fitted
with motorised geared units to suit the users
own choice of inverter.

Mechanically variable speed pumps
All Zone 1 Exd 800 series pumps and those
rated above 2.2KW are fitted with belt driven
mechanically variable speed gearboxes and
IP55 standard motors.
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Accessories
Pulsation dampers will be required for certain
applications. Watson-Marlow will supply
pulsation dampers from the Flowguard
range.
Tube failure detectors are available to order.
A choice of feet or castors for fitting to 825
and 840 pump frames are available.

7

800 SERIES

Connectors

800

Tubing
The Watson-Marlow 800 series pumps use a
Bioprene tube which meets USP and NFS Class
VI requirements. Bioprene also complies with
FDA 21 CFR 177.260 and meets USDA
standards for food handling.

800 series pumps may be used
with either tube elements fitted
with hygienic connectors or
extended element lengths. A
choice of connector types is
offered, including Triclamp
(Triclover and 3A compatible), IDF
and SMS sanitary, and RJT. These
are constructed from 316 stainless
steel and are totally autoclavable.

High pressure applications
For specific higher pressure
applications, use 3.5 bar “TH” tubing
elements for intermittent periods only.
Do not use quick connectors for this
process. Tubing previously used as a
pumping element should not be used
as a transfer section.

Operating and storage
temperatures

Tube lubricant
Translucent food machinery grease
(USDA-H1 approved for food contact)
is available for 800 series tubing to
prolong tube life.

Unless otherwise stated, all
pumps listed in this brochure may
be operated at ambient
temperatures between 5C and 40C
(41F and 104F). They may be
stored at temperatures between
-40C and 70C (-40F and 158F), but
allow time for acclimatisation
before operating.

Flow rates
All flow rates quoted in this brochure were obtained
pumping water at 20C (68F) with zero suction and
delivery heads.

High pressure tube life

Tube life

35

5000
4500 825TM 0 bar

30

4000
825TH 0 bar

25

Time (hours)

Time (hours)

3500
3000
2500
2000

825TM 2.0 bar

1500

0

0

20

60

40

80

100

RPM

5000
4500 840TM 0 bar
4000
3500 840TH 0 bar
3000
2500
2000 840TM 2.0 bar
1500
1000
500 840TH 3.5 bar
0
0
20

15

7 bar

5

825TH 3.5 bar

500

20

10

1000

Time (hours)

6

-50060

40
RPM

80

100

0
0

20

40

RPM

60

80

100

800 SERIES

825RA

825B/RA

825FB/R or DFB/R

Dimensions mm

825B/RA

825FB/R, 825VBI/R, 825DFB/R, 825DVB/R
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825VBI/R

825VB/R or DVB/R

3

8

800 SERIES

800

Materials of construction
Description

Pumphead body
Pumphead door
Pumphead rotor

Material

Aluminium alloy with epoxy polyester powder coat finish

Aluminium alloy with epoxy polyester powder coat finish
Aluminium alloy

Rotor rollers

316 stainless steel

Frame

Stainless steel 304L

Optional motor housing

Stainless-steel 304L

Door fixings

Stainless steel

Installation drawings
Installation drawings of all 800 series pumps
are available on request in A3 size.
Reproducible drawings are also available for a
modest fee.

Custom-built pumps

Motor fixings

Zinc plated high tensile steel bolts, stainless steel nuts and washers

Frame fixings

Stainless steel

Paint specification

Watson-Marlow Limited’s team of technical
support engineers is available to advise and
quote for your custom-built pumps with
electric, hydraulic or pneumatic motors, trolley
mounting, stainless steel baseplates etc.

The 800 series epoxy polyester powder coating
is based on a mixed polymer thermosetting
resin designed to combine the durability
associated with epoxies with the enhanced UV
and heat stability associated with polyesters.
This results in a high quality finish which is
abrasive and impact resistant.

CIP
The 800 series pumphead incorporates
retractable roller mechanisms which allow
clean-in-place or steam-in-place hose cleaning.
The roller mechanisms are simply unlocked and
disengaged from the standard pumping
position, providing maximum cleaning capacity
via a free flow of cleaning agents through the
hose.

SIP
The 800 series can be steamed-in-place at
135°C (2 bar) for a duration of one hour. Allow
15 minutes for pump to return to ambient
temperature prior to restarting pump.
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800 SERIES
25mm hygienic pumps

Flow rates
Up to 8,000 litres/hour depending
upon motor speed.

Pressures
Up to 3.5 bar continuous operation
governed by motor sizing.

Drive options
Fixed speed, variable speed
(inverter or mechanical variator),
all drives available with Exd
options. Contact Watson-Marlow
Technical Support for further
information.

40mm hygienic pumps

Duty rating
24 hour governed by motor sizing.

The 800 series pumps have been designed for hygienic
pumping up to 8000 litre/hour and pressures to 3.5
bar (51 psi), in the biotechnology, pharmaceutical and
food industries. Pumpheads are constructed of
aluminium with an epoxy powder coated white finish
and they offer true CIP (clean-in-place) and SIP
(steam-in-place) as the rollers retract to a nonoccluding position, allowing a complete flow-through
for cleaning.
All pumps are mounted on a stainless steel frame with
the option of a brushed stainless steel motor housing,
where belt variators are not required.
Watson-Marlow’s focus has been to minimise the total
cost of ownership over the lifetime of the pumps by
making them reliable, long-lasting, and simple to use
and maintain. Downtime is the true enemy of
productivity, and so minimising downtime and
whatever essential maintenance is required rewards
our care and your choice of pump.
For instance and (uniquely), access to the tube is
through a hinged door rather than a lift-off cover, and
the door is secured by two captive bolts rather than
sixteen or twenty loose ones, making tube changing
fast, simple and safe.
Bioprene tube elements with hygienic connectors are
autoclavable and can be fitted quickly and cleanly.
Where hygiene and system up-time is valued,
there is no better pump than a Watson-Marlow 800
series.

Unmatched warranties
The high quality of the design and
manufacture of Watson-Marlow
products allows us to offer
international warranties far
exceeding those available for
other pump types.
All 800 series pumps carry a two
year warranty.

W
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2

years

warranty

1

S

E

R

I

E

100/200

Low-flow pumps

100 series flow rates from 0.01 to 53
ml/min. Single channel. Fixed and
variable flow rates.

Multi-channel pumps

200 series flow rates from microlitres
to 32 ml/min. through up to 32
channels. Manual and auto-control.
● HB 0065

300

Low-cost pumps

Flow rates from 0.2 to 2,000 ml/min.
Fixed and variable speeds.
● HB 0060

500

Microprocessor controlled
pumps

The information contained in this document is
believed to be correct but Watson-Marlow Limited
accepts no liability for any errors it contains, and
reserves the right to alter specifications without
notice.

Flow rates from 0.01 to 2,200 ml/min.
1 to 48 channels. Manual, auto and
digital control.

IP55 rated pumps

Washdown pumps for tough
environments, and pneumatic or
baseplate-mounted pumps with Exd
motors for hazardous areas. Flow
rates to 2.2litre/min.
● HB 0062

600

Mid flow pumps

Cased pumps or baseplate-mounted
pumps for flows up to 15.8 litre/min
(4.2 US gpm). Fixed or variable speed
and single channel.
● HB 0063

700

High-flow pumps

IP55 rated pumps with manual or auto
control and baseplate-mounted
industrial pumps provide flows to 2,000
litre/hr (8.8 US gpm). Single or twin
channel.
● HB 0060

Watson-Marlow Limited

800

High-flow hygienic pumps

Belgium
Telephone 02 529 5858
Fax 02 529 5861

The Netherlands
Telephone 010 462 1688
Fax 010 462 3486

France
Telephone (1) 30 62 12 47
Fax (1) 30 66 11 22

Singapore
Telephone (65) 456 7274
Fax (65) 457 5912

Web www.watson-marlow.com/watson-marlow/
Email bs.support@watson-marlow.com

Web www.watson-marlow.com/watson-marlow/
Email fs.support@watson-marlow.com

Germany
Telephone 02183 42040
Fax 02183 82592

Web www.watson-marlow.com/watson-marlow/
Email ds.upport@watson-marlow.com

Italy
Telephone (03) 0687 1184
Fax (03) 0687 1352

Web www.watson-marlow.com/watson-marlow/
Email nl.support@watson-marlow.com

United Kingdom
Telephone +44 1326 370370
Fax +44 1326 376009

www.watson-marlow.com/watson-marlow/
Email support@watson-marlow.co.uk

United States of America
Telephone 800 282 8823
Fax 508 658 0041

Web www.watson-marlow.com/watson-marlow/
Email us.support@watson-marlow.com

Korea
Telephone 02 525 5755
Telex K26177
Fax 02 525 5764

Use Bioprene USP Class VI tubing for
flow rates up to 8,000 litre/hr (35 US
gpm). and pressures up to 3.5 bar (50
psi). True CIP and SIP facilities ideal
for biotech, pharmaceutical and food
industries. Single channel.
● HB 0057

900

High-flow, high-pressure
pumps

Use reinforced tubing in five different
materials for flow rates up to 10,000
litre/hr and pressures up to 15 bar
(210 psi). Single channel.
● HB 0056

Dispensers &
Robotic fillers
For repetitive and accurate dosing and
dispensing duties. Straightforward
stop/start volumes up to one litre in
five seconds or precision, balancecontrolled dispensing.
● HB 0039

OEM pumps

Web www.watson-marlow.com/watson-marlow/
Email k.support@watson-marlow.com

Pumpheads for use with customers’
own drives or plate-mounted
pumpheads and motors. Compact,
easy to install and to use. Single and
multi-channel with flow rates up to
2,700 ml/min.
● HB 0076

Tubing
Twelve different materials and over 50
sizes of tubing for the complete range
of Watson-Marlow pumps. Full
chemical compatibility tables with 450
fluids tabulated. Performance and
physical data.
● HB 0065

Members of the Spirax-Sarco Engineering Group
Watson-Marlow is a registered trademark of
Watson-Marlow Limited.
Publication ref: HB 0057
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● These brochures describe the full Watson-Marlow range

of peristaltic pumps, tubing and accessories.

■

ST DESIGN

S

BIOPRENE TUBING
Thermoplastic elastomer tubing
!Highly resistant to oxidising
agents "

Validated
processes
Bioprene peristaltic pump
tubing is fully approved for
food and pharmaceutical
applications. Validated
processes are supported.
Like Marprene, Bioprene
lasts at least 10 times as
long as tubing in other
materials. Long-life tubing
means stoppages for a
tube change are rare
events, easily fitted in with
general maintenance.

Easy sterilisation

USP, ISO and FDA approvals matter in maintaining
validated processes. Bioprene peristaltic pump tubing
offers long life and chemical resistance, and carries
the widest range of safety approvals
! USP Class VI FDA approvals
! Fully documented bio-compatibility and comprehensive
validation pack
! Safe for use in biomedical applications
! Ex-stock availability
! Comprehensive stock of a wide range of sizes
! UV opaque
! Fully weldable

Clean-in-place and

! No odour

steam-in-place (with

! Low extractables

tubing elements) are no

! Suitable for repeated autoclave cycles

problem for the tube that
has everything.

Watson-Marlow Bioprene: the best peristaltic pump tube
life with excellent chemical resistance
-505-

Meeting or exceeding FDA regulations

For long life and chemical compatibility
Bioprene offers exceptionally long life and resistance
to a wide range of chemicals. It is a first choice for
applications including metering tablet-coating materials, pH control and media feed in fermentation and
bioreactor metering, as well as pharmaceutical handling, dispensing, metering, transfer and filtration.

General industrial long-life transfer
tube. Highly resistant to oxidising
agensts such as ozone, peroxides
and sodium hypochlorite.
Bioprene
Material
Colour / transparency

Thermoplastic elastomer
Fair
313/314, 520R pumpheads: 10,000;
620R pumphead: 6,000

Operating temperature
Hardness, shore A (5 sec)
Specific gravity
Tear B, ppi

/50

0.5

1

/32

0.8

1

/16

1.6

1

1

1

1

FDA regulations 21 CFR 177.2600 for contact
with aqueous food

/16

1.6

903.0008.016

903.0008.J16

903.0008.R16

/16

1.6

903.0016.016

903.0016.J16

903.0016.R16

/16

1.6

903.0024.016

903.0024.J16

903.0024.R16

/16

1.6

903.0032.016

903.0032.J16

903.0032.R16

/16

1.6

903.0048.016

903.0048.J16

/16

1.6

903.0064.016

903.0064.J16

903.0064.R16

/16

1.6

903.0080.016

903.0080.J16

903.0080.R16

3.2

1

/16

4.8

1

1

/4

6.4

1

/16

8.0

1

903.0005.024

903.0008.J24

903.0016.024

903.0016.J24

/32

2.4

903.0032.024

903.0032.J24

/32

2.4

903.0048.024

903.0048.J24

400ft / 122m

903.0048.R24

/32

2.4

903.0064.024

903.0064.J24

300ft / 91m

903.0064.R24

/32

2.4

903.0080.024

903.0080.J24

200ft / 61m

903.0080.R24

/32

2.4

903.0096.024

903.0096.J24

150ft / 46m

903.0096.R24

903.0048.032

903.0048.I32

1

/8

3.2

3

/16

4.8

3

/4

6.4

3

5C-80C

5

/16

8.0

3

64 shore: 66; 73 shore: 74; 87 shore: 88

3

/8

9.6

3

64 shore: 0.97; 73 shore: 0.96; 87 shore: 0.95
6.4

1

/8

9.6

1

/2

12.7

1

/8

15.9

1

-

-

8.0

Weather resistance

Excellent

-

12.0

Sunlight resistance

Excellent

-

16.0

/8

9.6

3

/2

12.7

3

/8

15.9

3

3

/4

19.0

3

1

25.4

3

1

3

Elongation at break, %

64 shore: 473; 73 shore: 510; 87 shore: 547

1

Tensile stress at 100%
elongation, psi

64 shore: 367; 73 shore: 525; 87 shore: 987

5

Compression set, %

Gas permeability,
O2cc.cm x 10-8 /
cm2.sec.atm
Gas permeability rating
Water absorption
Odour

5.8

3

1

Fair
Good

5

Excellent

ASTM methods Hardness: ASTM D 2240; Specific gravity: ASTM D 792; Tear B, Ultimate
tensile strength, Elongation at break, Tensile stress at 100% elongation: ASTM D 412

903.0005.J24

903.0008.024
3

1

64 shore: 1007; 73 shore: 1410; 87 shore: 2263

903.0048.R16

2.4

1.6

Gamma, autoclave, EtO. CIP, SIP: refer to
Watson-Marlow for details

-

16ft / 5m

500ft / 152m

/32

/16

/4

Ultimate tensile
strength, psi

Part number
903.0005.R16

2.4

3

Coil size

903.0005.J16

/8

1

Part number

903.0005.016

/32

5

Coil size

1.6

1

3

Part number

/16

1

3

Coil size

Beige / opaque

Life, hours

Sterilisation methods

Wall

inch mm inch mm

Typical values

Spallation

Certification

Bore

50ft / 15m

903.0016.R24
903.0032.R24

/8

3.2

903.0064.032

903.0064.I32

200ft / 61m

903.0064.R32

/8

3.2

903.0096.032

903.0096.I32

150ft / 46m

903.0096.R32

/8

3.2

903.0127.032

903.0127.I32

/8

3.2

903.0159.032

903.0159.I32

-

4.0

903.0080.040

903.0080.I40

-

4.0

903.0120.040

10ft / 3m

903.0120.I40

-

4.0

903.0160.040

/16

4.8

903.0096.048

903.0160.I40
903.0096.I48

/16

4.8

903.0127.048

903.0127.I48

/16

4.8

903.0159.048

903.0159.I48

/16

4.8

903.0190.048

903.0190.I48

/16

4.8

903.0254.048

903.0254.I48

Custom sizes are
available to order, as
are other specific
requirements

United Kingdom
Telephone +44 (0) 1326 370370
Fax: +44 (0) 1326 376009
Email info@watson-marlow.co.uk
www.watson-marlow.co.uk
Belgium
Telephone +32 (0) 9 225 94 57
Fax: +32 (0) 9 233 06 49
Email info@watson-marlow.be
Brazil
Telephone +55 (11) 2155 4000
Fax: +55 (11) 2155 4001
Email info4brazil@watson-marlow.com
www.watson-marlow.com.br
China
Telephone +86 21 6485 4898
Fax: +86 21 6485 7366
Email mingshao@cn.spiraxsarco.com
www.watson-marlow.cn
Denmark
Telephone +45 43 94 00 65
Fax: +45 43 94 00 85
Email info@watson-marlow.dk
www.watson-marlow.dk

France
Telephone +33 (0) 1 34 87 12 12
Fax: +33 (0) 1 34 87 12 13
Email info@watson-marlow.fr
www.watson-marlow.fr
Germany
Telephone +49 (0) 2183 42040
Fax: +49 (0) 2183 82592
Email info@watson-marlow.de
www.watson-marlow.de
Italy
Telephone +39 03 06871184
Fax: +39 03 06871352
Email info@watson-marlow.it
www.watson-marlow.it
Korea
Telephone +82 (0) 32 820 3973
Fax: +82 (0) 32 811 0321
Email changwoojang@kr.spiraxsarco.com
www.watson-marlow.co.kr
Malaysia
Telephone +60 (3) 5635 3323
Fax: +60 (3) 5635 7717
Email sales@my.spiraxsarco.com
www.watson-marlow.com

Netherlands
Telephone +31 (0) 10 462 1688
Fax: +31 (0) 10 462 3486
Email info@watson-marlow.nl
www.watson-marlow.nl
South Africa
Telephone +27 11 796 2960
Fax: +27 11 794 1250
Email info@wmbpumps.co.za
www.watson-marlow.co.za
Sweden
Telephone +46 8 556 556 00
Fax: +46 8 556 556 19
Email info@watson-marlow.se
www.watson-marlow.se
United States of America
Telephone 800 282 8823
Fax: +1 978 658 0041
Email support@wmbpumps.com
www.watson-marlow.com
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www.watson-marlow.co.uk
Members of the Spirax-Sarco Engineering Group
The information contained in this document is believed to be
correct, but Watson-Marlow Bredel accepts no
liability for any errors it contains, and reserves the right to
alter specifications without notice.
WARNING These products are not designed
for use in, and should not be used for, patientconnected applications.

Watson-Marlow, Pumpsil, LoadSure, LaserTraceability,
Bioprene and Marprene are registered trademarks of
Watson-Marlow Limited. STA-PURE and CHEM-SURE are
trademarks of WL Gore and Associates INC. Fluorel is a
trademark of 3M.
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Bioprene for validation

Sartopore® 2 0.2 µm
Sterilizing Grade Filter Cartridges
Specifications

Membrane Filter Cartridges

Materials of Construction
Prefilter Membrane:

Polyethersulfone,
asymmetric

Endfilter Membrane:

Polyethersulfone,
asymmetric

Support Fleece:

Polypropylene

Core:

Polypropylene

End Caps:

Polypropylene

O-Rings:

Silicone (optional
EPDM or Viton)

Pore Size
0.45 µm + 0.2 µm

Description
Sartopore® 2 0.2 µm rated sterilizing grade
filter cartridges are designed for filtration
of a broad range of pharmaceutical products
where compliance with cGMP requirements
has to be fulfilled. Sartopore® 2 cartridges
feature a unique hydrophilic heterogeneous
double layer Polyethersulfone membrane
with broad chemical compatibility, high
thermal resistance and higher throughput
and flow-rate than any other sterilizing
grade filter cartridge.
Applications
Typical applications include sterilizing
grade filtration of:
– Therapeutics
– Biological Fluids
– Opthalmics
– SVPs, LVPs
– Antibiotics
– WFI
– Chemicals
– Cleaning and sanitizing agents
– Bulk pharmaceutical products
Compatibility
The polyethersulfone membrane is compatible
with a pH range from pH 1 to pH 14 and
unaffected by steam sterilization cycles
making Sartopore® 2 cartridges ideal for
filtration of solutions with high|low pH and
for SIP|CIP-cycles.

Performance
Sartopore® 2 cartridges provide an exceptionally high total throughput by fractionated
filtration due to the "built-in prefiltration" of
the 0.45 µm membrane. The asymmetric pore
structure of the polyethersulfone membrane
provides high flow rates at low pressure
drops.
Wettability
Sartopore® 2 cartridges can be easily wetted
out for integrity testing even after drying
at 80°C for 12 hours.
Microbiological Retention
Sartopore® 2 filter cartridges are fully
validated as sterilizing grade filter elements
according to HIMA and ASTM F-838-83
guidelines.
Quality Control
Each individual element is integrity tested
by diffusion and bubble point test prior
to release, assuring absolute reliability.
Documentation
Sartopore® 2 cartridges are designed, developed and manufactured in accordance with
an ISO 9001 certified Quality Management
System. A Validation Guide and Extractables
Guide are available for compliance with
regulatory requirements.
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Available Sizes |Filtration Area
Size 1
10”
0.6 m2 |6 ft2
Size 2
20”
1.2 m2 |12 ft2
Size 3
30”
1.8 m2 |18 ft2
Available Adapters | Connectors
21, 25, 27, 28
Operating Parameters
Max. Allowable
Differential Pressure:

5 bar|75 psi at 20°C
2 bar|29 psi at 80°C

Max. Allowable Back
Pressure:

2 bar|29 psi at 20°C

Specifications

Water Flow Rates for 10″, 20″ and 30″ Cartridges

Extractables
Sartopore® 2 0.2 µm rated filter cartridges
meet, or exceed the requirements for WFI
quality standards set by the current USP.
Regulatory Compliance
100% Individually integrity tested
Integrity test correlated to HIMA/ASTM
F 838-83 Bacteria Challenge Test
Non-pyrogenic according to USP Bacterial
Endotoxins

1

[psi]
15

Differential pressure [bar]
10″

0.75

20″

30″

0.5

7.5

0.25
0

0
0

Passes USP Plastics Class VI Test

2,000

4,000

6,000

8,000

10,000

12,000

14,000

Flow [l/h]

Non-fiber releasing according to 21 CFR
Standardized at 20°C

Sterilization
In-Line Steam Sterilization:
134°C, 20 min. at max differential pressure
of 0.5 bar|7.25 psi
Autoclaving:
134°C, 2 bar|29 psi, 30 min
Sterilization Cycles
In-Line Sterilization:
Autoclaving:

Total Throughput Comparison
100

Total throughput [kg at 95 % blockage]

80

Min. 25
Min. 25

60
40

Technical References

20

Validation Guide:
SPK 5732-e

0

Extractables Guide:
SPK 5731-e

Sartopore 2 PESU
0.45 | 0.2 µm 0.8 | 0.2 µm

PVDF
0.2 µm

PVDF
0.22 µm

Nylon
0.2 | 0.2 µm

10″ Cartridge format

Ordering Information
Order Code.

Pore size
[µm]

544**07H1
544**07H2
544**07H3

0.2
0.2
0.2

Test
Pressure
[bar|psi]
2.5|36
2.5|36
2.5|36

Max.
Diffusion
[ml/min]
18
36
54

Min. B.P.
[bar|psi]
3.2|46
3.2|46
3.2|46

Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen, Germany
Phone +49.551.308.0
Fax +49.551.308.3289
www.sartorius-stedim.com
USA Toll-Free +1.800.368.7178
UK +44.1372.737159
France +33.442.845600
Italy +39.055.63.40.41
Spain +34.91.3586102
Japan +81.3.3740.5407
Specifications subject to change
without notice. Printed and copyrighted
by Sartorius Stedim Biotech GmbH
W/sart-000 · G
Publication No.: SPK2030-e08066
Order No.: 85030-511-67
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GE Healthcare
Life Sciences

WAVE Bioreactor™
2/10 system

1

The right system
for your suspension cells
The WAVE Bioreactor 2/10 system is a widely
cited cell culture platform based on a singleuse presterilized bag called a Cellbag™
bioreactor. The rocking motion of the

2

Better
by design

Minimal cross-contamination
in a functionally closed system
Scale-up from 250 mL to 5 L of culture in a
target cell concentrations without the need

suitable for cell therapy research applications.

Sampling, monitoring, and additions
all take place within in a functionally
contamination associated with processes

such as T, TIL, and NK cells (1,2,3)
culture (2)

Customizable to meet
your changing needs

applications (1,3,4,5,6)
functionally closed Cellbag bioreactors free
of animal products (3)

For more information,

Table 1.
Bioreactor 2/10 system

Cell type

Cellbag bioreactors can be customized with

www.gelifesciences.com/
waveinfo

Yield (cells/mL)

T
TIL

7

NK

6

7

(5)
(2)
(3)

Higher cell densities in
a low-shear environment
Set the rocking motion of the Cellbag holder to

homogeneous culture enables higher cell densities
possible with static bags (2,3,5).

3

Take control
of process parameters

Spare luer port/optional pH probe

the WAVE Bioreactor 2/10 system.
Set, maintain, and control CO2 concentration using
a CO2
Perfusion Controller. Integral temperature control
means there is no need for an incubator.

Needleless sampling port

CO2/Air Mix Controller: An aeration system with CO2

Inoculation/Feed line

CO2-conditioned air to the Cellbag bioreactor.
Cellbag bioreactor:
sensors allow measurement of critical parameters such as pH
and gas transfer.

Perfusion Controller: Includes a scale and peristaltic
through weight-based perfusion.

Cell
culture
media

Wave

Rocking
motion

Wave

4

Easy scale-out
for multiple cultures

culture media.

Scale-out using the WAVE Bioreactor 2/10 system
compared to static cultures. Perform multiple
applications simultaneously by linking up to 10
systems together and monitor using the optional
PCDAQ software on a single PC.

5

More cells for less
with the Perfusion Controller

Cellbag bioreactor make the WAVE Bioreactor
2/10 system easier to use and considerably less
laborious than static cultures where multiple

compared to static culture (1,2,3,4,5,6).

Minimize media consumption

Optimize nutrient concentration and minimize

and absolute cell numbers than cells grown in static conditions.
(Reproduced with permission) (2).

Static culture

WAVE Bioreactor 2/10 system

the Perfusion Controller (2,3). Automatic media
0%

bioreactor reduces media consumption by 50%
compared to static culture.
Using a WAVE Bioreactor 2/10 system reduces

20%

40% 60% 80%
Media consumption

100%

Typical percentages of media consumption for an application
with TIL cells. Data based on an article by Sadeghi, A., et al (4).

culture performed using static culture bags (2).

Reduce hands-on-time
and lower costs
Reduce production time by up to 60% compared
to static cultures using the WAVE Bioreactor 2/10
system with perfusion (2,3,4,5) and lower costs
using a single Cellbag bioreactor for scale-up

Static culture

WAVE Bioreactor 2/10 system

0%

reduced.

20%

40% 60% 80%
Production time

100%

with TIL cells. Data based on an article by Sadeghi, A., et al (2).

Ordering information
Description

Code number

Cellbag 500mL (BC10, Basic)

28-9480-89

Cellbag 2L (BC10, Basic)

28-9378-00

Cellbag 2L (BC10, DO)

28-9377-99

Cellbag 2L (BC10, Perfusion, DO)

28-9376-52

Cellbag 10L (BC10, Basic)

28-9378-01

Cellbag 10L,(BC10, Perfusion, DO)

28-9376-62

Cellbag 20L (BC10, Basic)

28-9378-02

Cellbag 20L (BC10, DO)

28-9377-96

Cellbag 20L (BC10, Perfusion, DO)

28-9376-64

WAVE Bioreactor BASE2/10EH

28-9377-86

LID2/10W – OPAQUE

28-9376-33

Perfusion Controller PERFCONT2E

28-9884-64

WAVE Bioreactor BASE20/50EHT-L 100-120 V

28-9616-88

WAVE Bioreactor BASE20/50EHT-L 220-240 V

28-9616-89

WAVE Bioreactor BASE20/50EHTD-L 100-120 V

28-9436-72

WAVE Bioreactor BASE20/50EHTD-L 220-240 V

28-9436-95

WAVE Bioreactor BASE20/50EHT-CO2-L 100-120 V

28-9436-96

WAVE Bioreactor BASE20/50EHT-CO2-L 220-240 V

28-9436-97
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647TP[cWRPaT
;XUTBRXT]RTb
3PcP [T!(!"& !00

ATPShC^?a^RTbb

F0E41X^aTPRc^a$ bhbcT\
F0E41X^aTPRc^a$ bhbcT\5XV Xb_Pac^U
647TP[cWRPaT;XUTBRXT]RTbATPShC^?a^RTbb_[PcU^a\^U
aTPShc^dbT_a^SdRcbCWTbhbcT\XbPRT[[Rd[cdaTSTeXRT
U^acWT_a^SdRcX^]^UaTR^\QX]P]c_a^cTX]bX]\P\\P[XP]
P]SX]bTRcRT[[[X]TbX]QPcRWUTSQPcRWP]S_TaUdbX^]
Rd[cdaT2d[cdaT\TSXd\P]SRT[[bPaT[^PSTSX]c^PbX]V[T
dbT_aTbcTaX[XiTSQPVZ]^f]PbcWT2T[[QPVQX^aTPRc^aCWT
2T[[QPVQX^aTPRc^aXb_[PRTS^]P]T[TRcaXRa^RZX]VQPbTCWT
a^RZX]V\^cX^]^UcWXbQPbTX]SdRTbfPeTbX]cWTRT[[Rd[cdaT
dXSfXcWX]cWT2T[[QPVQX^aTPRc^ac^_a^eXSTTU RXT]c\XgX]V
P]SVPbcaP]bUTaCWTaTbd[cX]VT]eXa^]\T]cfXcWX]cWT2T[[QPV
QX^aTPRc^aRP]TPbX[hbd__^ac ¾ &RT[[b\;CWT2T[[QPV
QX^aTPRc^aaT`dXaTb]^R[TP]X]V^abcTaX[XiPcX^]_a^eXSX]VTPbh
^_TaPcX^]P]S_a^cTRcX^]PVPX]bcRa^bbR^]cP\X]PcX^]
0b_Pac^UATPShC^?a^RTbb_[PcU^a\cWTF0E41X^aTPRc^a
QaX]Vb TgXQX[XchP]Sb_TTSc^d_bcaTP\P]SS^f]bcaTP\
_a^RTbbX]V^UQX^[^VXRP[bCWT_a^SdRcaP]VTR^\_aXbTb
F0E41X^aTPRc^abhbcT\bF0E4<XgTacdQX]V
bTP[TabP]SUdbTabW^[[^f QTaP]S]^a\P[ ^f [cTab
_aT_PRZTSRWa^\Pc^VaP_WhR^[d\]bP]S«:C0aTPSh
RWa^\Pc^VaP_WhbhbcT\fXcWPSXb_^bPQ[T ^f_PcWPbfT[[
PbcWTPbbT\Q[XTbP]SR^]]TRcX^]bX]QTcfTT]CWT_[PcU^a\
XbbRP[PQ[TUa^\cWT[PQQT]RWc^\P]dUPRcdaX]V
WAVE Bioreactor 500/1000 system delivers:
~ 2^]eT]XT]RT)?aTbcTaX[XiTSbX]V[TdbT2T[[QPVQX^aTPRc^ab
_a^cTRcPVPX]bccWTaXbZ^URa^bbR^]cP\X]PcX^]aT`dXaT
]^R[TP]X]VP]SX]e^[eT\X]X\P[eP[XSPcX^]P]ScWThPaT
bd__[XTSX]PaTPShc^dbTU^a\Pc
~ AT[XPQX[Xch)2T[[QPVQX^aTPRc^abX]R[dSX]VP[[ ccX]VbP]S
[cTabPaTbd__[XTSbcTaX[TP]SaTPShU^adbTCWThPaT
bdXcPQ[TU^aR6<?R^\\TaRXP[_a^SdRcX^]P]SPQX^bPUTch
RPQX]TcXb]^caT`dXaTSU^aX]^Rd[PcX^]^abP\_[X]V

Fig 1. CWTF0E41X^aTPRc^a$ bhbcT\XbbdXcPQ[TU^aRd[cdaTe^[d\Tb
^U$c^$;

System descriptions
CWTF0E41X^aTPRc^a$ bhbcT\R^\_aXbTbX]cTVaP[
a^RZX]VcT\_TaPcdaTfTXVWcP]SPXa ^fR^]ca^[[TabCWT
bT[UR^]cPX]TSbhbcT\XbSTbXV]TSU^adbTfXcWf^aZX]V
Rd[cdaTe^[d\Tb^UQTcfTT]$P]S$;X]P__[XRPcX^]b
bdRWPbX]^Rd[d\bRP[Td_A3_a^RTbbSTeT[^_\T]c
R^\\TaRXP[_a^SdRcX^]ePRRX]T_a^SdRcX^]P]SP]cXQ^Sh
\P]dUPRcdaT5^aPSSXcX^]P[ TgXQX[Xch^_cX^]P[\^Sd[Tb
X]R[dSX]V3>2>!>!fTXVWc_TaUdbX^]P]S_7R^]ca^[RP]
QTPSSTSfWX[TQdX[cX]4cWTa]TcP]S<>31DBSPcP_^acb
P[[^fR^\\d]XRPcX^]fXcW^cWTab^UcfPaT

Applications
CWTF0E41X^aTPRc^abhbcT\XbbdXcPQ[TU^adbTfXcW
P]RW^aPVTST_T]ST]cRT[[bX]PSSXcX^]c^RT[[bdb_T]bX^]b
P]SWPbP__[XRPcX^]bX])

~ 5[TgXQX[Xch)<d[cX_[TX]bcad\T]cR^] VdaPcX^]bU^abdb_T]bX^]
\XRa^RPaaXTaQPcRWUTSQPcRW^a_TaUdbX^]Rd[cdaT

~ <^]^R[^]P[P]cXQ^SXTb

~ ETabPcX[Xch)CWT$ bhbcT\XbRP_PQ[T^UWP]S[X]V
Rd[cdaTe^[d\TbUa^\$c^$;

~ EXadb_a^SdRcX^]

~ 8]bTRcRT[[Rd[cdaT
~ 6a^fX]V_PcW^VT]b^a^cWTaWXVWR^]cPX]\T]cbhbcT\b
~ 8]^Rd[d\bRP[Td_
~ ?a^cTX]Tg_aTbbX^]
~ ?aX\PahRT[[[X]TTg_P]bX^]

Components

Quick-release bag holder

Touchscreen

AP_XSaT[TPbT2P\[^RZ[TeTabbTRdaTcWT2T[[QPVQX^aTPRc^a
X]_[PRT^]cWTa^RZX]V_[PcU^a\P[[^fX]VQPVbc^QT
PccPRWTSP]SaT\^eTSX]\X]dcTbCWTW^[STaSTbXV]T]bdaTb
cWPccWT2T[[QPVQX^aTPRc^aXb[^RZTSX]cWT^_cX\P[_^bXcX^]
U^a^ghVT]caP]bUTaP]S\XgX]V

CWTR^[^ac^dRWbRaTT]5XV![^RPcTS^]cWTR^]ca^[_P]T[^U
cWTF0E41X^aTPRc^a$ bhbcT\T]PQ[TbcWTbTcd_
R^]ca^[P]SeXTfX]V^UP[[RT[[Rd[cdaT_PaP\TcTabfWX[TSPcP
RP]QT\^]Xc^aTSVaP_WXRP[[hX]aTP[cX\TCWT\PX]\T]d
_a^eXSTbP]^eTaeXTf^UZTh^_TaPcX]VR^]SXcX^]bP]SXcXb
cWT\PX]PRRTbbbRaTT]U^aP[[R^]ca^[b3XUUTaT]cR^]ca^[
Qdcc^]bPaTSXb_[PhTSST_T]SX]V^]cWT^_cX^]bT]PQ[TS
?aTbbX]VcWTSTbXaTSQdcc^]fX[[cPZTh^dc^cWTaTb_TRcXeT
R^]ca^[bRaTT]CWTc^dRWbRaTT]XbW^dbTSX]PbcPX][TbbbcTT[
T]R[^bdaTP]SRP]QTcX[cTSP]Sa^cPcTSU^aTPbXTaeXTfX]V

Optional components
pH Monitor
CWT\^]Xc^aT]PQ[Tb^][X]T\TPbdaT\T]c^U_7dbX]VP
bX]V[TdbTT[TRca^RWT\XRP[_a^QT_aTX]bcP[[TSX]2T[[QPV
QX^aTPRc^ab

Dissolved oxygen monitor

Fig 2. CWTc^dRWbRaTT]
_a^eXSTbTPbhPRRTbb
c^P[[R^]ca^[Ud]RcX^]b

CWTSXbb^[eTS^ghVT]3>\^]Xc^a_a^eXSTbP\_[X RPcX^]
SXb_[PhP]SSPcPcaP]b\XbbX^]^U3>R^]RT]caPcX^]P[[^fX]V
aTP[cX\T\TPbdaT\T]c^U3>R^]RT]caPcX^]X]bXSTcWT
2T[[QPVQX^aTPRc^aCWT3>\^]Xc^aR^]ca^[[TafPbSTbXV]TS
U^adbTfXcW\X]XPcdaT QTa^_cXRSXbb^[eTS^ghVT]_a^QTb
3>>?C?A>14P]SXcRP]X]RaTPbTcWTa^RZX]VaPcT
Pdc^\PcXRP[[hc^\PX]cPX]^][X]TR^]ca^[^U3>

O2/air mix controller
Expansion slots
>_cX^]P[\^Sd[TbbdRWPbcWTSXbb^[eTS^ghVT]3>>!2>!
_7P]SSdP[bhbcT\R^]ca^[[TabRP]QTPSSTSc^bcP]SPaS
F0E41X^aTPRc^abhbcT\bc^\^]Xc^aP]SR^]ca^[PSSXcX^]P[
_PaP\TcTabPbh^daaT`dXaT\T]cbRWP]VTCWTbT\^Sd[Tb
_[dVX]c^cWTUa^]cP]SQPRZX]bcad\T]c_P]T[b5XV"^UcWT
QPbTd]XcP]SPaTT]PQ[TSeXPcWTX]bcad\T]c{bR^] VdaPcX^]
P]SRP[XQaPcX^]Ud]RcX^]bX]^aSTac^SXb_[PhcWT\^Sd[T
ePaXPQ[TbP]SR^]ca^[b^]cWTR^[^ac^dRWbRaTT]B_PaTaPRZb
PaTX]R[dSTSU^aUdcdaTX]bcad\T]c^_cX^]b

CWT>!PXa\XgR^]ca^[[TaR^]]TRcbc^Pbd__[h^U^ghVT]
P]S[^f_aTbbdaT=!bd__[hXUaT`dXaTSc^_a^eXST>!PXa
R^]RT]caPcX^]bQTcfTT]P]S$>!CWTX]bcad\T]c
R^]ca^[bT]aXRWTS^ghVT][TeT[bU^aX]bTRcRT[[QPRd[^eXadb
P]SWXVWRd[cdaTST]bXchP__[XRPcX^]b*XcXbP[b^dbTUd[U^a
\PX]cPX]X]V[^f^ghVT]T]eXa^]\T]cbU^a]TPaP]PTa^QXR
P__[XRPcX^]b

CO2/air mix controller
CWT2>!PXa\XgR^]ca^[[TaR^]]TRcbc^Pbd__[h^U 2>!
c^_a^eXST2>!PXaR^]RT]caPcX^]bQTcfTT]P]S $
2>!CWTX]bcad\T]cXbdbTUd[U^a_7R^]ca^[^UQXRPaQ^]PcT
QdUUTaTSRT[[Rd[cdaT\TSXP

Analog output card

Fig 3. 4g_P]bX^]b[^cbPaT_a^eXSTSU^acWT
X]bcP[[PcX^]^U^_cX^]P[X]bcad\T]cPcX^]

Linear electronic motor
0]T[TRcaXR[X]TPa\^c^aXbdbTSc^a^RZcWTQPbTd]Xcb^UcWT
F0E41X^aTPRc^a$ bhbcT\D][XZTVTPaTS\^c^ab
cWXbT[TRca^\PV]TcXRSTeXRTWPb^][h^]T\^eX]V_PacP]S
_a^eXSTbVaTPcTaaT[XPQX[XchCWT[X]TPa\^c^aU^[[^fbP_aTbTc
P]S^_cX\P[b_TTSP]SPRRT[TaPcX^]_a^ [Tc^_a^eXSTcWT
\^bcTUUTRcXeTfPeTU^aTU RXT]c[^fbWTPa\XgX]V

!  !(!"& !00

D_c^TXVWcRWP]]T[b^UP]P[^V^dc_dcbPaTPePX[PQ[TPb
P]^_cX^]U^aR^]ca^[[X]VX]bcad\T]cePaXPQ[TbbdRWPb
a^RZX]Vb_TTSfTXVWcPXa ^fcT\_TaPcdaT_73>2>!
P]S>!fXcWX]cWTXa_aTbTcaP]VTbCWT31!$_X]P]P[^V
^dc_dcR^]]TRc^aXb[^RPcTS^]cWTaTPa_P]T[^UcWTa^RZTa
QPbTd]XcCf^P]P[^V^dc_dcRPaSbPaTaT`dXaTSU^aSdP[
R^] VdaTSbhbcT\b

Loadcell
4[TRca^]XR[^PSRT[[\^Sd[Tb_a^eXST^][X]T\TPbdaT\T]c^U
2T[[QPVQX^aTPRc^afTXVWcP]SRP]QTdbTSU^aPdc^\PcTS
[[X]VP]SWPaeTbcX]V^U\TSXP0QdX[cX]_d\_R^]ca^[[Ta
\PX]cPX]bPR^]bcP]ce^[d\TU^a_TaUdbX^]^_TaPcX^]b
;^PSRT[[\^Sd[TbPaT^_cX^]P[UPRc^ahX]bcP[[TSPRRTbb^aXTb
U^aF0E41X^aTPRc^a$ bhbcT\

Technical information and specifications

Ordering information

WAVE Bioreactor 500/1000 system
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Cell culture

Xcellerex™ XDR cell culture
bioreactor systems
The Xcellerex XDR bioreactor product line offers the benefits
of single-use technology and stirred-tank design in a modular,
turnkey, bioreactor platform (Fig 1). Designed for scalability and
robustness, the XDR bioreactor systems provide the performance
and flexibility needed from process development to large-scale
biopharmaceutical manufacturing. XDR bioreactor systems
can be operated in batch, fed-batch, and perfusion modes.
XDR bioreactor systems offer the following benefits:
• Scalable and predictable stirred-tank performance
up to 2000 L
• Single-use technology eliminates costly and timeconsuming cleaning and cleaning validation
• Advanced automation and modular system design
to support a variety of installation scenarios
• Process and operational support from staff with
extensive manufacturing experience

System overview
The full line of XDR bioreactor systems are designed and
characterized to deliver scalable process equivalence from
4.5 L to 2000 L working volume (Fig 2), in both GMP and
non-GMP environments. The system design is based on the
same foundational principles as conventional stainless steel
bioreactors. Consistent vessel geometries, tight relationship
between consumables and equipment features, and a host
of accessories combine for an easily scalable, single-use
product line. Traditional scaling methodology, based on
measures such as shear, tip speed, power per unit volume,
kLa, and specific process sensitivities, can be used during
scale-up. Technology transfer using the XDR systems is
straightforward, minimizing the need for costly and timeconsuming process redesign. For enhanced utility across the
bioreactor platform, the minimum working volume is as low
as 20% of the maximum working volume.

Fig 1. Bioreactor system components: XDR vessel with frame-mounted I/O
cabinet and X-Station mobile control console.

The bioreactor bag assembly (XDA) is disposed after culture
termination and eliminates costly and time-consuming
cleaning-in-place (CIP) and steam-in-place (SIP) operations.
The XDA bag assembly is prepackaged with a low profile
impeller, a variety of sparge components, filters, and
tubing, for quick and hassle-free installation. The flexibility
of single-use technology enables quick changeover
between productions, for efficient equipment utilization.
Interconnection of bioreactor bag and equipment is key in
achieving the excellent performance that XDR bioreactor
systems deliver.
The modularity of the XDR product line stems from three key
system components: bioreactor frame, I/O cabinet, and the
X-Station mobile control console. The system components

Fig 2. The complete range of XDR bioreactor systems are available with
maximum working volumes ranging from 10 to 2000 L, from the smallest
XDR-10 (described separately in data file 29-0929-27) to the largest XDR-2000
system. Images are representative, some features and accessories may vary
depending on the bioreactor configuration.

can be used together for a complete turnkey system with true
plug-and-play performance. Alternatively, the components can
be used separately and integrated into existing infrastructure,
for enhanced flexibility. The jacketed vessel has a consistent
design and delivers integrated heating and cooling for efficient
temperature control throughout all scales. The versatile I/O
cabinet houses all critical process instrumentation such
as mass flow controllers, peristaltic pumps, and probe
transmitters. This instrumentation can be configured or
customized with up to six mass flow controllers as well as
up to four internal and two external pumps. The X-Station
mobile control console is the heart of the product line’s turnkey
capability. The power and versatility of the X-Station allow for
up to six XDR bioreactor systems to be controlled from one
single control unit. This truly modular design creates a processready system upon delivery and also supports integration into
a user-preferred automation platform.

XDR system components
Well-mixed bioreactor vessel
Constructed of 304 grade stainless steel (304 SS), the jacketed
vessel enables efficient heat transfer and, together with an
external temperature control unit (TCU), offers highly accurate
temperature control of the cell culture. The bioreactor vessel
features load cells for weight measurement and locking casters
with leveling feet. Other features include a bioreactor bag tubing
manager for convenient positioning and routing of the bag
tubing and a high-performance, bottom-mounted, magnetically
coupled drive system. Because of the bottom drive, there are no
shafts to install from the top of the bioreactor vessel, minimizing
ceiling height requirements. To aid in coupling and decoupling of
the drive system with the bioreactor bag, motor lifting assistive
devices are integral with the two largest bioreactor systems.
The systems are equipped with inlet and exhaust filter
holders and vessel sidewall viewing ports. A lower sidewall
port opening makes room for a sampling port as well as
probes for pH, dissolved oxygen (DO), and temperature. An
optional perfusion-specific bag loading door is available to
accommodate cell retention devices. The 1000 L and 2000 L
systems feature integrated bag loading doors that, along
with the semiautomatic bag hoist, simplifies bag insertion
without the need for climbing ladders. An efficient exhaust
gas filter heater is also included to avoid condensate that
could compromise exhaust filter performance.
The complete XDR bioreactor system product portfolio
supports operating volumes from 4.5 L up to 2000 L. The
smallest process development system is discussed in detail in
a separate data file (29-0929-27).

Versatile I/O cabinet
Fabricated in 304 SS, the NEMA4X-rated I/O cabinet houses
devices for liquid and gas management as well as pH and
DO transmitters. Profibus™ standard is used in device
communication and communication to X-Station or other control
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systems (e.g., Rockwell, DeltaV™, Honeywell, Siemens, and
Mitsubishi systems). Standard XDR gas and liquid management
configurations cover the majority of cell culture applications.
Liquid management
The I/O cabinet can be configured with up to four variablespeed peristaltic pumps with ranges to support liquid addition
or removal. The pumps can be programmed for fed-batch and
perfusion culturing and easily calibrated using Wonderware™
software.
Gas management
Up to six mass flow controllers offer multiple sparging regimes,
CO2 abatement at large scale, and overlay gas addition. The
XDR systems include a gas manifold to distribute the various
gases to the available bag destinations: sparger or headspace.
Measurements of DO and pH
DO and pH can be measured using conventional polarographic
sensors and glass electrodes, respectively. These sensors can
be autoclaved prior to use in a specially designed probe sheath.
Aseptic insertion into the bioreactor bag is conveniently done
using single-use connector technology. Alternatively, an optical
DO sensor and a single-use pH probe are available ready for
use to minimize start-up time. The flexibility of the system allows
the sensor technology to be mixed for use of conventional
and single-use technologies simultaneously. All sensors are
connected to the I/O panel through transmitters.
Measurement of dissolved carbon dioxide
Conventional, reusable, insertion-type, probe technology is
used for monitoring of dissolved carbon dioxide. A dedicated
transmitter is available optionally for integration into the I/O
panel.

Plug-and-play X-Station mobile control console
X-Station is a stand-alone, mobile control console featuring
intuitive process control, data historian, and industrial-quality
automation hardware and software (Fig 3). The control
system provides real-time data acquisition, enables accurate
process control, and offers convenient, real-time trending.
X-Station is capable of measuring and controlling up to six
XDR bioreactor systems simultaneously.
Inside the 304 SS cover is housed a
scalable programmable logic controller
(PLC)/programmable automation
controller (PAC) and a server-class
computer running user interface and
data historian software. X-station comes
with a 19” touchscreen, industrial, wash
down-resistant mouse, a QWERTY
keyboard and a built-in uninterruptible
power supply (UPS). Profibus and Ethernet
communication standards are included
for equipment and local area network
connectivity.

Fig 3. The X-Station
mobile control
console.

XDA bioprocessing consumables
The XDR bioreactor bag is an essential part of the process
performance achieved with XDR bioreactor systems.
Constructed with a contact layer of USP class VI-compliant
low-density polyethylene (LDPE) plastic, the bioreactor bags
are robust to withstand process conditions. All bioreactor
bag assemblies incorporate a seal-less, bottom-mounted,
impeller/sparger assembly with a centrally positioned
integral magnet (Fig 4A). Installed in the bioreactor vessel, the
impeller/sparger assembly couples with the magnetic drive
head, creating a powerful and robust agitation system with
minimal risk of seal leakage. Up to eight sparge elements
are included in the impeller/sparge assembly (Fig 4B). Each
sparge element may be configured with various porosities,
drilled holes, or a combination of both to support both
macro- and microsparging. Each of the standard sparge
elements have been validated to provide out-of-the-box
performance consistent with current cell culture practices.
A)

B)

Fig 4. (A) Impeller for XDR-2000 with four pitched blades. (B) Impeller/sparger
assembly for XDR-200 with three pitch blades and eight sparge elements.

The XDA bioreactor bags are available in Pro, Development,
or Custom formats. Pro-type bags are available for all
bioreactor systems and have validated sparge configurations,
established based on customer feedback and our own
biomanufacturing experience. Development bags are
available for XDR-50 and XDR-200 bioreactor systems and
differ from the Pro bags primarily in the configuration of the
sparge elements. Development bags may be used in a broad
array of process development activities where various microor macrosparging regimes are evaluated. Custom bioreactor
bags can be modified with tubing type and quantity,
connection type, filter element, or sparger configuration.
Custom bags can also incorporate a CO2-removal sparge
wand to address processes sensitive for dissolved CO2.
All bioreactor bags for cell culture include a magnetically
coupled, M40e 40°, pitched-blade impeller with ceramic
bearings. Ceramic bearings, originally developed for
aggressive mixing applications and fermentation, provide
excellent overall performance. The medical-grade ceramic
bearings meet the relevant industry requirements for
leachables, extractables, and particulates according to the
bag validation guide (for more information, please contact
your sales representative). Special impellers are available for
microcarrier applications.

Additional bag components include tubing with a combination
of weldable sections and aseptic connectors for liquid
addition/removal, a disposable pressure sensor, and filters for
exhaust, sparge, and overlay/headspace gas. XDA bioreactor
bags support both insertion-type reusable probes and singleuse probes. Probe configurations include reusable probes
only, single-use probes only, or mixed reusable and singleuse probes. For details on probes, see section “Measurement
of DO and pH”.
To assist in efficient bioreactor operation, a number of
supplementary XDA bag-related accessories are optionally
available. Like the main bioreactor bags, these accessories
are tightly coupled to the equipment design to be adaptable
to varied process requirements and to support operational
efficiency. XDA accessories include seal-and-store sample
manifolds, foam traps, X-Connect tubing sets, and exhaust
filter tubing sets.

Qualification support
The XDR bioreactor systems are designed for use in
environments that require 21 CFR Part 11 and Good
Automated Manufacturing Practice (GAMP) 5. The systems
are delivered with an operating manual, system specification,
drawings to support qualification, and major component
documentation. Industry standard installation and operation
qualification (IQ/OQ) packages are available as an option.

Applications
XDR cell culture bioreactor systems have successfully been
used to cultivate a wide range of cell types and organisms
including CHO cells, Vero cells, and MDCK cells. In addition,
a fermentor system is available for microbial applications
including E. coli, Pseudomonas spp., and yeast (see data
file 29-0929-29). XDR bioreactor systems can be operated
in batch, fed-batch, and perfusion (or chemostat) modes.
Bioreactor bag design can be process-dependent, requiring
customization for proper use and performance.

System specifications
Standard cell culture specifications are listed in Table 1.

Ordering information
Related literature

Code number

Xcellerex XDR-10 cell culture bioreactor system, data file

29-0929-27

Xcellerex XDR-50 MO fermentor system, data file

29-0929-29

Xcellerex XDUO Quad Mixing System, data file

29-0483-66

Xcellerex XDM Quad Mixing System, data file

29-0483-67

For more information on the bioreactor systems, please contact your local sales representative.
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Table 1. Specifications of standard configuration XDR cell culture bioreactor systems

Specification

XDR-50*

XDR-200

XDR-500

XDR-1000

XDR-2000

Max. working volume (L)

50

200

500

1000

2000

Min. working volume (L)

22

40

100

200

400

Volume turn-down ratio

2.2:1

5:1

5:1

5:1

5:1

Aspect ratio (H/D)

1.5:1

1.5:1

1.5:1

1.5:1

1.5:1

Filter heater assembly

1

1

1

1

1

Additional filter heater assemblies (optional)

1

1

1

1

1

Not applicable

Not applicable

Not applicable

Semi-automatic

Semi-automatic

Development:
29-0410-65
Pro: 29-0410-60

Development:
29-0410-66
Pro: 29-0410-61

Pro: 29-0410-63

Pro: 29-0410-64

Vessel

Jacketed 304 SS

Bag hoist
Impeller, M40e pitched-blade type

3 blades at 40° pitch

Standard bag assembly

Custom bag assembly

4 blades at 40° pitch

Pro: 29-0410-62

Available on request

Process instrumentation
pH probes†

1
(optional second probe)

2

2

2

2

DO probes†

1
(optional second probe)

2

2

2

2

MFC§ (standard)

4

4

4

5

5

Additional MFC‡ (optional)

2

2

2

1

1

Internal pumps (standard)

3
(2× low flow,
1× high flow)

3
(2× low flow,
1× high flow)

3
(2× low flow,
1× high flow)

4
(2× low flow,
2× high flow)

4
(2× low flow,
2× high flow)
Not applicable

Additional internal pumps (optional)

1

1

1

Not applicable

External pumps (optional)§

2

2

2

2

2

Temperature control unit¶
(heating, kW/cooling, HP)

3/1

9/1.5

9/1.5

9/1.5

9/1.5

3

4

4

4

4

Load cells

X-Station control unit
Interfaces

19”/52.4 mm touchscreen, wash-down compatible keyboard and mouse; includes built-in UPS

Hardware

Rockwell/Allen Bradley

Operator Interface

Wonderware HMI††

HMI Data Historian

Wonderware

††

Compliance

Built to GAMP5 standards/ 21 CFR Part 11 compliant‡‡

* For specifications of XDR-50 MO fermentation system, please see data file 29-0929-29.
†
Single-use or reusable probes
‡
Thermal mass flow controllers
§
External pumps are Profibus devices and may be Watson-Marlow™ 520, 620, or 720 series depending on required flow rate.
¶
Optional standalone heating/cooling TCU listed. Other TCU configurations available, including units that use facility chilled water/glycol.
††
Human-machine interface
‡‡
Customer will need to implement appropriate operating procedures to be fully 21 CFR part 11 compliant. The XDR is built to support this two-part compliance.
Note! For specifications of XDR-10 bioreactor system, please see data file 29-0929-27.

For local office contact information, visit
www.gelifesciences.com/contact
www.gelifesciences.com
GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden

GE, imagination at work, and GE monogram are trademarks of General Electric Company.
Xcellerex is a trademark of GE Healthcare companies.
DeltaV is a trademark of Emerson Electric Co. Wonderware is a trademark of Invensys plc. Profibus is a
trademark of PROFIBUS Nutzerorganisation e.V. Watson-Marlow is a trademark of Watson Marlow Pumps
Limited.
© 2014 General Electric Company—All rights reserved.
First published Feb. 2014
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TECHNISERV 3L GLASS TO 25,000L PRODUCTION
BIOREACTORS POWERED BY CONTROL PLATFORMS
FROM EMERSON, SIEMENS OR ALLEN BRADLEY.

SCAL-TECH® MINI
Glass Laboratory Scale

Established in 1982,the Techniserv Automation & Integration Group can
supply the Emerson DeltaV, Siemens DCS and/or Allen Bradley Control
Logics based control systems on Bioreactors from our 3L glass to 25,000L
production systems with Identical look, feel, and recipe function on any
size reactor.

3L,5L,7L,15L,20L

SCAL-TECH® BENCH
15L S/S 20L S/S 30L S/S
TCM
TCM

TCM
Harvest
Unit

TCM

Seed
Reactor
30L S/S Through 200L S/S

REACTOR
#1

REACTOR
#2

SCAL-TECH® Pro Suites
200L S/S Through 25,000L S/S

Filtration
Unit

TECHNISERV, INC.
Company Profile:
The Techniserv, Inc. Bioreactor and Fermentation and Process Equipment divisions are focused on providing both standard and custom process
systems to the Pharmaceutical, Biotech and related high purity industries, and have supplied many large modular systems to these companies. Our capabilities in design, fabrication, software development and validation allow delivery of
fully Turnkey integrated systems. Techniserv’s client list encompasses the majority of the largest US and International
Bio-Pharmaceutical manufacturers.
Featuring Emerson Delta V Operating System

Established in 1982, Techniserv’s Control System Integration
division also provides alternate customized control solutions utilizing conventional control platforms including Allen Bradley PLC’s, Emerson Delta-V DCS and Siemens PCS-7 DCS. Techniserv has developed many SCADA
systems utilizing packages such as Intellution, Rockwell RSView, Wonderware and more.
Techniserv, Inc. employs ten (10) electrical and automation engineers in the Control System Integration division,
eleven (11) mechanical and process engineers in the Bioreactor and Fermentation and Process Equipment
divisions, and multiple dedicated project managers and validation specialists.
Techniserv’s off the self standard bioreactor and fermentor systems can incorporate the Emerson Delta V control
package. For the first time, Techniserv can offer a Delta V based DCS control platform that seamlessly supports 3L
Glass through 25,000L production reactors.

Control Platforms:
Allen Bradley PLC
Emerson DeltaV DCS
Siemens PCS-7 DCS

Contacts:
Paul Heaps Sr.
CEO
paul_heaps1@techniservinc.com

Migration from Lab to Production
FDA 21CFR Part 11 Compliant
Utilizes Bused I/O Technologies
Supports PAT

Techniserv, Inc.
351 South Eaton St.
Berwick PA 18603
Phone: (570) 759-2315
Fax: (570) 759-2785
Web Site:
www.techniservinc.com

Paul Heaps II
President
paul_heaps2@techniservinc.com
Michael S. Smith
Vice President
Operations
michael_smith@techniservinc.com

Jacketed Tanks
Our cylindrical jacketed tanks are custom made to satisfy your
process, mixing, and temperature control requirements. Built
from 304, 304L, 316, or 316L stainless steel. Our jacketed
tanks can be easily adapted to meet your dimensional
requirements. All standard sizes have optional features that
allow for made-to-order applications.

Features at a glance:
•
•
•
•
•
•
•

Standard sizes 18 to 7,000 gallon
304, 304L, 316, 316L stainless steel
2B, #4/180, #7/320, and electropolish available
Flat, sloped, dished, or 15 ° cone bottom
ASME or non-ASME code stamped designs
Jackets available: embossed, dimple, half pipe, laser
Jacket design: pressure 150 psi, temperature 366° F

ISO 9001 Certified
600 Main Street
Sharpsville, PA 16150
office: 724-962-1100
fax: 724-962-1226
email: Sales@scacon.com
www.sharpsvillecontainer.com

Jacketed Tanks

Sharpsville Container is known for high quality fabrication in
stainless steel and exotic alloys. Our vessels, whether they are
process or transport, ASME, UN, or Heat Transfer are
manufactured for the Food, Chemical, Beverage, PetroChemical and Pharmaceutical markets. The size of vessels that
we manufacture range from 1 gallon to 25,000 gallons. With
our standard line and custom design expertise, we are capable
of meeting or exceeding your fabrication requirements. Our
reputation for quality and service continues to exceed our
customers’ expectations.
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3OLIDS EJECTING CENTRIFUGE
-ANY NEW BIOLOGICAL PRODUCTS ARE DERIVED FROM FRAGILE ORGAN
ISMS !LTHOUGH RELATIVELY EASY TO SEPARATE THE TRICK IS ACCOM
PLISHING THE SEPARATION IN A GENTLE MANNER WITHOUT DESTROY
ING THE SHEAR SENSITIVE CELL WALL MEMBRANES THAT ISOLATE THE
COMPLEX INTRACELLULAR PROTEINS FROM THE EXTRACELLULAR LIQUID )F
THIS CAN BE AVOIDED DOWNSTREAM PURIFICATION OF THE TARGET
PROTEINS BECOMES MUCH EASIER
!PPLICATIONS
4HE MACHINE IS DESIGNED FOR CLARIlCATION DUTY %SPECIALLY WHEN
CLARIFYING LIQUIDS FROM SHEAR SENSITIVE PARTICLES !PPLICATIONS
THAT REQUIRES LOW OXYGEN PICK UP CAN ALSO TAKE ADVANTAGE OF
THE HERMETIC FEATURES THIS MACHINE OFFERS
3TANDARD DESIGN
4HE MACHINE CONSISTS OF A FRAME THAT HAS A HORIZONTAL DRIVE
SHAFT WORM GEAR LUBRICATING OIL BATH AND HOLLOW VERTICAL
BOWL SPINDLE IN THE LOWER PART 4HE BOWL IS MOUNTED ON TOP
OF THE SPINDLE INSIDE THE SPACE FORMED BY THE UPPER PART
OF THE FRAME THE RING SOLIDS COVER THE COLLECTING COVER AND
THE FRAME HOOD 4HE LIQUID DISCHARGE SYSTEM ALSO RESTS ON
THIS STRUCTURE !LL PARTS IN CONTACT WITH THE PROCESS LIQUID
ARE MADE OF STAINLESS STEEL 4HE BOWL IS OF THE SOLIDS EJECT
ING DISC TYPE WITH AN AUTOMATIC HYDRAULIC OPERATING SYSTEM
FOR DISCHARGING )T IS A SO CALLED TIMER TRIGGERED PARTIAL DIS
CHARGE SYSTEM MEANING THAT ONLY PART OF THE BOWL CONTENT
IS EMPTIED DURING PRE SET DISCHARGE INTERVALS 4HE DISCHARGE
TAKES PLACE AT FULL SPEED WITHOUT ANY INTERRUPTION OF THE FEED
4HE CENTRIFUGE IS AVAILABLE WITH MAIN CONNECTIONS AS SANI
TARY FLANGES AND ALL OTHER UTILITY CONNECTIONS CLAMP TYPE 4HE
ELECTRIC MOTOR IS OF STANDARD TYPE AND HAS A BUILT IN VARI
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EQUIPPED WITH NOZZLES FOR FLUSHING OF THE BOWL TOP THE BOWL
BOTTOM AND THE CYCLONE
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application bulletin
No. 104-03

Industries, Inc.

Autoclave Systems – Heaters – Reactors –
for Vulcanizing Rubber, Plastic Products
and Composites
WSF has the experience and job-proven track
record of manufacturing rubber vulcanizing
equipment for production, R&D or process
simulation. We can provide a complete system
or furnish exactly what you need to maximize
your efficiency, versatility and profitability.
• Vulcanizers to ASME Code Standards in a wide
range of sizes and design pressures.
• Vertical or horizontal configurations using steam,
air-plus-steam, steam-water or “dry” heat.
• Controls to any degree of sophistication.
• Includes patented RAPIDOOR® for quick
access and external RAPID/LOADER®.
• Innovations include our unique RAPID/CURE®
continuous vulcanizer for wire, cable and hose.

Automated autoclave system for processing
rubber hose features a vertical-slide RAPIDOOR
and unique wheel-less, cart-loading
mechanism and ergonomic
load-positioning system.
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Data Sheet

Eshmuno® S resin
For superior downstream mAB purification
Eshmuno® is a unique family of ionexchange resins specifically designed for
highly productive downstream bioprocessing. The cation exchanger Eshmuno® S is
the first member of the Eshmuno® resin
family and is highly productive in direct
capture and post-protein A steps.

Benefits
t Superior productivity for mAB downstream
processing
t More selectivity and HCP removal
t Active tentacle adsorption
t Robust and safe packing procedures
t Tangible savings in cost and development time

Eshmuno® S resin characteristics
Type

Strong cation exchanger

Functional group

-SO3

Base matrix

Surface grafted rigid polyvinyl ether
hydrophilic polymer

Lysozym capacity

115–165 mg/mL settled resin

Ionic capacity

50–100 µeq/mL settled resin

Mean particle size

75–95 µm

IgG dynamic capacity

>60 mg/mL (2 min. residence time)

Pressure drop (100 x 16 mm,
5 mL/min., 150 cm/h)

<1.0 bar

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

Superior productivity for mAB
downstream processing

Binding capacity of purified mAB03 on Eshmuno® S resin
70

Superior mAB binding capacity in direct capture step

DBC (mg/mL)
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30

20 cm i.d. column; 19,5 cm bed height; 8% compression
recorded in 150 mM NaCl

20
10
0

pH 5.5
3.5 mS/cm
25 mM acetate/
25 mM phosphate

DBC of mAB03 5 mg/mL in buffer A, 2 min. residence time,
1 mL scout column

90

60

pH 5
3.5 mS/cm
25 mM acetate/
25 mM phosphate

Figure 2.

Net pressure drop (bar)

In combination with the excellent pressure flow behaviour
(Fig. 3) an outstanding productivity of more than
40 mg/mL x h (dimension for productivity) for Eshmuno® S
resin can be achieved, resulting in considerable manufacturing cost savings in mAB production.

CEX2

20

A similar superior binding capacity can be shown in
post-protein A purification steps. Fig. 2 illustrates the
increased binding capacity of Eshmuno® S resin in an
intermediate purification step of mAB03.

Pressure versus flow curve of
Eshmuno® S resin

CEX1

50

DBC mAB03

Eshmuno S resin exhibits a superior binding capacity for
antibodies compared to other modern cation-exchangers.
Fig. 1 shows the dynamic binding capacity (DBC) for
direct capture of a monoclonal antibody mAB02 at 5%
breakthrough and 5 min. residence time from a real
diluted feedstock. The DBC of Eshmuno® S resin is
approximately 50% higher than the capacity of other
surface-grafted cation exchangers.

Escmuno® S resin

60

®

Eschmuno® S resin

CEX1

CEX2

Figure 1.
mAB02 DC, 5% breakthrough, 4.3 mS/cm, pH 6.0 [mAB02]
= 0.62 mg/mL, 5 min. residence time, 1 mL scout column

More selectivity and HCP removal

Active tentacle technology

A crucial property of any ion exchange material in
biochromatography is the ability to specifically select the
biomolecule of interest. While Eshmuno® S resin carries
the same functional group like Fractogel® SO³ resin, a
slightly modified selectivity can be observed (Fig. 4),
which allows a wider flexibility for the specific purification challenge.

Merck KGaA was the first manufacturer of a biochromatography resin (Fractogel®) with tentacle structure
(Fig. 6). The main advantage of this tentacle chemistry
is the increased amount of sterically accessible ligands
to more effectively bind the biomolecule of interest thus
increasing the capacity of the resin.

The result: Eshmuno® S resin is the most efficient resin in
the removal of host cell proteins (Fig. 5).
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Eshmuno® S resin combines both, the reliable tentacle
technology with the properties of a new hydrophilic
polyvinyl ether base matrix. The polymer matrix allows
the use of much higher flow rates, while the biomolecule
is still strongly bound by the tentacle.

Chymotrypsinogen A
Cytochrome C
Lysozyme

Eshmuno® S resin

Figure 4.
A mixture of Chymotrypsinogen A, Cytochrome C, and
Lysozyme was separated under standard conditions
160
140

HCP clearance

120
100
80
60
40
20
0

Eschmuno® S

IEX1

IEX2

Figure 5.
HCP Clearance factor of mAB02, 5% breakthrough, 4.3 mS/cm,
pH 6.0, 5 min. residence time, 1 mL scout column

Figure 6.
Resin tentacles forming a three-dimensional ion exchange
network, enable easy access of the proteins to the ligands

Robust and safe packing
procedures
®

Eshmuno S resin can be easily packed into production
scale columns for biochromatography either by simple
flow packing or axial compression. To prevent corrosion
of the tubing system, Eshmuno® columns can be packed
using 0.01 M sodium hydroxide solutions and even pure
water resulting in plate numbers >2400/m with good
peak symmetry.

Ordering Information
Description

Eshmuno® S resin

Catalogue No.

1.20078

For the packing of Eshmuno® and sanitization of the
column we recommend EMD Millipore chemicals
especially dedicated for the use in biopharmaceutical
production with the brandname EMPROVE® bio.

Tangible savings in cost and
development time
With the use of Eshmuno® S resin in downstream
processing considerable manufacturing cost savings can
be achieved. The productivity of purification in a model
process of a monoclonal antibody could be increased
5-fold by using Eshmuno® S resin instead of a conventional soft-gel ion exchanger. The use of Eshmuno® S
resin instead of a protein A based capture step can save
up to 30% of your purification costs.

To Place an Order or Receive
Technical Assistance
In the U.S. and Canada, call toll-free 1-800-645-5476

www.millipore.com
EMD Millipore and the M mark are trademarks of Merck KGaA, Darmstadt, Germany.
Eshmuno and Fractogel are registered trademarks of Merck KGaA, Darmstadt, Germany.
Lit. No. DS5222EN00 06/2012 DP SBU-12-06680 Printed in the USA.
©2012 EMD Millipore Corporation, Billerica, MA 01821 USA. All rights reserved.

For other countries across Europe and the world,
please visit www.millipore.com/offices
For Technical Service, please visit
www.millipore.com/techservice
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Ion exchange media

Capto™ S
Capto Q
Capto DEAE
Capto S, Capto Q and Capto DEAE are, respectively, strong cation, strong
anion and weak anion exchange BioProcess™ media for capture and
intermediate purification of proteins from large feed volumes by packed
bed chromatography.
All Capto media provide:
• Raised productivity with high dynamic binding capacity at high
flow.
• Increased yield with rapid mass transfer.
• Reduced process time with high volume throughput.
• Cost-effective processing with smaller unit operations.
• For effective and rigorous CIP procedures.
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3 Method optimization ....................................................... 10
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8 Ordering information ...................................................... 31

2

28-4074-52 AD

1 BioProcess media
BioProcess media are developed and supported for productionscale chromatography. All BioProcess media are produced with
validated methods and are tested to meet manufacturing
requirements. Secure ordering and delivery routines give a reliable
supply of media for production scale. Regulatory Support Files
(RSF) are available to assist process validation and submissions to
regulatory authorities. BioProcess media cover all purification
steps from capture to polishing.

2 Properties of Capto S, Capto Q
and Capto DEAE
For ion exchange chromatography, Capto S uses a sulfonate group
(Fig 1a), Capto Q uses a quartenary amine group (Fig 1b) and Capto
DEAE uses a diethylaminoethyl group (Fig 1c).
-

SO 3

O

Fig 1a. The strong cation exchange group of Capto S.

OH
O

+
N(CH3)3

Fig 1b. The strong anion exchange group of Capto Q.
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3

O

+

NH(CH2CH3)2

Fig 1c. The weak anion exchange group of Capto DEAE.

Capto S, Capto Q and Capto DEAE are designed to increase speed,
capacity, and throughput in capture and intermediate purification
of biomolecules. By offering high capacity at high flow velocities
with low back pressure, process cycle times may be reduced and
productivity increased.
Capto S, Capto Q and Capto DEAE are based on the same high flow
agarose matrix which is designed to give low back pressures at
high fluid velocities (700 cm/h in a 1 m diameter column with 20 cm
bed height at ‹ 3 bar in water). Note that the back pressure will vary
with column type and medium bed height. Figure 2 shows the
pressure/flow curve for Capto S packed in AxiChrom™ 1000.
All media have dextran surface extenders for increased capacity,
and fast mass transfer.

4
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Fig 2. Pressure/flow curve for Capto S compared to Q Sepharose™ Fast Flow.
Running conditions: AxiChrom 1000 for Capto S, Chromaflow™ 1000 for
Q Sepharose Fast Flow, 20 cm packed bed, with water at 20ºC. The pressure
includes pressure drop from the bed and the column. System/tubing
pressure is excluded.
The highly cross-linked agarose base matrix gives the media high chemical
and physical stability. Characteristics such as capacity, elution behavior, and
pressure/flow rate are unaffected by the solutions commonly used in
process chromatography and cleaning procedures (Tables 1, 2 and 3).
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Table 2. Characteristics of Capto Q
Matrix

High flow agarose with a dextran surface extender

Ion exchange type

Strong anion, Q

Charged group

–N+(CH3)3

Total ionic capacity

0.16 to 0.22 mmol Cl¯/ml medium

Particle size1

90 µm (d50v)

Flow velocity

700 cm/h in a 1 m diameter column with 20 cm
bed height at 20°C using process buffers with the
same viscosity as water at ‹ 3 bar (0.3 MPa)

Dynamic binding
capacity2

› 100 mg BSA/ml medium

pH stability3
Working range

2 to 12

Cleaning-in-place

2 to 14

Working temperature

4°C to 30°C

Chemical stability

All commonly used aqueous buffers, 1 M acetic
acid, 1 M NaOH4, 8 M urea, 6 M guanidine
hydrochloride, 30% isopropanol and 70% ethanol

Avoid

Oxidizing agents, anionic detergents

Storage

20% ethanol

1
2

3

4

d50v is the median particle size of the cumulative volume distribution.
Dynamic binding capacity at 10% breakthrough as measured at a residence time of 1
minute, 600 cm/h in a Tricorn 5/100 column with 10 cm bed height, in a 50 mM TrisHCl buffer, pH 8.0.
Working range pH: pH interval where the medium can be operated without significant
change in function.
Cleaning-in-place pH: pH stability where the medium can be subjected to cleaning- or
sanitization-in-place without significant change in function.
No significant change in dynamic binding capacity and carbon content after 1 week
of storage in 1 M NaOH at 40°C.

28-4074-52 AD
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3 Method optimization
The aim of designing and optimizing an ion exchange separation
process is to identify conditions that promote binding of the
highest amount of target molecule, in the shortest possible time
with highest possible product yield and purity. Design the method
in laboratory scale.
For certain proteins, dynamic binding capacities increase at
increased conductivity. Therefore, we recommend scouting for
optimal dynamic binding conditions on Capto S, Capto Q and
Capto DEAE, for the target protein at conductivities between
2 mS/cm and 15 mS/cm as well as scouting for optimal binding pH.
For Capto S and Capto DEAE, the dynamic binding capacities
decrease for some proteins at lower temperatures. Screening for
buffer concentration at the temperature where the process is
intended to be run will give the optimal dynamic binding capacity.
Since Capto S, Capto Q and Capto DEAE allow efficient capture at
high fluid velocities, pay special attention to optimizing elution
conditions to avoid tailing peaks when eluting the protein of
interest.
Balancing product recovery against throughput is the major
consideration when optimizing a method. The dynamic binding
capacity for the target protein should be determined using process
feedstock. Since the dynamic binding capacity is a function of the
fluid velocity applied during sample application, the breakthrough
capacity must be defined over a range of different residence times
to show the optimal level of throughput.
When designing a process it is also important to take the cleaning
of the media into consideration. Capto DEAE can be more
challenging to clean than Capto S and Capto Q, for more details,
see Chapter Maintenance.
For more information about method development and
optimization, consult the handbook, Ion exchange
Chromatography & Chromatofocusing: Principles and Methods,
(11-0004-21).

10
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4 Scale-up
Principles for scale-up
After optimizing the method at laboratory scale, the process can
be scaled up. Scale-up is typically performed by keeping bed
height and linear fluid velocity constant while increasing bed
diameter and volumetric flow rate. However, since optimization is
preferentially performed with small column volumes, in order to
save sample and buffer, some parameters such as the dynamic
binding capacity may be optimized using shorter bed heights than
those being used in the final scale. As long as the residence time is
kept constant, the binding capacity for the target molecule
remains the same.
Other factors, such as clearance of critical impurities, may change
when column bed height is modified and should be validated using
the final bed height. The residence time is approximated as the bed
height (cm) divided by the linear fluid velocity (cm/h) applied during
sample loading.

Suggested procedure for scale-up
1 Select the bed volume according to required binding capacity.
Keep sample concentration and gradient slope constant.
2 Select a column diameter to obtain a bed height of 10 cm to
40 cm. The high rigidity of the Capto S, Capto Q and Capto DEAE
base matrix allows for bed heights well above 20 cm.
3 The larger equipment used when scaling up may cause some
deviations from the method optimized at small scale. In such
cases, check the buffer delivery system and monitoring system
for time delays or volume changes. Different lengths and
diameters of outlet tubing can cause zone spreading on larger
systems.

28-4074-52 AD
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Calculating amount of medium
The amount of medium needed can be calculated by: column
cross-sectional area (cm2) × bed height (cm) × compression factor
(settled medium bed height/ packed medium bed height).

Washing the medium
Equilibrate all materials to room temperature. Mount the glass
filter funnel onto the filtering flask. Pour the medium into the funnel
and wash with approximately 5 to 10 ml 10 mM NaCl per ml
medium.

Preparing the packing slurry
The slurry concentration should be 40 to 60% in 10 mM NaCl,
measured in a measuring cylinder after settling overnight.

Equipment needed
An ÄKTA design system or a stand-alone pump that can deliver
20 ml/min is used. The pump filter unit and the flow restrictor
should be removed due to the high flow velocity used in the column
packing in order to decrease the system backpressure.
For packing Tricorn 5/100 column
Tricorn 5/100 column, Tricorn 5/100 glass tube (used as a packing
reservoir), packing connector 5-5 and bottom unit.
For packing Tricorn 10/100 column
Tricorn 10/100 column, Tricorn 10/100 packing equipment, which
includes the 10 mm packing connector, Tricorn 10/100 glass tube
(used as a packing reservoir), and bottom unit with filter holder, cap
and stop plug.
When working with large volumes, real feed or repeated loading,
Tricorn coarse filter kits are recommended to reduce the risk of
clogging. Use Tricorn 5 Coarse Filter Kit (11-0011-53) or Tricorn 10
Coarse Filter Kit (11-0012-54).

14
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Packing procedure
To pack the column, use 10 mM NaCl in distilled water and proceed
as follows:
1 Rinse the column and packing tube in 10 mM NaCl.
2 Insert a bottom filter into the filter holder and wet the filter.
3 Wet the O-ring on the filter holder by dipping the filter holder
into water, buffer, or 20% ethanol.
4

Insert the filter holder into the column tube. Ensure that the
“keyed” part of the filter holder fits into the slot on the threaded
section on the column tube. Screw the end cap onto the column
tube.

5 Pour the packing solution into the tube and ensure that the
liquid drips from the column. Insert a stop plug into the bottom
unit when approximately 1 cm of packing solution remains.
6 Screw a suitable Tricorn packing connector onto the top of the
column tube. The Tricorn packing connector must be fitted with
suitable O-rings (included with the Tricorn packing connector).
Screw the Tricorn packing tube into the upper fitting of the
Tricorn packing connector.
7 Mount the column and packing unit vertically on a lab stand.
8 Fill both column tube and packing tube with slurry. Avoid
formation of air bubbles in the gel by pouring it along a thin
capillary.
9 Attach an extra bottom unit or an adapter unit to the top of the
packing tube. Fill the capillary from the pump with packing
solution and connect the pump to the top of the packing unit,
remove the stop plug from the bottom of the column tube.
10 Pack the medium at 540 cm/h (1.8 ml/min in Tricorn 5/100,
7.1 ml/min in Tricorn 10/100). When the liquid above the
medium bed is clear, continue packing for 10 min.
11 Pack the medium for an additional 10 min at 3000 cm/h (Tricorn
5/100: 9.8 ml/min, Tricorn 10/100: 39.3 ml/min).

28-4074-52 AD
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12 Switch off the pump and connect a stop plug into the bottom
unit. Remove the packing tube and packing connector. If
necessary, remove excess medium with a Pasteur pipette or
spatula by re-suspending the top of the packed bed. Ensure
that the medium surface is as even as possible.
13 Add packing solution to the upper edge of the column tube.
14 Place a pre-wetted filter on top of the fluid in the column.
Note: The top coarse filter is inserted by another procedure.
See separate instruction included in Tricorn coarse filter
kits.
15 Prepare the adapter unit by screwing the guiding ring, inside
the adapter unit, down to the lower end position.
16 Wet the O-ring on the adapter unit by dipping it in water,
packing solution, or 20% ethanol.
17 Screw the guiding ring back 1.5 turns.
18 Mount the top adapter unit onto the column tube, ensuring the
inner part of the guiding ring fits into the slot on the column
tube threads. Ensure that there are no air bubbles.
Note: The top adapter should be connected but not fully
screwed down.
19 Connect the pump, remove the stop plug and start a flow
(Tricorn 5/100: 1 ml/min (300 cm/h), Tricorn 10/100: 5 ml/min
(380 cm/h)).
20 Slowly screw the adapter unit down until the filter meets the
bed surface. Ensure that the filter meets the bed horizontally.
21 Increase the flow to 3000 cm/h (Tricorn 5/100: 9.8 ml/min,
Tricorn 10/100: 39.3 ml/min).
22 If the medium bed compresses, slowly screw the adapter unit
down to the medium surface with maintained flow.
23 Pack the medium for 5 min. If the bed has compressed further,
screw the adapter unit down to the medium surface.
24 Stop the flow and connect a stop plug to the bottom unit.

16
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7 Maintenance
For best performance from Capto S, Capto Q and Capto DEAE, and
to maximize the working life time of the media, follow the
procedures described below.

Equilibration
After packing, and before a chromatographic run, equilibrate with
equilibration buffer by washing with at least five bed volumes for
Capto S and Capto Q and at least 10 bed volumes for Capto DEAE,
or until the column effluent shows stable conductivity and pH
values. The equilibration step can be shortened by first washing
with a high concentration buffer to obtain approximately the
desired pH value and then washing with equilibration buffer until
the conductivity and pH values are stable.

Regeneration
After each separation, elute any reversibly bound material with a
high ionic strength solution (e.g., 1–2 M NaCl in buffer). Regenerate
the medium by washing with at least five bed volumes of
equilibration buffer for Capto S, Capto Q and Capto DEAE, or until
the column effluent shows stable conductivity and pH values.

Cleaning-In-Place
Cleaning-In-Place (CIP) is a procedure that removes contaminants
such as lipids, endotoxins, and precipitated or denatured proteins
that remain in the packed column after regeneration. This type of
contamination occurs frequently when working with feedstock.
Regular CIP prevents the build-up of contaminants in the packed
bed and helps to maintain the capacity, flow properties, and
general performance of Capto S, Capto Q and Capto DEAE.
A specific CIP protocol should be designed for each process
according to the type of contaminants present. The frequency of
CIP depends on the nature and the condition of the feedstock, but
for capture steps, CIP is recommended after each cycle.
Note:

28-4074-52 AD

For some contaminants a more rigorous CIP procedure can
be required for Capto DEAE than for Capto S and Capto Q,
see CIP protocols, below.
29

CIP protocols
Precipitated, hydrophobically
bound proteins or lipoproteins

Wash with 1 M NaOH at 40 cm/h with
reversed flow direction. Contact time 1
to 4 h, dependent on feed. If the
removal of contaminants is not
satisfactory for Capto DEAE, use 1 M
NaOH containing 1 M NaCl as CIP
solution.

Ionically bound proteins

Wash with 0.5 to 2 column volumes (CV)
of 2 M NaCl with reversed flow
direction. Contact time 10 to 15 min.

Lipids and very hydrophobic
proteins

Wash with 2 to 4 CV of up to 70%
ethanol1 or 30% isopropanol with
reversed flow direction. Contact time 1
to 2 h, dependent on feed. Alternatively,
wash with 2 to 4 CV of 0.1% nonionic
detergent with reversed flow direction.
Contact time 1 to 2 h, dependent on
feed.

1

Specific regulations may apply when using 70% ethanol since the use of explosionproof areas and equipment may be required.

Sanitization
To reduce microbial contamination in the packed column,
sanitization using 0.5 to 1 M NaOH with a contact time of 1 h is
recommended. The CIP protocol for precipitated, hydrophobically
bound proteins or lipoproteins sanitizes the medium effectively.

Storage
Store unused medium in the container at a temperature of
4°C to 30°C. Ensure that the cap is fully tightened. Packed media
and bulk media should be stored in 20% ethanol containing 0.2 M
sodium acetate (Capto S) or 20% ethanol (Capto Q and Capto
DEAE). After storage, equilibrate with at least five column volumes
of starting buffer for Capto S and Capto Q and at least 10 bed
volumes of starting buffer for Capto DEAE before use.

30
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8 Ordering information
Product

Quantity

Code No

Capto S

25 ml

17-5441-10

100 ml

17-5441-01

1l

17-5441-03

5l

17-5441-04

10 l

17-5441-05

60 l

17-5441-60

25 ml

17-5316-10

100 ml

17-5316-02

1l

17-5316-03

5l

17-5316-04

10 l

17-5316-05

60 l

17-5316-60

25 ml

17-5443-10

100 ml

17-5443-01

1l

17-5443-03

5l

17-5443-04

10 l

17-5443-05

60 l

17-5443-60

Capto Q

Capto DEAE

Capto S bulk media products are supplied in suspension in 20%
ethanol containing 0.2 M sodium acetate. Capto Q and Capto DEAE
bulk media products are supplied in suspension in 20% ethanol.
For additional information, including a Data File, please contact
your local GE Healthcare representative.
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Related product

Quantity

Code No

HiScreen Capto S

1 x 4.7 ml

28-9269-79

HiScreen Capto DEAE

1 x 4.7 ml

28-9269-82

Tricorn 5/100 column

1

18-1163-10

Tricorn 10/100 column

1

18-1163-15

HiScale 16/20

1

28-9644-41

HiScale 16/40

1

28-9644-24

HiScale 26/20

1

28-9645-14

HiScale 26/40

1

28-9645-13

HiScale 50/20

1

28-9644-45

HiScale 50/40

1

28-9644-44

Related literature

Code No

Movie

Column Packing – The Movie

18-1165-33

Handbook

Ion Exchange Chromatography &
Chromatofocusing: Principles and Methods

11-0004-21

Data file

Capto Q, Capto S and Capto DEAE

11-0025-76

Application notes

High productivity capture of -chymotrypsin
on Capto S cation exchange

28-4078-15

Screening and optimization of the loading
conditions on Capto S

28-4078-16

Capto S cation exchanger for post-Protein A
purification of monoclonal antibodies

28-4078-17

High-productivity capture of Green
Fluorescent Protein on Capto Q

11-0026-20

Screening of loading conditions on Capto S
using a new high-throughput format,
PreDictor plates

28-9258-40

Process-scale purification of monoclonal
antibodies - polishing using Capto Q

28-9037-16

Purification of a monoclonal antibody using
ReadyToProcess columns

28-9198-56

Use of Capto ViralQ for the removal of
genomic DNA from influenza virus produced in
MDCK cells
28-9769-69
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Antibody Purification

Ab Buffer Kit
Introduction

Buffer preparation.

Ab Buffer Kit contains 10X stock solutions of Binding and Elution
buffers and ready to use Neutralizing buffer. The buffers are optimized
for rapid purification of monoclonal and polyclonal IgG using
immobilized Protein A or Protein G.
The kit eliminates time-consuming buffer preparation and thus
promotes fast, reproducible and convenient purification work.
The buffers have been prepared using the highest quality chemicals
and water, and have been filtered through a 0.45 µm filter.

Table 1. Buffer preparation for 1 purification on 1 ml HiTrap columns.

The following protocols can be used with buffers from Ab Buffer Kit:
• Protocol 1, using 1 ml or 5 ml HiTrap™ columns.
• Protocol 2, using SpinTrap™ columns (Protein A HP SpinTrap,
Protein G HP SpinTrap and Ab SpinTrap).
• For Ab purification using multiwell plates, please follow the
instruction provided with the Protein A HP or Protein G HP
MultiTrap™ product.

Table 2. Buffer preparation for 1 purification on 5 ml HiTrap columns.

Kit content

Protocol
1

Buffer

Buffer content

Formulation Volume

Binding Buffer

0.2 M sodium
phosphate, pH 7.0*

10X

50 ml

Elution Buffer

1 M glycine-HCl,
pH 2.7

10X

15 ml

Neutralizing buffer 1 M Tris-HCl, pH 9*
*

Protocol 1
Use this protocol for:
• HiTrap Protein G HP
• HiTrap Protein A HP
• HiTrap Protein A FF

Recommendations
•

•
•

•

Recommended flow rates:
Approx. 1–3 ml/min for HiTrap 1 ml columns
Approx. 5–10 ml/min for HiTrap 5 ml columns.
Prepare buffers according to Table 1 or 2.
Prepare collection tubes by adding 60 to 200 µl of Neutralizing
buffer per ml of fraction to be collected. In this way the final pH
of the eluted antibodies will be approximately neutral, which
preserves the activity of acid labile IgG.
Check also the relevant column instructions.

Stock
solution

Distilled
water

Final
volume

Binding buffer

2.5 ml

22.5 ml

25 ml

Elution buffer

0.5 ml

4.5 ml

5 ml

Buffer

Stock
solution

Distilled
water

Final
volume

Binding buffer

12.5 ml

112.5 ml

125 ml

Elution buffer

2.5 ml

22.5 ml

25 ml

Prepare the sample by centrifugation (10 000 × g, 20 min) or filter
(0.45 µm) if there are particles present or the appearance is
cloudy.
-

If the sample is serum or ascites fluid, dilute the sample 1:1
with Binding buffer.

2

Fill the syringe with Binding buffer. Remove the stopper and
connect the column to the syringe (with the provided adapter)
"drop to drop" to avoid introducing air into the column.

3

Remove the snap-off end at the column outlet.

4

Wash the column with 10 column volumes (CV) of Binding buffer
(1 CV = 1 ml for HiTrap 1-ml column; 1 CV = 5 ml for HiTrap 5-ml
column).

5

Apply the sample, using a syringe fitted to the Luer adapter.
Collect the flowthrough.

6

Wash with 5 to 10 CV of Binding buffer or until no material
appears in the effluent. Collect wash fractions.

7

Elute with 2 to 5 CV of Elution buffer. Collect 1-ml fractions in
collection tubes containing Neutralizing buffer.

Ready to use 25 ml

Containing 20% ethanol as a preservative

Buffer
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Antibody Purification

Protocol 2

Protocol

Use this protocol for:
• Ab SpinTrap
• Protein A HP SpinTrap
• Protein G HP SpinTrap

1

Invert and shake the Ab SpinTrap column repeatedly to
resuspend the medium.

2

Loosen the top cap one-quarter of a turn and break off the
bottom closure.

Recommendations

3

Place the column in a 2-ml microcentrifuge tube and centrifuge
for 30 s at 70 to 100 × g to remove the storage liquid.

4

Remove the top cap. Equilibrate the column by adding 600 µl
Binding buffer. Centrifuge for 30 s at 70 to 100 × g.

5

Add the sample. Maximum sample volume is 600 µl/load.

6

Secure the top cap tightly and incubate for 4 min with gentle
mixing (mixing with an end-over-end mixer machine is
recommended but other methods can also be used).

7

Loosen the top cap one-quarter of a turn, centrifuge for 30 s at
70 to 100 × g.
Several sample applications can be performed provided that the
capacity of the column is not exceeded. Repeat this step after
each application. Empty the microcentrifuge tube as needed.

•
•

•
•
•

The protocol is optimized for room temperature. If performed at
a lower temperature, a longer incubation time may be needed.
Use Ab SpinTrap columns with a standard microcentrifuge.
Place a column in a 2-ml microcentrifuge tube to collect liquid
during centrifugation.
Prepare buffers according to Table 3.
Prepare two collection tubes per sample for eluted fractions by
adding 30 µl Neutralizing buffer to a 2-ml microcentrifuge tube.
Check also the relevant column instructions.

Buffer preparation
Table 3. Buffer preparation for 10 purifications on Ab SpinTrap
columns or 20 reactions using MultiTrap multiwell plates.
Buffer

Stock
solution

Distilled
water

Final
volume

8

Wash with 600 µl Binding buffer. Centrifuge for 30 s at 70 to
100 × g.

Binding buffer

2 ml

18 ml

20 ml

9

Repeat the wash.

Elution buffer

1 ml

9 ml

10 ml

10 Elute the bound antibody by adding 400 µl Elution buffer to the
column.
11 Place the column in a 2-ml microcentrifuge tube containing 30 µl
Neutralizing buffer.
12 Centrifuge for 30 s at 70 × g.
The eluted fraction contains the purified antibody.
13 Repeat this step one time, collecting the second elution in a fresh
2-ml microcentrifuge tube containing 30 µl Neutralizing buffer.
Most of the bound antibody is eluted after two elution steps.
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Antibody Purification

Ordering information
Products
Description

Quantity

Code No.

Ab Buffer Kit

1

28-9030-59

Description

Quantity

Code No.

Protein A HP SpinTrap
Protein G HP SpinTrap
Ab SpinTrap
Protein A HP MultiTrap
Protein G HP MultiTrap
HiTrap Protein G HP, 1 ml
HiTrap Protein G HP, 1 ml
HiTrap Protein G HP, 5 ml
HiTrap Protein G HP, 5 ml
HiTrap Protein A HP, 1 ml
HiTrap Protein A HP, 1 ml
HiTrap Protein A HP, 5 ml
HiTrap Protein A HP, 5 ml
HiTrap rProtein A FF, 1 ml
HiTrap rProtein A FF, 1 ml
HiTrap rProtein A FF, 5 ml
HiTrap rProtein A FF, 5 ml

16 columns
16 columns
50 columns
4 × 96-well plates
4 × 96-well plates
2 columns
5 columns
1 column
5 columns
2 columns
5 columns
1 column
5 columns
2 columns
5 columns
1 column
5 columns

28-9031-32
28-9031-34
28-4083-97
28-9091-33
28-9091-35
17-0404-03
17-0404-01
17-0405-01
17-0405-03
17-0402-03
17-0402-01
17-0403-01
17-0403-03
17-5079-02
17-5079-01
17-5080-01
17-5080-02

Related products

Literature

3

Title

Code No.

Antibody Purification Handbook
Affinity Chromatography Handbook
Affinity Chromatography Columns and Media
Product Profile

18-1037-46
18-1022-29
18-1121-86

Instructions 28-9034-55 AC

www.gelifesciences.com/sampleprep

Antibody Purification
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Drop Design, SpinTrap, MultiTrap, and HiTrap are trademarks of GE Healthcare companies.
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Filters
V I R U S R E M OVA L FO R
B I OT H E R A PE U T I C
PRO D U C T S

Planova™ BioEX Filters

PVDF Hollow Fiber Filter
Construction
™

6

Effective for High-Pressure and
High-Concentration Usage
2

Flow rate is dependent on pressure. Higher pressure yields
faster processing.

Relationship between h-IgG throughput
and h-IgG concentration

Planova BioEX filters can withstand high-concentration solutions, thereby increasing the quantity of protein to be processed.

7

Planova™ BioEX Performance

High LRV for Parvoviruses and

Laboratory-Scale and Process-Scale

Larger Viruses
Planova™

2
2
2

2

2

Standard Clamp Connections and
SIP Capability

2
2

2

Removability of PPV, MVM and A-MuLV
for Planova BioEX

Ferrule connection nozzle design
enhances connection stability.

Predictable Results

Not detected

Even for high-volume filtration of high-concentration
solutions, Planova BioEX removes parvoviruses and larger
viruses.

Product Applications

Examples of Protein Recovery Rate
Polyclonal IgG
(30mg/ml)
Planova 15N
Planova 20N
Planova 35N
Planova BioEX
NT: Not tested

Nomenclature

Monoclonal IgG
(20mg/ml)

Factor VIII
(100IU/ml)

Contact Information
North & South America

Europe

Asia & Oceania

Warning
Planova™

Planova™

Intelligent BioProcessing Systems
Automated, Aseptic Transfer of Liquids into Multiple,
Single-use Storage Bags
Summary:
The Fill Master aseptically transfers solution into multiple, plastic storage bags. The Fill
Master controls up to twelve, pneumatically operated tube pinch valves to direct the
liquid flow from the reservoir into sterile storage bags. Only the internal tube walls and
the inside bag surfaces are in contact with the liquid. The high-accuracy, low-shear
peristaltic pump action provides gentle and reproducible bag filling. In the
programmable, volume dispensing mode, the Fill Master meters a user-defined volume
of liquid, then automatically switches to the next empty storage bag to be filled. Up to 12
storage bags can be serially filled in this fashion. Once filled, the bags can be
aseptically sealed using a sterile tube welder.

Features:
There are several Fill Master models to choose from. For example, the Fill Master 104B
peristaltic pump head (max. pump rate is 14.6 liters/min with #184 Silicone tubing)
allows for a continuous tube connection to be made between the reservoir and the
storage bag manifold. A typical sterile fluid handling bag manifold, which may include
multiple storage bags, as well as integral tubing, QC bags, sterilizing filter and
connectors, are available pre-sterilized (i.e. gamma irradiated). Contact SciLog for info.
When ordering a sterile fluid handling bag manifold, the size and material of the integral
tubing must be specified. The Fill Master 104B peristaltic pump head can accommodate
the following tubing sizes: #26, 6.4 mm ID (0.15 to 2.60 liters/min); #73, 9.6mm ID (0.31
to 5.94 liters/min); #82, 12.7 mm ID (0.53 to 9.25 liters/min) and #184, 15.9 mm ID (0.80
to 14.50 liters/min) A range of tube materials can be used: Silicone, Pharmed, PVC and
C-Flex (heat sealable). Other Fill Master models accommodate additional sizes.
An optional, disposable pressure transmitter can be placed in front of the in-line
sterilizing filter to monitor filter backpressure. With the pressure transmitter connected to
the Fill Master, excessive pressure build-up as well as associated leaks and bag failures
are prevented. The Fill Master will stop all pumping action when a user-defined safe
pressure limit is exceeded.
-541-Drive #4, Middleton, WI 53562-2562
SciLog Inc, 8845 S. Greenview
Web: www.scilog.com Tel: 800-955-1993 Fax: 608-824-0509

Automated Bag Filling Operation: Fill Master Metering Program
The Fill Master Volume-Flow mode (Mode 30) allows you to enter (in “EDIT”) and store an
automated metering program. The following is a simple program to fill three, 20 liter storage
bags. Change the RATE and TIME program steps to suit your storage bag volume. Add
additional “RUN” program blocks to increase the number of bags (up to 12) you want to fill.
000
001
002
003
004
005

START
CW
RUN
V 100000
RATE: 5.0L/min
TIME: 00:04:00

The following program steps have been entered in Mode 30:
Motor Runs Clock-wise
Motor is turned “ON”
Pinch Valve V1 is Energized, other V-valves are De-energized
Pump Rate 5 liters per minute
Pump Runs 4 minutes, Bag #1 is filled with 20 Liters

006
007
008

STOP
V 020000
TIME: 00:00:02

Pump “Off”
Pinch Valve V2 is Energized, other V-valve are De-energized
2 Second Time delay

009
010
011

RUN
RATE: 5.0 L/min
TIME: 00:04:00

Pump “ON”
Pump Rate 5 liters per minute
Pump Runs 4 Minutes, Bag #2 is filled with 20 Liters

012
013
014

STOP
V 003000
TIME: 00:00:02

Pump “Off”
Pinch Valve V3 is Energized, other V-valves are De-energized
2 Second Time Delay

015
016
017
018
019
020

RUN
RATE: 5.0 L/min
TIME: 00:04:00
STOP
V 000000
COUNT: 1

Pump “ON”
Pump Rate 5.0 liters per minute
Pump Runs 4 Minutes, Bag #3 is filled with 20 Liters
Pump “Off”
All V-Valves are De-energized
The Program Steps 000 to 020 are executed once

021

END

ORDERING INFORMATION:
Catalog #:

SciLog Customer Service: 1-800-955-1993

Description:

800-104BFILL Fill Master 104B mounted with a Watson-Marlow 620R peristaltic pump head, 0.5 HP motor;
90VDC; 250 RPM max.; 7.8: 1 Speed Reducer. The 620R peristaltic pump head has two (2)
pump rollers and accommodates continuous pump tubing of the following sizes: 6.4mm ID (#26),
0.15 to 2.60 L/M); 9.6mm ID (#73) 0.31 to 5.94 L/M; 12.7mm ID (#82), 0.53 to 9.25 L/M; and
15.9mm ID (#184), 0.80 to 14.5 L/M, wall thickness is 3.2mm (0.125”) for all tube sizes
800-450

Multiple-Valve Controller: Remote control of twelve (12) electrically actuated air flow valves
(Clippard) for automated pneumatic operation of twelve (12) pinch valves or sanitary diaphragm
valves. Fully programmable from the Fill Master via dedicated serial port or manual control from
front panel of the multi-Valve Box. Optional inputs for valve position sensors.

934-VALVE

Tubing Pinch Valve: Specify Tubing OD: 0.125”, 0.250”, 0.375”, 0.50”, 0.75”, and wall thickness.
The valve is pneumatically actuated. Ideal for maintaining sterility, only tubing comes in contact
with your process solution. Requires a Multi-Valve Controller for actuation and control. The MultiValve Controller is fully programmable from the Fill Master via dedicated serial port or manual
control from front panel of multi-Valve Box. Optional inputs for valve position sensors.

AN 8002, Copyrighted. Last Revision: 12/22/05

-542SciLog Inc, 8845 S. Greenview Drive #4, Middleton, WI 53562-2562
Web: www.scilog.com Tel: 800-955-1993 Fax: 608-824-0509

,ABTAINER 3YSTEM


"IO0ROCESS #ONTAINER 3YSTEMS FOR SMALL VOLUME LIQUID HANDLING
APPLICATIONS IN BIORESEARCH AND BIOPHARMA PRODUCTION
!NIMAL $ERIVED #OMPONENT &REE !$#& &ILM  3IZES RANGE FROM  M,¯ ,

!PPLICATIONS
 #OLLECTION STORAGE AND TRANSPORT OF STERILE LIQUIDS
 $ELIVERY OF MEDIA TO SMALL SCALE BIOTECHNOLOGY PRODUCTION SYSTEMS
 &ORMULATION AND FILLING OF STERILE MEDIA BUFFERS AND OTHER PROCESS LIQUIDS
 #HROMATOGRAPHY FEED AND FRACTION COLLECTION
 "IOREACTOR AND FERMENTATION FEED AND HARVEST
 4RANSPORTATION AND STORAGE OF BULK INTERMEDIATE PRODUCT
 &REEZINGTHAWING HEAT INACTIVATION AND IRRADIATION OF PRODUCT
(Y1#8  &ILM
 2EGULATORY FRIENDLY DUE TO !$#&
STATUS AND LOW EXTRACTABLES
 )MPROVED SHELF LIFE OF MEDIA DUE TO
SUPERIOR BARRIER PROPERTIES
 3CALABILITY FROM  M,¯ , IN
SAME FILM
&LEXIBLE AND 3ECURE #ONTAINERS
 3AVE STORAGE SPACE
 3AFER THAN CARBOYS
 %ASY TO HANDLE HANDLING SYSTEMS
AVAILABLE
3INGLE 5SE !RRIVE 3TERILE AND
2EADY TO USE
 .O CLEANING OR STERILIZATION
 -INIMIZE VALIDATION REQUIREMENTS
 ,ABOR AND COST SAVING
2ANGE OF 3TANDARD 0RODUCTS
 )NTEGRATE WITH MOST INDUSTRY
STANDARD CONNECTION SYSTEMS
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BIO-PHARM

CIP Washers

Clean-In-Place Systems

Sani-Matic Clean-In-Place Systems for the Bio-Pharm
industry are custom engineered to specific plant
application and utility requirements to ensure
effective and efficient cleaning of process
equipment automatically.
Proper CIP design and sizing will not only ensure
sufficient flow and pressure to remove residue
adequately, and rinse thoroughly. Sani-Matic
CIP designs will also save cycle time, reduce
water and chemical usage, and minimize
discharge and utility costs. Balancing all
factors to create an optimum system is
our goal. CIP Systems can be designed to
recirculate or provide “once-through”
cleaning, depending on the product residue.
Multi-tank systems can provide additional
benefits of faster turnaround time if cleaning
processes are more frequent.

Our manufacturing
facilities and processes are
controlled and efficient,
ensuring that your system is compliant and on-schedule. Project
management and documentation
is detailed and complete, saving
you time and resources while
achieving your project’s
budget and target
start-up date.

WHAT MAKES US
DIFFERENT?
Sani-Matic has the expertise to engineer an effective
solution for your cleaning application. Specialists in cleaning
technology, the Sani-Matic team will provide valuable
insight and guidance during your project from beginning
to end. Developing a creative design concept based on
decades of practical experience, we can ensure you are
purchasing a system which is dependable and cost-effective
for the long term. Sani-Matic has in-house programming
staff and field technical service with the expertise to develop
and optimize your cleaning cycles and integrate the CIP
functions with your plant Process control systems.
Because the Sani-Matic team understands the unique
challenges of cleaning, we add value to your CIP projects.
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®

CIP: CLEAN-IN-PLACE
CLEAN-IN-PLACE
CIP

One Tank
Single-use System

• Single-use source of wash solution and rinse water
• Lower space requirement
• Portable or stationary design is available
• Once through or recirculated

Two Tank
Detergent & Rinse System

• Permits once through or recirculated flow of wash solution
• Used where water utilities are limited
• Reduced wash cycle times
CIP DESIGN SIZING FACTORS

CIP system sizing is determined by dimensions of the vessels
and pipelines to be cleaned.
Supply pump flow is determined by the vessel size and the
largest pipeline diameter. Turbulent cleaning action requires
5-7 fps flow in lines. Proper cascading cleaning action by
a sprayball is 3 gpm per ft of tank circumference.
Pressure is determined by the spray device requirement
(typically 25psi, plus any line loss).
Sizing the wash and rinse tank volume is determined by the
pipeline holdup volume (gal per 100ft) and the available inlet
-547water capacity and the estimated cleaning program time.

CIP Washers
Controls

Sani-Matic has in-house programmers and authorized UL
panel shop who design, manufacture, pre-test, startup and
support of all types of Control Systems for cleaning systems.
Because the team specializes in cleaning applications,

Easier/Faster to Validate

Sani-Matic has developed expertise and efficiencies that have
advantages over other fabricators or process integrators.
Sani-Matic has designed, manufactured and supported
thousands of CIP systems and other cleaning related systems.
Understanding the unique aspects of an effective cleaning

UltraFlow

RECOVER DETERGENT TANK

RECOVER RINSE TANK

SANITIZER PUMP

DETERGENT CONDUCTIVITY

2

1

1

1
1
1
1
1
1
1

1
1
1
1
1
1
1

1
1
1
1
1
1

1
1
1
1
1
1
1
1
1

1

1
1

1
1

1

1
1

1

1
1
1

1
1
1
1
1
1
1

1
1

N7:3

TEMP 4

5

1

1

DESTINATION WORD

TEMP 3 (DETERGENT WASH)

6

1

WORD 2, N15:0

TEMP 2 (RINSE)

8

1

FILE

TEMP 1 (PRERINSE)

9

1

10

1

11

DETERGENT TANK FILL OFF
2

1
1
1
1
1
1
1

OPCODE NUMBER

SUCTION DRAIN Valve
6

1
1

BURST SUPPLY PUMP

RINSE TANK RETURN
7

1

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

RETURN PUMP

RINSE TANK OUTLET
8

1

0
0
0
0
0
0
0
0
4
0
4
0
4
0
0
0
0
0
0
0
0
4
0
0
0
4
0
4
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DETERGENT TANK RETURN
9

1

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

14

DETERGENT TANK OUTLET

1

N7:2

CONDUCTIVITY HOLD

OPCODE NUMBER

TEMPERATURE HOLD

10

1
1

0
0
0
0
1
0
1
0
C
8
4
0
4
0
1
0
0
0
0
0
0
0
0
1
1
1
1
1
1

SUPPLY PUMP

PUMPBACK TO DRAIN
PUMPBACK W/ DETERGENT RECOVERY
PUMPBACK W/ ACID RECOVERY
RINSE TO DRAIN
RINSE TO DRAIN WITH RETURN CONDUCTIVITY HOLD
RINSE WITH DET RECOVERY AND RETURN CONDUCTIIVITY HOLD
RINSE WITH ACID RECOVERY AND RETURN CONDUCTIVITY HOLD
RINSE W/ DETERGENT RECOVERY
RINSE W/ ACID RECOVERY

1
1
1

0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

15

DETERGENT WASH
ACID WASH
CHASE RINSE TO DRAIN W/ DETERGENT
CHASE RINSE TO DRAIN W/ ACID
CHASE RINSE TO DRAIN W/ DETERGENT AND CONDUCTIVITY HOLD
CHASE RINSE TO DRAIN W/ ACID AND CONDUCTIVITY HOLD
CHEMICAL SANITIZE

1

DESTINATION WORD

BURST PRE RINSE TO DRAIN

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

WORD 1, N14:0

PRE RINSE TO DRAIN

FILE

**PROGRAM END**
**SAN PROGRAM START**
**CIP PROGRAM END**
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OPCODE CHART
DESCRIPTION
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OPCODE NUMBER

program, Sani-Matic developed a very flexible & easy-tounderstand OP-Code Recipe Editor that allows the customer

0
0
0
0
C
0
D
0
C
C
C
C
C
C
C
0
0
0
0
0
4
4
4
C
C
C
C
C
C

0
0
0
0
8
0
8
0
2
1
2
1
2
1
0
0
0
0
0
0
0
0
0
4
4
4
4
4
4

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
0
0
0
4
0
4
0

0
0
0
0
0
0
0
0
2
0
2
0
2
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0

to manipulate the system hardware to optimize their cleaning
programs. This can result shorter total cycle time, lower water
& chemical usage, more precise control to setpoints and
detailed alarms which reduce troubleshooting time.
Soon to be released, the new Sani-Trend Data Acquisition
System collects and stores cleaning cycle data, events/alarms,
and operator information onto a PC. Operating usage of
water, chemical, and utilities may be calculated and trended.
Sani-Trend reports are in easy to use Excel format, and provide
reliable, secure information giving you valuable insight on your
cleaning process.

The Sani-Matic UltraFlow CIP is patented technology which
uses an eductor, vortex air separation chamber and modulating
valves to control the CIP supply and return flows. This unique
CIP design successfully brings air & water back in the return
flow, separates the air, keeping the supply pump primed. The
UltraFlow uses much less water than traditional CIPs and is
flexible to clean a wide variety of circuits.

UltraFlow technical
brochure available
separately.

ADVANTAGES
• Reduce water usage

• Lower chemical consumption

• Eliminate installation costs

• Increase flexibility

THE IDEAL SOLUTION FOR:
• Vessels with low and/or small outlets
• Variable supply and return flow (1 to 100 GPM)
• Portable - Avoid investment in permanent supply & return lines
• Locations with limited/low water volume available
• Economical replacement for an existing or outdated CIP
• Installations where available floor space is limited

-548• Not appropriate for “once through” non-recirculated processes

CIP CLEAN-IN-PLACE

CIP Features
Spray Devices

Sani-Matic designs and manufactures a complete range of
sprayballs and associated solution tubes and tank fittings.

Custom Engineered
and Precision Drilled

Utilizing the latest technology, Sani-Matic has engineered
a method to model a process vessel in 3D and design the
most effective spray device and drill pattern to ensure
proper coverage of all ports and surfaces. With decades of
experience in spray technology and Bio-Pharm CIP applications,
the Sani-Matic team understands the spray dynamics required
to ensure adequate flows, pressures and geometries will
dependably clean your process equipment.
Sani-Matic provides complete documentation and ID marking
for ease of validation and future replacement. Responsive

• Custom engineered in 3D
• Precision drilled
• Pass Riboflavin testing first time
• Documented for future replacement without re-validating

Documentation
Faster & Easier Validation
• Operation and maintenance manuals
• Recommended spare parts list
• Instrument lists
• Instrumentation calibration procedures
• Performance data

service and reliable delivery make Sani-Matic the preferred
supplier of Spray Devices in the market today.

Sani-Matic personnel are
active participants in the
following organizations:

Manufacturing work team dedicated to Bio-Pharm

ISPE-International Society of
Pharmaceutical Engineers

ASME certified shop – welding
inspector and trainer

Co-developer & Co-leader of
“Cleaning Technology” course

Project Management – manage
Gantt scheduling, change orders,
FAT

ASME-American Society of
Mechanical Engineers

• Material certificates

Authorized UL panel shop

BPE (Bio Processing Equipment)
CIP task group

Complete Technical
Service Staff offering:

AWS-American Welding Society

Documentation

• As built assembly drawings

D18 Team committee for sanitary
welding

Field start-up and training

• As built process and instrumentation diagrams

3A-Sanitary Standards

• Weld qualification and inspection records
• Inspection test results, reports and certificates
• ASME data
• Component catalog cut sheets

• As built electrical drawings

Member of board of directors
and task committees

• Annotated PLC ladder diagrams
OPTIONAL

In-house engineering and operations

• (FRS/FDS) Functional Design Specifications
• Control System Design Specification (HRS and SRS)
• (FAT) Factory Acceptance Test report
• (SAT) Site Acceptance Test document

Custom engineered to order
– solidworks 3D Cadd designs
Electrical design and programming in-house

• IQ/OQ installation and operation qualification
• Cleaning and passivation report
• Weld video record (Boroscope)

®

1915 S. Stoughton Road • P.O. Box 8662 • Madison, WI 53708
Phone: 608-222-2399 • Fax: 608-222-5348 • info@sanimatic.com

www.sanimatic.com

Pharm CIP-5536 3/07
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Factory support after start-up
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Integritest® 4N Integrity Test Instrument
Central Instrument Management Tool
Installation and Operators Manual
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Monoclonal Antibody Production via Fluidized Bioreactor Technology

Appendix I: MSDS Sheets
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Material Safety Data Sheet
Phosphoric acid, 85% MSDS
Section 1: Chemical Product and Company Identification
Product Name: Phosphoric acid, 85%

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

Catalog Codes: SLP5569, SLP4555, SLP1732
CAS#: Mixture.

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400

RTECS: Not applicable.
TSCA: TSCA 8(b) inventory: Phosphoric Acid; Water

Order Online: ScienceLab.com

CI#: Not available.

CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300

Synonym: Phosphoric Acid 85%; Phosphoric Acid;
Orthophosphoric acid

International CHEMTREC, call: 1-703-527-3887

Chemical Name: Not applicable.

For non-emergency assistance, call: 1-281-441-4400

Chemical Formula: Not applicable.

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Phosphoric Acid

7664-38-2

85-88

Water

7732-18-5

12-15

Toxicological Data on Ingredients: Phosphoric Acid: ORAL (LD50): Acute: 1530 mg/kg [Rat]. DERMAL (LD50): Acute: 2740
mg/kg [Rabbit]. DUST (LC50): Acute: &gt;850 mg/m 1 hours [Rat].

Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, . Hazardous in case of skin contact
(corrosive, permeator), of eye contact (corrosive). Slightly hazardous in case of inhalation (lung sensitizer). Liquid or spray
mist may produce tissue damage particularly on mucous membranes of eyes, mouth and respiratory tract. Skin contact may
produce burns. Inhalation of the spray mist may produce severe irritation of respiratory tract, characterized by coughing,
choking, or shortness of breath. Severe over-exposure can result in death. Inflammation of the eye is characterized by
redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening, or, occasionally, blistering.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. The substance may be toxic to blood, liver, skin, eyes, bone marrow. Repeated
p. 1

or prolonged exposure to the substance can produce target organs damage. Repeated or prolonged contact with spray mist
may produce chronic eye irritation and severe skin irritation. Repeated or prolonged exposure to spray mist may produce
respiratory tract irritation leading to frequent attacks of bronchial infection. Repeated exposure to a highly toxic material may
produce general deterioration of health by an accumulation in one or many human organs.

Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: of metals
Explosion Hazards in Presence of Various Substances: Non-explosive in presence of open flames and sparks, of shocks.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards:
Reacts with metals to liberate flammable hydrogen gas. Formation of flammable gases with aldehydes, cyanides, mercaptins,
and sulfides.
Special Remarks on Explosion Hazards: Mixtures with nitromethane are explosive. (Phosphoric Acid)

Section 6: Accidental Release Measures
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Small Spill:
Dilute with water and mop up, or absorb with an inert dry material and place in an appropriate waste disposal container. If
necessary: Neutralize the residue with a dilute solution of sodium carbonate.
Large Spill:
Corrosive liquid. Poisonous liquid. Stop leak if without risk. Absorb with DRY earth, sand or other non-combustible material.
Do not get water inside container. Do not touch spilled material. Use water spray curtain to divert vapor drift. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of sodium carbonate. Be careful that the product is not present at a concentration
level above TLV. Check TLV on the MSDS and with local authorities.

Section 7: Handling and Storage
Precautions:
Do not ingest. Do not breathe gas/fumes/ vapor/spray. Never add water to this product. In case of insufficient ventilation,
wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid
contact with skin and eyes. Keep away from incompatibles such as oxidizing agents, combustible materials, metals, alkalis.
May corrode metallic surfaces. Store in a metallic or coated fiberboard drum using a strong polyethylene inner package.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area.

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
threshold limit value. Ensure that eyewash stations and safety showers are proximal to the work-station location.
Personal Protection:
Face shield. Full suit. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Gloves. Boots.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits:
Phosphoric Acid TWA: 1 STEL: 3 (mg/m3) from ACGIH (TLV) [United States] TWA: 1 STEL: 3 (mg/m3) from OSHA (PEL)
[United States] TWA: 1 STEL: 3 (mg/m3) from NIOSH TWA: 1 STEL: 3 (mg/m3) [Mexico]Consult local authorities for
acceptable exposure limits.

Section 9: Physical and Chemical Properties
Physical state and appearance: Liquid. (Syrupy liquid Viscous liquid.)
Odor: Odorless.
Taste: Acid.
Molecular Weight: Not applicable.
Color: Clear Colorless.
pH (1% soln/water): Acidic.
Boiling Point: 158°C (316.4°F)
Melting Point: 21°C (69.8°F)
Critical Temperature: Not available.
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Specific Gravity: 1.685 @ 25 C (Water = 1)
Vapor Pressure: 0.3 kPa (@ 20°C)
Vapor Density: 3.4 (Air = 1)
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in hot water. Soluble in cold water.

Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials
Incompatibility with various substances: Reactive with oxidizing agents, combustible materials, metals, alkalis.
Corrosivity:
Extremely corrosive in presence of copper, of stainless steel(304), of stainless steel(316). Highly corrosive in presence of
aluminum. Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Reacts with metals to liberate flammable hydrogen gas. Incompatible with sodium tetrahydroborate producing a violent
exothermic reaction. Heat generated with: alcohols, glycols, aldehydes, amides, amines, azo-compounds, carbamates,
caustics, esters, ketones, phenols and cresols, organophosphates, epoxides, combustible materials, unsaturated halides,
organic peroxides. Formation of flammable gases, with aldehydes, cyanides, mercaptins, and sulfides. Formation of toxic
fumes with cyanides, fluorides, halogenated organics, sulfides, and organic peroxides. Do not mix with solutions containing
bleach or ammonia. Incompatible with nitromethane, chlorides + staiinless steel. (Phosphoric Acid)
Special Remarks on Corrosivity:
Minor corrosive effect on bronze. Severe corrosive effect on brass. Corrosive to ferrous metals and alloys.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Dermal contact. Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
Acute oral toxicity (LD50): 1530 mg/kg [Rat]. Acute dermal toxicity (LD50): 2740 mg/kg [Rabbit].
Chronic Effects on Humans: May cause damage to the following organs: blood, liver, skin, eyes, bone marrow.
Other Toxic Effects on Humans:
Extremely hazardous in case of inhalation (lung corrosive). Very hazardous in case of skin contact (irritant), of ingestion, .
Hazardous in case of skin contact (corrosive, permeator), of eye contact (corrosive).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: Not available.
Special Remarks on other Toxic Effects on Humans:
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Acute Potential Health Effects: Skin: Corrosive and causes severe skin irritation and can cause severe skin burns. May affect
behavior (somnolence or excitement) if absorbed through skin. Eyes: Corrosive. Liquid or vapor causes severe eye irritation
and can cause severe eye burns leading to permanent corneal damage or chemical conjunctivitis. Ingestion: May be harmful
if swallowed. Causes irritation and burns of the gastrointestinal (digestive) tract. Causes severe pain, nausea, vomiting,
diarrhea hematemesis, gastrointestinal hemmorrhaging, and shock. May cause corrosion and permanent tissue destruction
of the esophagus and digestive tract. May affect behavior and urinary system, liver (hepatocellular damage, hepatic enzymes
increased), blood (blood dyscrasia). May also

Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are less toxic than the product itself.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
DOT Classification: Class 8: Corrosive material
Identification: : Phosphoric acid (Phosphoric Acid) UNNA: 1805 PG: III
Special Provisions for Transport: Not available.

Section 15: Other Regulatory Information
Federal and State Regulations:
Connecticut hazardous material survey.: Phosphoric Acid Illinois toxic substances disclosure to employee act: Phosphoric
acid Illinois chemical safety act: Phosphoric acid New York release reporting list: Phosphoric acid Rhode Island RTK
hazardous substances: Phosphoric acid Pennsylvania RTK: Phosphoric acid Minnesota: Phosphoric acid Massachusetts
RTK: Phosphoric acid Massachusetts spill list: Phosphoric acid New Jersey: Phosphoric acid New Jersey spill list: Phosphoric
acid Louisiana spill reporting: Phosphoric acid California Director's list of hazardous substances: Phosphoric acid TSCA 8(b)
inventory: Phosphoric Acid; Water SARA 313 toxic chemical notification and release reporting: Phosphoric acid CERCLA:
Hazardous substances.: Phosphoric acid: 5000 lbs. (2268 kg)
Other Regulations: OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive liquid.
DSCL (EEC):
R34- Causes burns. S26- In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S45In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
HMIS (U.S.A.):
Health Hazard: 3
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Fire Hazard: 0
Reactivity: 0
Personal Protection:
National Fire Protection Association (U.S.A.):
Health: 3
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Full suit. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Wear appropriate respirator
when ventilation is inadequate. Face shield.

Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/10/2005 08:47 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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1. PRODUCT AND COMPANY IDENTIFICATION
1.1

1.2

Product identifiers
Product name

:

EX-CELL® ACF CHO Medium without L-glutamine,
animal component free

Product Number
Brand
REACH No.

:
:
:

C9098
Sigma
A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

Relevant identified uses of the substance or mixture and uses advised against
Identified uses

1.3

1.4

:

Laboratory chemicals, Manufacture of substances

Details of the supplier of the safety data sheet
Company

:

Sigma-Aldrich
3050 Spruce Street
SAINT LOUIS MO 63103
USA

Telephone
Fax

:
:

+1 800-325-5832
+1 800-325-5052

Emergency telephone number
Emergency Phone #

:

(314) 776-6555

2. HAZARDS IDENTIFICATION
2.1

Classification of the substance or mixture
Not a hazardous substance or mixture.

2.2

GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.

2.3

Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS
3.2

Mixtures
Synonyms

:

CHO Medium

No ingredients are hazardous according to OSHA criteria.
No components need to be disclosed according to the applicable regulations.
4. FIRST AID MEASURES
4.1

Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.

Sigma - C9098
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In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
4.2

Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3

Indication of any immediate medical attention and special treatment needed
no data available

5. FIREFIGHTING MEASURES
5.1

Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2

Special hazards arising from the substance or mixture
Nature of decomposition products not known.

5.3

Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.

5.4

Further information
no data available

6. ACCIDENTAL RELEASE MEASURES
6.1

Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.

6.2

Environmental precautions
Do not let product enter drains.

6.3

Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4

Reference to other sections
For disposal see section 13.

7. HANDLING AND STORAGE
7.1

Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2

Conditions for safe storage, including any incompatibilities
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C

7.3

Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1

Control parameters
Components with workplace control parameters
Contains no substances with occupational exposure limit values.

8.2

Exposure controls
Appropriate engineering controls
General industrial hygiene practice.

Sigma - C9098
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Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards such as
NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after
use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and
to the specific work-place., The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1

Information on basic physical and chemical properties
a)

Appearance

Form: powder

b)

Odour

no data available

c)

Odour Threshold

no data available

d)

pH

no data available

e)

Melting point/freezing
point

no data available

f)

Initial boiling point and
boiling range

no data available

g)

Flash point

no data available

h)

Evapouration rate

no data available

i)

Flammability (solid, gas) no data available

j)

Upper/lower
flammability or
explosive limits

no data available

k)

Vapour pressure

no data available

l)

Vapour density

no data available

m) Relative density

no data available

n)

Water solubility

no data available

o)

Partition coefficient: noctanol/water

no data available

p)

Auto-ignition
temperature

no data available

q)

Decomposition
temperature

no data available

r)

Viscosity

no data available

s)

Explosive properties

no data available

t)

Oxidizing properties

no data available

Sigma - C9098
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9.2

Other safety information
no data available

10. STABILITY AND REACTIVITY
10.1

Reactivity
no data available

10.2

Chemical stability
Stable under recommended storage conditions.

10.3

Possibility of hazardous reactions
no data available

10.4

Conditions to avoid
no data available

10.5

Incompatible materials
Strong oxidizing agents

10.6

Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION
11.1

Information on toxicological effects
Acute toxicity
no data available
Inhalation: no data available
Dermal: no data available
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:

No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.

ACGIH:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by ACGIH.

NTP:

No component of this product present at levels greater than or equal to 0.1% is identified as a
known or anticipated carcinogen by NTP.

OSHA:

No component of this product present at levels greater than or equal to 0.1% is identified as a
carcinogen or potential carcinogen by OSHA.

Reproductive toxicity
no data available
no data available
Specific target organ toxicity - single exposure
no data available
Sigma - C9098
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Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
12. ECOLOGICAL INFORMATION
12.1

Toxicity
no data available

12.2

Persistence and degradability
no data available

12.3

Bioaccumulative potential
no data available

12.4

Mobility in soil
no data available

12.5

Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6

Other adverse effects
no data available

13. DISPOSAL CONSIDERATIONS
13.1

Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

14. TRANSPORT INFORMATION
DOT (US)
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods
15. REGULATORY INFORMATION
REACH No.

:

A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

SARA 302 Components
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the
threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards
No SARA Hazards
Massachusetts Right To Know Components
Sigma - C9098
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No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components
EX-CELL® ACF CHO Medium

CAS-No.
-

Revision Date

CAS-No.
-

Revision Date

New Jersey Right To Know Components
EX-CELL® ACF CHO Medium

California Prop. 65 Components
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other
reproductive harm.
16. OTHER INFORMATION
HMIS Rating
Health hazard:
Chronic Health Hazard:
Flammability:
Physical Hazard
NFPA Rating
Health hazard:
Fire Hazard:
Reactivity Hazard:

0
0
0
0
0
0

Further information
Copyright 2014 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a
guide. The information in this document is based on the present state of our knowledge and is applicable to the
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing
slip for additional terms and conditions of sale.
Preparation Information
Sigma-Aldrich Corporation
Product Safety – Americas Region
1-800-521-8956
Version: 4.9
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Material Safety Data Sheet
Sodium chloride MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium chloride

Contact Information:

Catalog Codes: SLS3262, SLS1045, SLS3889, SLS1669,
SLS3091
CAS#: 7647-14-5

Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

RTECS: VZ4725000

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400

TSCA: TSCA 8(b) inventory: Sodium chloride

Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300

CI#: Not applicable.
Synonym: Salt; Sea Salt

International CHEMTREC, call: 1-703-527-3887

Chemical Name: Sodium chloride

For non-emergency assistance, call: 1-281-441-4400

Chemical Formula: NaCl

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Sodium chloride

7647-14-5

100

Toxicological Data on Ingredients: Sodium chloride: ORAL (LD50): Acute: 3000 mg/kg [Rat.]. 4000 mg/kg [Mouse].
DERMAL (LD50): Acute: &gt;10000 mg/kg [Rabbit]. DUST (LC50): Acute: &gt;42000 mg/m 1 hours [Rat].

Section 3: Hazards Identification
Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of
inhalation.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for
bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. Repeated or
prolonged exposure is not known to aggravate medical condition.

Section 4: First Aid Measures
Eye Contact:
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Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention.
Skin Contact:
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water
may be used.
Serious Skin Contact: Not available.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention if symptoms appear.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: When heated to decomposition it emits toxic fumes.
Special Remarks on Explosion Hazards:
Electrolysis of sodium chloride in presence of nitrogenous compounds to produce chlorine may lead to formation of explosive
nitrogen trichloride. Potentially explosive reaction with dichloromaleic anhydride + urea.

Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.

Section 7: Handling and Storage
Precautions:
Keep locked up.. Do not ingest. Do not breathe dust. Avoid contact with eyes. Wear suitable protective clothing. If ingested,
seek medical advice immediately and show the container or the label. Keep away from incompatibles such as oxidizing
agents, acids.
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Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Hygroscopic

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection:
Splash goggles. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits: Not available.

Section 9: Physical and Chemical Properties
Physical state and appearance: Solid. (Solid crystalline powder.)
Odor: Slight.
Taste: Saline.
Molecular Weight: 58.44 g/mole
Color: White.
pH (1% soln/water): 7 [Neutral.]
Boiling Point: 1413°C (2575.4°F)
Melting Point: 801°C (1473.8°F)
Critical Temperature: Not available.
Specific Gravity: 2.165 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in cold water, hot water. Soluble in glycerol, and ammonia. Very slightly soluble in alcohol. Insoluble in
Hydrochloric Acid.

Section 10: Stability and Reactivity Data
Stability: The product is stable.
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Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, high temperatures.
Incompatibility with various substances: Reactive with oxidizing agents, metals, acids.
Corrosivity: Not considered to be corrosive for metals and glass.
Special Remarks on Reactivity:
Hygroscopic. Reacts with most nonnoble metals such as iron or steel, building materials (such as cement) Sodium chloride is
rapidly attacked by bromine trifluoride. Violent reaction with lithium.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals:
WARNING: THE LC50 VALUES HEREUNDER ARE ESTIMATED ON THE BASIS OF A 4-HOUR EXPOSURE. Acute oral
toxicity (LD50): 3000 mg/kg [Rat.]. Acute dermal toxicity (LD50): >10000 mg/kg [Rabbit]. Acute toxicity of the dust (LC50):
>42000 mg/m3 1 hours [Rat].
Chronic Effects on Humans: MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/
or yeast.
Other Toxic Effects on Humans: Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Special Remarks on Toxicity to Animals: Lowest Published Lethal Dose (LDL) [Man] - Route: Oral; Dose: 1000 mg/kg
Special Remarks on Chronic Effects on Humans:
Causes adverse reproductive effects in humans (fetotoxicity, abortion, ) by intraplacental route. High intake of sodium chloride,
whether from occupational exposure or in the diet, may increase risk of TOXEMIA OF PREGNANCY in susceptible women
(Bishop, 1978). Hypertonic sodium chloride solutions have been used to induce abortion in late pregnancy by direct infusion
into the uterus (Brown et al, 1972), but this route of administration is not relevant to occupational exposures. May cause
adverse reproductive effects and birth defects in animals, particularly rats and mice (fetotoxicity, abortion, musculoskeletal
abnormalities, and maternal effects (effects on ovaries, fallopian tubes) by oral, intraperitoneal, intraplacental, intrauterine,
parenteral, and subcutaneous routes. While sodium chloride has been used as a negative control n some reproductive
studies, it has also been used as an example that almost any chemical can cause birth defects in experimental animals
if studied under the right conditions (Nishimura & Miyamoto, 1969). In experimental animals, sodium chloride has caused
delayed effects on newborns, has been fetotoxic, and has caused birth defects and abortions in rats and mice (RTECS, 1997).
May affect genetic material (mutagenic)
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause skin irritation. Eyes: Causes eye irritation. Ingestion: Ingestion of large
quantities can irritate the stomach (as in overuse of salt tablets) with nausea and vomiting. May affect behavior (muscle
spasicity/contraction, somnolence), sense organs, metabolism, and cardiovascular system. Continued exposure may
produce dehydration, internal organ congestion, and coma. Inhalation: Material is irritating to mucous membranes and upper
respiratory tract.

Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
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Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.

Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Sodium chloride
Other Regulations: EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): Not controlled under WHMIS (Canada).
DSCL (EEC):
R40- Possible risks of irreversible effects. S24/25- Avoid contact with skin and eyes.
HMIS (U.S.A.):
Health Hazard: 1
Fire Hazard: 0
Reactivity: 0
Personal Protection: E
National Fire Protection Association (U.S.A.):
Health: 1
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Splash goggles.

Section 16: Other Information
References:
-Hawley, G.G.. The Condensed Chemical Dictionary, 11e ed., New York N.Y., Van Nostrand Reinold, 1987. -SAX, N.I.
Dangerous Properties of Indutrial Materials. Toronto, Van Nostrand Reinold, 6e ed. 1984. -The Sigma-Aldrich Library of
Chemical Safety Data, Edition II.
Other Special Considerations: Not available.
Created: 10/11/2005 12:33 PM
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Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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Material Safety Data Sheet
Sodium hydroxide, Pellets, Reagent ACS MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium hydroxide, Pellets, Reagent ACS

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

Catalog Codes: SLS4090
CAS#: 1310-73-2

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400

RTECS: WB4900000
TSCA: TSCA 8(b) inventory: Sodium hydroxide

Order Online: ScienceLab.com

CI#: Not available.
Synonym: Caustic Soda

CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300

Chemical Name: Sodium Hydroxide

International CHEMTREC, call: 1-703-527-3887

Chemical Formula: NaOH

For non-emergency assistance, call: 1-281-441-4400

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Sodium hydroxide

1310-73-2

100

Toxicological Data on Ingredients: Sodium hydroxide LD50: Not available. LC50: Not available.

Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of skin contact (corrosive, irritant, permeator), of eye contact (irritant, corrosive), of ingestion,
of inhalation. The amount of tissue damage depends on length of contact. Eye contact can result in corneal damage or
blindness. Skin contact can produce inflammation and blistering. Inhalation of dust will produce irritation to gastro-intestinal or
respiratory tract, characterized by burning, sneezing and coughing. Severe over-exposure can produce lung damage, choking,
unconsciousness or death. Inflammation of the eye is characterized by redness, watering, and itching. Skin inflammation is
characterized by itching, scaling, reddening, or, occasionally, blistering.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. The substance is toxic to lungs. Repeated or prolonged exposure to the
substance can produce target organs damage. Repeated exposure of the eyes to a low level of dust can produce eye irritation.
Repeated skin exposure can produce local skin destruction, or dermatitis. Repeated inhalation of dust can produce varying
degree of respiratory irritation or lung damage.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek medical attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: of metals
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available. Slightly explosive in presence of heat.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards:
sodium hydroxide + zinc metal dust causes ignition of the latter. Under proper conditions of temperature, pressure and state
of division, it can ignite or react violently with acetaldehyde, ally alcohol, allyl chloride, benzene-1,4-diol, chlorine trifluoride,
1,2 dichlorethylene, nitroethane, nitromethane, nitroparaffins, nitropropane, cinnamaldehyde, 2,2-dichloro-3,3-dimethylbutane.
Sodium hydroxide in contact with water may generate enough heat to ignite adjacent combustible materials. Phosphorous
boiled with NaOH yields mixed phosphines which may ignite spontanously in air. sodium hydroxide and cinnamaldehyde +
heat may cause ignition. Reaction with certain metals releases flammable and explosive hydrogen gas.
Special Remarks on Explosion Hazards:
Sodium hydroxide reacts to form explosive products with ammonia + silver nitrate. Benzene extract of allyl benzenesulfonate
prepared from allyl alcohol, and benzene sulfonyl chloride in presence of aquesous sodium hydroxide, under vacuum
distillation, residue darkened and exploded. Sodium Hydroxde + impure tetrahydrofuran, which can contain peroxides, can
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cause serious explosions. Dry mixtures of sodium hydroxide and sodium tetrahydroborate liberate hydrogen explosively at
230-270 deg. C. Sodium Hydroxide reacts with sodium salt of trichlorophenol + methyl alcohol + trichlorobenzene + heat to
cause an explosion.

Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. If necessary: Neutralize the residue with
a dilute solution of acetic acid.
Large Spill:
Corrosive solid. Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of acetic acid. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.

Section 7: Handling and Storage
Precautions:
Keep container dry. Do not breathe dust. Never add water to this product. In case of insufficient ventilation, wear suitable
respiratory equipment. If you feel unwell, seek medical attention and show the label when possible. Avoid contact with skin
and eyes. Keep away from incompatibles such as oxidizing agents, reducing agents, metals, acids, alkalis, moisture.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 23°C (73.4°F).

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection:
Splash goggles. Synthetic apron. Vapor and dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor and dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling
this product.
Exposure Limits:
CEIL: 2 from ACGIH (TLV) [United States] [1995] Consult local authorities for acceptable exposure limits.

Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Not available.
Molecular Weight: 40 g/mole
Color: White.
pH (1% soln/water): 13.5 [Basic.]
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Boiling Point: 1388°C (2530.4°F)
Melting Point: 323°C (613.4°F)
Critical Temperature: Not available.
Specific Gravity: 2.13 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility: Easily soluble in cold water.

Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Not available.
Incompatibility with various substances:
Highly reactive with metals. Reactive with oxidizing agents, reducing agents, acids, alkalis, moisture.
Corrosivity: Not available.
Special Remarks on Reactivity:
Hygroscopic. Much heat is evolved when solid material is dissolved in water. Therefore cold water and caution must be
used for this process. Sodium hydroxide solution and octanol + diborane during a work-up of a reaction mixture of oxime
and diborane in tetrahyrofuran is very exothermic, a mild explosion being noted on one occassion. Reactive with water,
acids, acid chlorides, strong bases, strong oxidizing agents, strong reducing agents, flammable liquids, organic halogens,
metals (i.e aluminum, tin, zinc), nitromethane, glacial acetic acid, acetic anhydride, acrolein, chlorohydrin, chlorosulfonic acid,
ethylene cyanohydrin, glyoxal, hydrochloric acid, sulfuric acid, hydrosulfuric acid, nitric acid, oleum, propiolactone, acylonitrile,
phorosous pentoxide, chloroethanol, chloroform-methanol, tetrahydroborate, cyanogen azide, 1,2,4,5 tetrachlorobenzene,
cinnamaldehyde. Reacts with formaldehyde hydroxide to yield formic acid, and hydrogen.
Special Remarks on Corrosivity: Very caustic to aluminum and other metals in presence of moisture.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Dermal contact. Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
LD50: Not available. LC50: Not available.
Chronic Effects on Humans: Causes damage to the following organs: lungs.
Other Toxic Effects on Humans:
Extremely hazardous in case of inhalation (lung corrosive). Very hazardous in case of skin contact (corrosive, irritant,
permeator), of eye contact (corrosive), of ingestion, .
Special Remarks on Toxicity to Animals:
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Lowest Published Lethal Dose: LDL [Rabbit] - Route: Oral; Dose: 500 mg/kg
Special Remarks on Chronic Effects on Humans: May affect genetic material (mutagenic). Investigation as a mutagen
(cytogenetic analysis), but no data available.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May be harmful if absorbed through skin. Causes severe skin irritation and burns. May
cause deep penetrating ulcers of the skin. Eyes: Causes severe eye irritation and burns. May cause chemical conjunctivitis
and corneal damage. Inhalation: Harmful if inhaled. Causes severe irritation of the respiratory tract and mucous membranes
with coughing, burns, breathing difficulty, and possible coma. Irritation may lead the chemical pneumonitis and pulmonary
edema. Causes chemical burns to the respiratory tract and mucous membranes. Ingestion: May be fatal if swallowed. May
cause severe and permanent damage to the digestive tract. Causes severe gastrointestinal tract irritation and burns. May
cause perforation of the digestive tract. Causes severe pain, nausea, vomiting, diarrhea, and shock. May cause corrosion and
permanent destruction of the esophagus and digestive tract.

Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
DOT Classification: Class 8: Corrosive material
Identification: : Sodium hydroxide, solid UNNA: 1823 PG: II
Special Provisions for Transport: Not available.

Section 15: Other Regulatory Information
Federal and State Regulations:
Illinois toxic substances disclosure to employee act: Sodium hydroxide Illinois chemical safety act: Sodium hydroxide New
York release reporting list: Sodium hydroxide Rhode Island RTK hazardous substances: Sodium hydroxide Pennsylvania
RTK: Sodium hydroxide Minnesota: Sodium hydroxide Massachusetts RTK: Sodium hydroxide New Jersey: Sodium hydroxide
Louisiana spill reporting: Sodium hydroxide California Director's List of Hazardous Substances: Sodium hydroxide TSCA 8(b)
inventory: Sodium hydroxide CERCLA: Hazardous substances.: Sodium hydroxide: 1000 lbs. (453.6 kg)
Other Regulations:
OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the
European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive solid.
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DSCL (EEC):
HMIS (U.S.A.):
Health Hazard: 3
Fire Hazard: 0
Reactivity: 2
Personal Protection: j
National Fire Protection Association (U.S.A.):
Health: 3
Flammability: 0
Reactivity: 1
Specific hazard:
Protective Equipment:
Gloves. Synthetic apron. Vapor and dust respirator. Be sure to use an approved/certified respirator or equivalent. Wear
appropriate respirator when ventilation is inadequate. Splash goggles.

Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 06:32 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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MATERIAL SAFETY DATA SHEET
SECTION 1 - IDENTIFICATION OF THE MATERIAL AND SUPPLIER
Material Name:
Catalogue Number:
Other Names:
Recommended Use:
Supplier Name:
Street Address:
Telephone Number:
Emergency Contact:

Phosphate buffered saline, pH 7.4
APBS-1L
Sorenson's Saline; Phosphate Buffered Saline.
Used as a buffer or cell wash dilution in microscopy in hospital and pathology
laboratories.
ProSciTech
1/11 Carlton Street, Kirwan, Qld. 4817 Australia
(07) 4773 9444 - 8:30am – 5:00pm, Monday to Friday (excluding Public Holidays)
(07) 4773 9444 - 8:30am – 5:00pm, Monday to Friday (excluding Public Holidays)

SECTION 2 - HAZARDS IDENTIFICATION
Hazard Classification:
Not classified as hazardous according to criteria for Classifying Hazardous Substances [NOHSC:1008].
Hazardous and/or Dangerous Nature:
NON-HAZARDOUS SUBSTANCE. NON-DANGEROUS GOODS.
Risk Phrases:
None allocated.
Safety Phrases:
S24/25: Avoid contact with skin and eyes.
Refer to Section 15 for Poisons Schedule.

SECTION 3 - COMPOSITION /INFORMATION ON INGREDIENTS
Mixture Substance:
Ingredients
SODIUM CHLORIDE
POTASSIUM DIHYDROGEN PHOSPHATE
DISODIUM HYDROGEN ORTHOPHOSPHATE
POTASSIUM CHLORIDE
WATER

Cas Number(s)
7647-14-5
7778-77-0
7558-79-4
7447-40-7
7732-18-5

Proportion (%)
0.8
0.02
0.1
0.02
99

SECTION 4 - FIRST AID MEASURES
If swallowed, DO NOT induce vomiting. If victim is conscious give water. If sickness
persists transport to hospital or doctor.
Move victim to fresh air. Apply resuscitation if victim is not breathing - If trained
Inhalation:
personnel available administer oxygen if breathing is difficult.
If material is splashed into eyes, immediately, flush with plenty of water for 15 minutes,
Eye Contact:
ensuring eye lids are held open. If irritation persists transport to hospital or doctor.
If material is splashed onto the skin, remove any contaminated clothing and wash skin
Skin Contact:
thoroughly with water and soap if available. If irritation persists transport to hospital or
doctor.
Eyebath/eyewash, Safety shower & general washroom facilities.
First Aid Facilities:
Medical Attention & Special Treatment:
Treat symptomatically.
Additional Information:
Not available.
Ingestion:

SECTION 5 - FIRE FIGHTING MEASURES
Suitable Extinguishing Media:
Use extinguishing media suitable for surrounding fire situation. This material is not a flammable or combustible
liquid.
Hazards from Combustion Products:
Decomposes on heating emitting oxides of carbon.
Precautions for Fire Fighters:
Fire fighters to wear Self-contained breathing apparatus (SCBA) in confined spaces, in oxygen deficient
atmospheres or if exposed to products of decomposition. Full protective clothing is also recommended. If safe to
do so, move undamaged containers from fire area.

Part Number(s):

MATERIAL SAFETY DATA SHEET

54-111-04, 54-111-05

Form WI04-11A Rev. 1

Product Name: Sterilizable Cheek Retractor

Release Date: April 10, 2007

1. Product and Company Identification
Trade Name & Synonyms
Sterilizable cheek retractor
Chemical Name
Polyethersulfone-polymer. Chemical family: Polyethersulfone.
C.A.S. Number
25154-01-2

MSDS Code Number
CKE 12, 2S
Manufacture / Distributor
GAC International Inc.
Address
355 Knickerbocker Ave.
Bohemia, NY USA 11716
Information Telephone Number
1-631-419-1700
Emergency Telephone Number
1-631-419-1700

Grades or Minor Variant Identities
NA
Product Use (for Canada)
NA

2. Composition of Ingredients
Hazardous Components
Polyethersulfone

C.A.S. Number
25154-01-2

Exposure Limits

N/A

%

NA

3. Hazard Identification
Emergency Overview
This product has non-hazardous ingredient as defined under the criteria of the federal OSHA hazard communication standard 29 CFR 1910.1200.
Routes of
Exposure
Eye

Signs and Symptoms
NA

Single, Repeated, or
Lifetime Exposure
NA

Severity (Mild,
Moderate, Severe)
NA

Skin

NA

NA

NA

Inhalation

NA

NA

NA

Ingestion

NA

NA

Other

NA

NA

Acute and Chronic
Health Effect(s)
Acute: Mechanical irritation.
Chronic: None
NA

Target
Organ(s)
NA
NA

NA

Acute: No significant health
hazard.
Chronic: None.
NA

NA

NA

NA

NA

Medical Conditions Aggravated by Exposure
None. Human effects and symptoms of over exposure: None
Carcinogenicity (IARC, NTP)
None
Potential Environmental Effects
Potential health effects: None. Exposure limits: None.

4. First Aid Measures
Routes of Exposure
Eye
Skin
Inhalation

First Aid Instructions
N/A
N/A
N/A

Immediate Medical Attention
NA
NA
NA

Delayed Effects
NA
NA
NA

Ingestion

N/A

NA

NA

Other

NA

NA

NA

Note to Physicians (Treatment, Testing, and Monitoring)
NA
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NA

MATERIAL SAFETY DATA SHEET
Form WI04-11A Rev. 1

Product Name: Sterilizable Cheek Retractor

Part Number(s):
54-111-04, 54-111-05
Release Date: April 10, 2007

5. Fire and Explosion Data
Flashpoint & Method:

Flammable (Explosive) Limits in Air

Autoignition Temperature

°C / °F Non-flammable

LEL: N/A

NA

Flame Propagation or Burning
NA

UEL: N/A

Properties Contributing to
Fire Intensity
NA

Flammability Classification

Other
NA

Health- 0, Flammability-0 , Reactivity0

Extinguishing Media

Extinguishing Media to Avoid

N/A

NA

Protection and Procedures for Firefighters
None
Unusual Fire and Explosion Hazards
NA

6. Accidental Release Measures
Containment Techniques
NA
Spill/Leak Clean-Up Procedures and Equipment
Remove by mechanical means.
Evacuation Procedures
NA
Special Instructions
NA
Reporting Requirements
NA

7. Handling and Storage
Handling Practices and Warnings
None
Storage Practices and Warnings
( C / F). Storage temperature: Ambient.
Shelf life: 3 years.

8. Exposure Control/Personal Protection
Ventilation

Other Engineering Controls

None

NA

Routes of Entry:
Eye/Face

Personal Protective Equipment (PPE) for Normal Use:

PPE for Emergencies:

None

NA

Skin

None

NA

Inhalation

None

NA

General Hygiene Considerations and Work Practices
NA
Protective Measures During Repair and Maintenance of Contaminated Equipment

NA
Other Protective Measures and Equipment

None
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MATERIAL SAFETY DATA SHEET
Form WI04-11A Rev. 1

Product Name: Sterilizable Cheek Retractor

Part Number(s):
54-111-04, 54-111-05
Release Date: April 10, 2007

9. Physical and Chemical Characteristics
Appearance

Odor

Color: Various F.D.A allowable colors.

Odorless

Normal Physical State:

Boiling Point

°C / °F N/A

Melting Point

°C / °F N/A

Freezing Point

°C / °F N/A

Liquid

Gas

Solid

(Other)

Specific Gravity or Density (H20=1)

Solubility in Water

pH

1.37 g/cm3

Insoluble

N/D

Vapor Pressure (mm Hg @ 20°C)

Vapor Density (AIR= 1)

Evaporation Rate (Butyl Acetate = 1)

N/A

NA

NA

Other
Bulk density: Approximately 10.01 LBS /CM3.
% Volatile by volume: N/A

10. Stability and Reactivity Data
Incompatibility (Materials to Avoid)
None known.
Hazardous Products Produced During Decomposition
By fire; carbon monoxide, carbon dioxide.
Hazardous Polymerization?
May Occur
Stability?
Stable

Conditions to Avoid
°C / °F

May Not Occur

NA

Conditions to Avoid
Unstable

°C / °F None known.

11. Toxicological Information
Toxicity Data, Epidemiology Studies, Carcinogenicity, Neurological Effects, Genetic or Reproductive Effects, or Structure Activity Data
No component of this product present at levels greater than 0.1 % is identified as a carcinogen by the U.S. National toxicology program, the U.S.
occupational safety and health act, or the international agency on research on cancer (IARC).

12. Ecological Information
Toxicity, Environmental Fate, Physical/Chemical Data, or Other Data Supporting Environmental Hazard Statements
N/A

13. Disposal Considerations
Regulations

Waste disposal method: In accordance to federal, state or local regulations.
Properties (Physical/Chemical) Affecting Disposal

NA
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Part Number(s):

MATERIAL SAFETY DATA SHEET

54-111-04, 54-111-05

Form WI04-11A Rev. 1

Product Name: Sterilizable Cheek Retractor

Release Date: April 10, 2007

14. Transport Information
Regulated for shipping?
Yes

No

Proper Shipping Name

Packing Group

Sterilizable cheek retractor

NA

Do changes in quantity, packaging, or shipment method change product classification?
Yes
No NA

Hazard Class

Identification Number

Not regulated

NA

Other

Freight class bulk: Not regulated.
Freight class package: Not regulated.
Product label: Not regulated.
Hazard class division number: Not regulated

15. Regulatory Information
Federal Regulations
Sara title III: This product is not reportable under section 302.4 of SARA and 40 CFR part 355.
Hazardous substances: None.
Section 311/312
Hazard categories: None.
Section 313 Toxic chemicals: None
RERA Status: Non-hazardous.
International Regulations

NA
Other

NA

16. Other Information
Supplier Number: 31/ 54

Supplier Release: NA

N/A = not applicable. NA = not available, N/E = not established. N/D = not determined.
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RepliGen
MATERIAL SAFETY DATA SHEET:
Recombinant Protein A (Revision 1)

RepliGen Corporation
41 Seyon Street
Building #1, Suite 100
Waltham, MA 02453
Phone: (781) 250-0111
Fax: (781) 250-0115

SECTION 1 – PRODUCT IDENTIFICATION
Supplier:

RepliGen Corporation
41 Seyon Street, Building #1, Suite 100
Waltham, MA 02453
Phone: (781) 250-0111; Fax: (781) 250-0115

Product Name:
Synonyms
Catalog No(s):

Recombinant Protein A
rPA50, srPA50, rSPA, rProteinA, rProtein A, Protein A
10-1001, 10-1501, 10-2001

SECTION 2 – COMPOSITION / INFORMATION ON INGREDIENTS
Purified Recombinant Protein A, derived from genetically modified Escherichia coli. Product is
provided frozen in an aqueous buffer.
SECTION 3 – HAZARDS IDENTIFICATION
Emergency Overview:

No specific hazards identified

HMIS:

Health Hazard: 0 (No significant risk to health.)
Flammability: 0 (Will not burn)
Reactivity:
0 (Stable)

NFPA:

Health Hazard: 0 (Poses no health hazard,)
Fire:
0 (Will not burn)
Reactivity:
0 (Stable, not reactive with water)

Potential Health Effects:

No health effects have been identified.
May be harmful if inhaled, swallowed, or absorbed through skin.
May cause eye irritation.

SECTION 4 – FIRST AID MEASURES
If swallowed:
In case of eye contact
Skin contact
If inhaled

Induce vomiting. Get medical attention
Flush eyes with clean water for at least 15 minutes
Flush skin with water
Move to fresh air. Get medical attention

SECTION 5 – FIRE FIGHTING MEASURES
Non Flammable
Flash point:
Ignition point:
Fire Extinguishing media

RepliGen Corporation MSDS

No specific fire hazard
N/A
N/A
Use any suitable media as for the surrounding fire

Recombinant Protein A
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RepliGen Corporation
41 Seyon Street
Waltham, MA 02453

Phone: (781) 250-0111
Fax: (781) 250-0115
Revision 1

Recombinant Protein A (rPA50, srPA50, rSPA, rProteinA, rProtein A, Protein A)

SECTION 6 – STEPS TO BE TAKEN IN THE EVENT OF A SPILL OR DISCHARGE:
Personal Protection

Wear lab coat, gloves and eye protection.
Treat with procedures appropriate for biological materials. Soak
up spill with absorbent material and collect in a closed container
suitable for incineration. Clean the affected area with disinfectant
solution. Do not allow material to enter soil, waterways or drains.

Disposal procedure:

Dispose of in accordance with all applicable federal, state, and
local environmental regulations.

SECTION 7 – HANDLING AND STORAGE
Ventilation:
Respiratory Protection:
Eye/skin Protection
Storage:
Special precautions:

Keep in a well ventilated area
N/A
Standard laboratory practices recommended.
Keep container closed. Store frozen for optimum shelf life.
N/A

SECTION 8 – EXPOSURE CONTROLS/PERSONAL PROTECTION
General

Standard laboratory practices recommended. Clean any exposed
skin after handling, before leaving the working area, and before
eating, smoking or using the lavatory.
Dispose of, or clean any contaminated clothing before re-use.

PPE

Personal protective equipment should be selected to provide
adequate protection based upon the procedures being
performed.
Wear laboratory coat, gloves and safety glasses when handling.
Respiratory protection not required

SECTION 9 – PHYSICAL AND CHEMICAL PROPERTIES
Appearance:
pH
Flash point
Ignition point
Explosion limits
Solubility

Frozen aqueous solution
pH 5 - 8
Will not burn
Will not ignite
No risk of explosion
Soluble in water

SECTION 10 – STABILITY AND REACTIVITY
Stability:
Hazardous polymerization:
Decomposition products:

Stable
Will not occur
No known hazardous decomposition products

SECTION 11 – TOXICOLOGICAL INFORMATION
Acute toxicity:
Irritation:
Sensitization:
Carcinogenicity
Mutagenicity
Teratogenicity
RepliGen Corporation MSDS

No known significant effects
No known significant effects. May be a skin or eye irritant.
No known significant effects
No known significant effects
No known significant effects
No known significant effects
Recombinant Protein A
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RepliGen Corporation
41 Seyon Street
Waltham, MA 02453

Phone: (781) 250-0111
Fax: (781) 250-0115
Revision 1

Recombinant Protein A (rPA50, srPA50, rSPA, rProteinA, rProtein A, Protein A)

SECTION 12 – ECOLOGICAL INFORMATION
No known hazards
SECTION 13 – DISPOSAL CONSIDERATIONS
Dispose of in accordance with all applicable federal, state, and local environmental regulations.
Do not allow spilled material to enter soil, waterways or drains
SECTION 14 – TRANSPORT INFORMATION
IATA
DOT Road Transport

Not classified
Not Regulated

SECTION 15 – REGULATORY INFORMATION
OSHA/SARA/CWA/CAA:

No known hazards

EU Risk and Safety Statements:
• Not classified
SECTION 16 – OTHER INFORMATION
The material published in this Material Safety Data Sheet has been compiled from our experience
and data presented in various technical publications. It is the user's responsibility to determine the
suitability of this information for the adoption of necessary safety precautions.
Repligen makes no warranty or representation about the accuracy or completeness nor fitness for
purpose of the information contained herein.

RepliGen Corporation MSDS

Recombinant Protein A
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Material Safety Data Sheet
Sodium bicarbonate MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium bicarbonate

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

Catalog Codes: SLS3241, SLS2446, SLS3868
CAS#: 144-55-8

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400

RTECS: VZ0950000
TSCA: TSCA 8(b) inventory: Sodium bicarbonate
CI#: Not available.
Synonym: Baking Soda; Bicarbonate of soda; Sodium
acid carbonate; Monosodium carbonate; Sodium hydrogen
carbonate; Carbonic acid monosodium salt

Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400

Chemical Name: Sodium Bicarbonate
Chemical Formula: NaHCO3

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Sodium bicarbonate

144-55-8

100

Toxicological Data on Ingredients: Not applicable.

Section 3: Hazards Identification
Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of
inhalation.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. Repeated or prolonged exposure is not known to aggravate medical condition.

Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention if irritation occurs.
p. 1

Skin Contact:
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water
may be used.
Serious Skin Contact: Not available.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: When heated to decomposition it emits acrid smoke and irritating fumes.
Special Remarks on Explosion Hazards: Not available.

Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.

Section 7: Handling and Storage
Precautions:
Do not ingest. Do not breathe dust. If ingested, seek medical advice immediately and show the container or the label. Keep
away from incompatibles such as acids.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area.

Section 8: Exposure Controls/Personal Protection
p. 2

Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits: Not available.

Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Saline. Alkaline.
Molecular Weight: 84.01g/mole
Color: White.
pH (1% soln/water): Not available.
Boiling Point: Not available.
Melting Point: Not available.
Critical Temperature: Not available.
Specific Gravity: Density: 2.159 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Soluble in cold water. Slightly soluble in alcohol. Solubility in Water: 6.4, 7.6, 8.7, 10.0, 11.3, 12.7, 14.2, 16.5, 19.1 g/100
solution at 0, 10, 20, 30, 40, 50, 60, 80, adn 100 deg. C, respectively. Solubility in Water: 6.9, 8,2, 9.6, 11.1, 12.7, 14.5, 16.5,
19.7, and 23.6 g/100g water at 0, 10, 20, 30, 40, 50, 60, 80, 100 deg. C, respectively.

Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, Moisture. Stable in dry air, but slowly decomposes in moist air.
Incompatibility with various substances: Reactive with acids.
p. 3

Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Reacts with acids to form carbon dioxide. Dangerous reaction with monoammonium phosphate or a sodium-potassium alloy.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Inhalation. Ingestion.
Toxicity to Animals: Acute oral toxicity (LD50): 3360 mg/kg [Mouse].
Chronic Effects on Humans: Not available.
Other Toxic Effects on Humans: Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans:
Sodium Bicarbonate as produced genetic effects in rats (unscheduled DNA synthesis). However, no affects have been found
in humans.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause mild skin irritation. Eyes: May cause mild eye irritation. Inhalation: May
cause respiratory tract irritation. Symptoms may include coughing and sneezing. Ingestion: Symptoms of overexposure to
Sodium Bicarbonate include thirst, abdominal pain, gastroenteritis, and inflammation of the digestive tract. Chronic Potential
Health Effects: Skin: Repeated or prolonged skin contact may cause irritation, drying or cracking of the skin. Ingestion and
Inhalation: Chronic toxicity usually occurs within 4 to 10 days following ingestion of very large amounts. Repeated or prolonged
ingestion or inhalation of large amounts may cause metabolic abnormalities, and sodium retention. Metabolic abnormalities
such as acidosis, hypernatremia, hypochloremia, alkalosis, hypocalcemia, or sodium retention may affect the blood, kidneys,
respiration (cyanosis, apnea secondary to metabolic acidosis or pulmonary edema), and cardiovascular system (tachycardia,
hypotension). Severe toxicity may also affect behavior/central nervous system/nervous system. Neurological changes may
result from metabolic abnormalities. These may include fatigue, irritability, dizziness, mental confusion, paresthesia, seizures,
tetany, cerebral edema Medical Conditions Aggravated by Exposure: Persons with pre-existing skin conditions might have
increased sensitivity. Predisposing conditions that contribute to a mild alkali syndrome include, renal disease, dehydration, adn
electrolyte imbalance, hypertension, sarcoidosis, congestive heart failure, edema, or other sodium retaining conditions.

Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The product itself and its products of degradation are not toxic.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
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DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.

Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Sodium bicarbonate
Other Regulations: Not available.
Other Classifications:
WHMIS (Canada): Not controlled under WHMIS (Canada).
DSCL (EEC):
This product is not classified according to the EU regulations. Not applicable.
HMIS (U.S.A.):
Health Hazard: 1
Fire Hazard: 0
Reactivity: 0
Personal Protection: E
National Fire Protection Association (U.S.A.):
Health: 1
Flammability: 0
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Safety glasses.

Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/10/2005 08:26 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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MATERIAL SAFETY DATA SHEET
REF: 91/155/EEC AND AMENDMENTS WITH RESPECTIVE NATIONAL IMPLEMENTATIONS

SODIUM CITRATE
1.0
1.1
1.2

SUBSTANCE IDENTIFICATION
Commercial product name: Sodium Citrate including anhydrous, dehydrate etc
Chemical characterisation: Trisodium salt of 2-hydroxypropane-1,2,3, tricarboxylate

1.3
1.4
1.5
1.6
1.7
1.8

Formula:
Molecular weight:
approx 258 - 294
CAS No:
6132-04-3
EINECS No.:
200-675-3
FOR USE IN FOOD as a food aditive
Manufactured by:
Archer Daniels Midland Company, 4666 Faries Parkway,
Decatur, Illinois 62526, U.S.A.
1.9
Supplied by:
ADM Australia Pty Ltd, PO Box 281, Suite 1003, Level 10,
1 Newland Street, Bondi Junction, NSW 2022
1.10 Australian Emergency Telephone Number: 0417285396

2.0

2.1
2.2
2.3

COMPOSITION

Totally 100% sodium citrate
Volatile matter 6-12 % maximum after drying for 4 hours at 180°C
Sodium ion content typically 23 - 24%

3.0 HAZARDS IDENTIFICATION
3.1
Sodium citrate is not classified as a Dangerous Substance within the definitions of EC
Directive 67/584
3.2
Contact with eyes (e.g. dust particles) may cause irritation.
4.0 FIRST AID MEASURES
4.1
Flush affected parts with plenty of water
5.0 FIRE FIGHTING MEASURES
5.1
All types of fire extinguisher are suitable
5.2
Firefighters wear protective clothing and NIOSH approved respirator
6.0 ACCIDENTAL RELEASE MEASURES
6.1
After spillage/leakage : Recover by vacuum, or broom and shovel. Flush area with water to
remove final traces.
Effective: 10 April, 2009 Page 1 of 3
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7.0 HANDLING AND STORAGE

7.1
7.2

Store in tightly closed containers, away from extreme heat and humidity. Maximum 25°C and 50%
relative humidity.
Industrial Hygiene: Good ventilation required if process creates the formation of dust.

8.0 EXPOSURE CONTROLS / PERSONAL PROTECTION
8.1 Personal precautions:
Avoid breathing dust.
Avoid contact with eyes.
8.2 Respiratory protection:
Approved nuisance dust mask
8.3 Hand protection:
Standard work gloves
8.4 Eye protection:
Goggles or safety glasses
9.0
9.1
9.2
9.3
9.4
9.5
9.6

PHYSICAL AND CHEMICAL PROPERTIES
Appearance: Crystals
Colour: Colourless
Odour: Odourless
Molecular weight: 258 - 294
Change in physical state: Loss of water above 180°C, with decomposition
Specific gravity Bulk density: 1.97 920-1150 kg/m3 (typical range)

9.8
Vapour pressure: N/A - solid
9.9
Viscosity: N/A - solid
9.10 Solubility - in water (25°C) 40 - 60% w/w
- in ethanol (25°C) Insoluble
9.11 pH (5% solution) (25°C) 7 - 9
9.12 Flash point N/A
9.13 Explosive properties N/A
9.14 Flammability: Requires external heat to burn
9.12 Thermal decomposition: Above 230°C may evolve carbon monoxide
and carbon dioxide
10.0 STABILITY AND REACTIVITY
10.1 Shelf life :
Sodium citrate is chemically stable if stored under cool, dry
conditions; 25°C maximum and 50% relative humidity. It
deliquesces in moist air. Physical properties may change on
storage: re-test recommended periodically based on actual
storage conditions.
10.4 Reactivity:

Sodium citrate is a neutral salt with low activity.

11.0 TOXICOLOGICAL INFORMATION
11.1 LD50 (dog):
Not available
12.0 ECOLOGICAL INFORMATION
12.1 Not Available
12.2 Not AVailable

Effective: 10 April, 2009
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13.0 DISPOSAL CONSIDERATIONS
13.1 Sodium citrate is suitable for landfill or disposal to sewer depending
upon local regulations.
14.0 TRANSPORT INFORMATION
14.1 No special considerations
15.0 REGULATORY INFORMATION
15.1 Sodium citrate is an EU permitted Food Additive (E 332). Conditions of use:
Quantum Satis. The US Food and Drug Administration classifies potassium citrate as
a GRAS (Generally Recognised As Safe) food ingredient.
15.2 According to the Joint Expert Committee on Food Additives of WHO/FAO potassium
Citrate may be used without limitation according to Good Manufacturing Practices.
16.0 ADDITIONAL INFORMATION
16.1 See Product Data Sheet.
Effective: 10 April, 2009 Page 1 of 3
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Material Safety Data Sheet
Sodium phosphate tribasic MSDS
Section 1: Chemical Product and Company Identification
Product Name: Sodium phosphate tribasic

Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396

Catalog Codes: SLS2650, SLS4072
CAS#: 7601-54-9
RTECS: TC9490000
TSCA: TSCA 8(b) inventory: Sodium phosphate tribasic
CI#: Not available.
Synonym: Trisodium Phosphate Anhydrous; Phosphoric
Acid, Trisodium Salt; Trisodium Orthophosphate
Chemical Name: Sodium Phosphate Tribasic

US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400

Chemical Formula: Na3PO4

Section 2: Composition and Information on Ingredients
Composition:
Name

CAS #

% by Weight

Sodium phosphate tribasic

7601-54-9

100

Toxicological Data on Ingredients: Sodium phosphate tribasic: ORAL (LD50): Acute: 4150 mg/kg [Rat [information from
other supplier]]. DERMAL (LD50): Acute: &gt;7940 mg/kg [Rabbit [information from other supplier]]. &gt;300 mg/kg [Rabbit
[Registry of Toxic Effects of Chemical Substances database]].

Section 3: Hazards Identification
Potential Acute Health Effects:
Hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Slightly hazardous in case
of skin contact (permeator). Corrosive to eyes and skin. The amount of tissue damage depends on length of contact. Eye
contact can result in corneal damage or blindness. Skin contact can produce inflammation and blistering. Inhalation of dust
will produce irritation to gastro-intestinal or respiratory tract, characterized by burning, sneezing and coughing. Severe overexposure can produce lung damage, choking, unconsciousness or death.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Not available. TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available. Repeated exposure of the eyes to a low level of dust can produce eye irritation.
Repeated skin exposure can produce local skin destruction, or dermatitis. Repeated inhalation of dust can produce varying
degree of respiratory irritation or lung damage.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention immediately.
Skin Contact:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing
and shoes. Cover the irritated skin with an emollient. Cold water may be used.Wash clothing before reuse. Thoroughly clean
shoes before reuse. Get medical attention immediately.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek medical attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention immediately.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention if symptoms appear.
Serious Ingestion: Not available.

Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available. Slightly explosive in presence of heat.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Containers may explode when heated

Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. If necessary: Neutralize the residue with
a dilute solution of acetic acid. Finish cleaning by spreading water on the contaminated surface and dispose of according to
local and regional authority requirements.
Large Spill:
Corrosive solid. Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray
to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Call for assistance on disposal.
Neutralize the residue with a dilute solution of acetic acid. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.
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Section 7: Handling and Storage
Precautions:
Keep container dry. Do not ingest. Do not breathe dust. Never add water to this product. Wear suitable protective clothing. In
case of insufficient ventilation, wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the
container or the label. Avoid contact with skin and eyes. Keep away from incompatibles such as moisture.
Storage: Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 23°C (73.4°F).

Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Synthetic apron. Gloves (impervious).
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
handling this product.
Exposure Limits:
TWA: 15 (mg/m3) from OSHA (PEL) [United States] Inhalation Total. TWA: 5 (mg/m3) from OSHA (PEL) [United States]
Inhalation Respirable. TWA: 5 STEL: 5 (mg/m3) from AIHA InhalationConsult local authorities for acceptable exposure limits.

Section 9: Physical and Chemical Properties
Physical state and appearance: Solid.
Odor: Odorless.
Taste: Not available.
Molecular Weight: 163.94 g/mole
Color: White.
pH (1% soln/water): 11.9 [Basic.]
Boiling Point: Not available.
Melting Point: 75°C (167°F)
Critical Temperature: Not available.
Specific Gravity: 1.62 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility:
Easily soluble in hot water. Soluble in cold water.
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Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Moisture
Incompatibility with various substances: Reactive with moisture.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity: Hygroscopic. Sodium Phosphate Tribasic forms a strong caustic solution similar to soda lye
Special Remarks on Corrosivity: When wet, mild steel and brass may be corroded by sodium phosphate tribasic.
Polymerization: Will not occur.

Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Inhalation. Ingestion.
Toxicity to Animals:
Acute oral toxicity (LD50): 4150 mg/kg [Rat [information from other supplier]]. Acute dermal toxicity (LD50): >300 mg/kg
[Rabbit [Registry of Toxic Effects of Chemical Substances database]].
Chronic Effects on Humans: Not available.
Other Toxic Effects on Humans:
Extremely hazardous in case of skin contact (corrosive), of eye contact (corrosive), of inhalation (lung corrosive). Hazardous in
case of skin contact (irritant), of ingestion, . Slightly hazardous in case of skin contact (permeator).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: May affect genetic material (mutagenic)
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: Causes skin irritation with possible burning pain and corrosive damage. It may be
absorbed through the skin. Eyes: Causes eye irritation. It causes immediate and severe pain followed by conjunctival edema
and corneal clouding. Later cataract formation may occur. This substance may cause eye burns. Inhalation: May be harmful
if inhaled. Inhalation of dust may Cause respiratory tract and mucous membrane irritation with coughing, sneezing, choking,
difficulty breathing, and pulmonary edema. Ingestion: May be harmful if swallowed. May cause severe gastrointestinal
(digestive) tract irritation with severe nausea, vomiting, abdominal discomfort, violent purging, diarrhea, and burning sensation.
Ingestion of large amounts may induce hypcalcemia or hypnatremia characterized by tetanus-like spasms, due to the
sequestration of calcium ions by the phosphate moiety. It may also cause caustic burns of the mouth oropharnyx, esophagus,
or gastrointestinal tract.

Section 12: Ecological Information
Ecotoxicity:
Ecotoxicity in water (LC50): 220 mg/l 96 hours [Bluegill sunfish]. 120 mg/l 96 hours [Rainbow Trout]. 177 mg/l 50 hours
[Daphnia].
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are as toxic as the original product.
Special Remarks on the Products of Biodegradation: Not available.

Section 13: Disposal Considerations
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Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.

Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: : Not available. UNNA: 9148 PG: III
Special Provisions for Transport: Not applicable.

Section 15: Other Regulatory Information
Federal and State Regulations:
New York release reporting list: Sodium phosphate tribasic Pennsylvania RTK: Sodium phosphate tribasic Minnesota: Sodium
phosphate tribasic Massachusetts RTK: Sodium phosphate tribasic New Jersey: Sodium phosphate tribasic California
Director's List of Hazardous Substances: Sodium phosphate tribasic TSCA 8(b) inventory: Sodium phosphate tribasic
CERCLA: Hazardous substances.: Sodium phosphate tribasic: 5000 lbs. (2268 kg)
Other Regulations:
OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the
European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS E: Corrosive solid.
DSCL (EEC):
R35- Causes severe burns. S1/2- Keep locked up and out of the reach of children. S26- In case of contact with eyes, rinse
immediately with plenty of water and seek medical advice. S36/37- Wear suitable protective clothing and gloves. S39- Wear
eye/face protection. S45- In case of accident or if you feel unwell, seek medical advice immediately (show the label where
possible).
HMIS (U.S.A.):
Health Hazard: 2
Fire Hazard: 0
Reactivity: 0
Personal Protection: C
National Fire Protection Association (U.S.A.):
Health: 2
Flammability: 0
Reactivity: 2
Specific hazard:
Protective Equipment:
Gloves (impervious). Synthetic apron. Wear appropriate respirator when ventilation is inadequate. Safety glasses.

Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
p. 5

Created: 10/09/2005 06:35 PM
Last Updated: 05/21/2013 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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Material Safety Data Sheet
TEAc-N
Perfluoroalkyl Ethyl Acrylates (Narrow Distribution)
Revised 03- November-2009
1. PRODUCT AND COMPANY IDENTIFICATION
Material Identification
Product name:

TEAc-N (narrow distribution)

Chemical name:

Perfluoroalkyl ethyl acrylates, mixture
1H,1H,2H,2H-Perfluoroalkyl-1-acrylates

Chemical formula:

CH2=CHC(O)OCH2CH2(CF2CF2)nF, n = 3, 4, 5,
mostly n = 4
CnH7FmO2; n = 9,11,13,15 ; m = 2n-9

;

Company Identification
Distributor

Top Fluorochem Co., Ltd.
Building C2, 3rd Floor
479 Chun Dong Road
XinZhuang Industrial Park
Minhang District
Shanghai, P. R. China 201108

Manufacturer

Fuxin Hengtong Fluorine Chemicals Co., Ltd.
Fuxin Chemicals Community
West Pingan St.
Haizhou District
Fuxin City, Liaoning Province, P. R. China

Emergency Call

+86-21-54833399

2. COMPOSITION AND INFORMATION ON INGREDIENTS
Components
Material
Perfluoroalkylethyl acrylates
2,6-Di-tert-butyl-4-methylphenol

CAS Number
65605-70-1
128-37-0

EINECS
NA
204-881-4

TSCA Listed
NA
Yes

Amount
30 ppm

3. HAZARDS IDENTIFICATION
Potential Health Effects
Skin contact:

May cause irritation.

Eye contact:

May cause irritation.

Inhalation of spray or mist:

May cause nasal, throat, or lung irritation.

Inhalation of large amounts:

May be toxic to the lungs.

Symptoms:

May be modest initially, followed in hours by severe
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shortness of breath requiring prompt medical
attention.
Carcinogenicity Information:

None of the components present in this material at
concentrations equal to or greater than 0.1 % are
listed by IARC, NTP, OSHA or ACGIH as a
carcinogen.

4. FIRST AID MEASURES
Inhalation:

If inhaled, remove to fresh air. If not breathing, give
artificial respiration. If breathing is difficult, give
oxygen. Call a physician.

Skin Contact:

Flush skin with water after contact. Wash
contaminated clothing before reuse.

Eye Contact:

In case of contact, immediately flush eyes with plenty
of water for at least 15 minutes. Call a physician.

Ingestion:

If swallowed, do not induce vomiting. Immediately
give 2 glasses of water. Never give anything by
mouth to an unconscious person. Call a physician.

Note to Physicians:

Activated charcoal mixture may be administered.
To prepare activated charcoal mixture, suspend 50
grams activated charcoal in 400 mL water and mix
thoroughly. Administer 5 mL/kg, or 350 mL for an
average adult.

5. FIRE FIGHTING MEASURES
Flammable Properties
Flash point:
Method:

> 110 °C (> 230 °F)
PMCC

Hazardous Decomposition Products:

Hazardous decomposition products include carbon
dioxide, carbon monoxide, and hydrogen fluoride.
Toxic gases or particles may be formed during
combustion. These products may cause severe
eye, nose, throat, and lung irritation or toxic effects.

Extinguishing Media:

Water spray, foam, dry chemical, CO2.

Fire Fighting Instructions:

Evacuate personnel to a safe area. Keep personnel
removed and upwind of fire. Wear self-contained
breathing apparatus. Wear full protective
equipment. Avoid breathing decomposition
products.

6. ACCIDENTAL RELEASE MEASURES
Safeguards (Personnel)
NOTE:

Review FIRE FIGHTING MEASURES and
HANDLING (Personnel) sections before proceeding
with clean-up. Use appropriate personal protective
equipment during clean-up.

Spill clean up:

Soak up with sawdust, sand, oil dry or other
absorbent material. Shovel or sweep up.
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7. HANDLING AND STORAGE
Handling Requirements:

Avoid breathing vapors or mist.
Avoid contact with eyes, skin, or clothing.
Wash thoroughly after handling.
Do not store or consume food, drink, or tobacco in
areas where they may become contaminated with
this material.
Avoid circumstances that produce respirable
particles unless suitable ventilation and respirator
are used.

Storage conditions:

Keep container and store in a cool place.
Keep container tightly closed.

8. EXPOSURE CONTROLS AND PERSONAL PROTECTION
Engineering Controls:

Keep container tightly closed. Use only with
adequate ventilation. Vent heated extruder or dryer
fumes outside work area. Do not aerosolize. In
spray applications, use airless type pressure spray
equipment at less than 60 psi, and exhaust ducts,
drip pans, or other design features to minimize
worker exposure to mists and overspray.

Personal Protective Equipment
Eye/face protection:

Wear safety glasses or cover-all chemical splash
goggles.

Respirators:

Where there is potential for airborne exposures wear
NIOSH approved respiratory protection.

Protective clothing:

Where there is potential for skin contact have
available and wear as appropriate impervious gloves,
apron, pants, and jacket.

Exposure Guidelines
PEL (OSHA):

None established.

TLV (ACGIH):

None established.

9. PHYSICAL AND CHEMICAL PROPERTIES
Boiling Point
Melting Point
Flash Point
pH
Density
Odor
Form
Color
Refractive Index
Solubility in Water

100 to 220 °C (212 to 428 °F) @ 10 mm Hg
Approx.
-1 to 25 °C
> 110 °C
3 to 5 @ 20 °C
1.6 g/mL @ 25 °C
Mild acrylic
Semi-solid
Pale to medium yellow
nD25 = 1.3332
Negligible
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10. STABILITY AND REACTIVITY
Chemical Stability:

Stable at normal temperatures and storage
conditions. Air inhibits polymerization.
Incompatible with peroxides and free radical
sources.

Decomposition:

Decomposes with heat. Hazardous decomposition
products include carbon dioxide, carbon monoxide,
and hydrogen fluoride. Toxic gases or particles
may be formed during combustion. These products
may cause severe eye, nose, throat, and lung
irritation or toxic effects.

Polymerization:

Polymerization can occur. Conditions leading to
polymerization are free radical sources, heat, and UV
light.

11. ECOLOGICAL INFORMATION
General:

Take care to prevent chemicals from entering the
ground, water courses or drainage systems.

12. DISPOSAL CONSIDERATIONS
Disposal Operations:

Material should be disposed of in accordance with
local, state and federal regulations.

Disposal of Packaging:

Dispose of as special waste in compliance with local
and national regulations. Observe all federal, state
and local environmental regulations.
The user's attention is drawn to the possible
existence of regional or national regulations
regarding disposal.

13. TRANSPORTATION INFORMATION
Mode
UN Number
Class (Subsidiary)
Proper Shipping Name
Hazard Label (Subsidiary)
Packing Group
Shipping Hazard Label

DOT/IMDG/IATA
None. Non-hazardous for transport.
None. Non-hazardous for transport.
None. Non-hazardous for transport.
None. Non-hazardous for transport.
None. Non-hazardous for transport.
None. Non-hazardous for transport.

14. REGULATORY INFORMATION
U.S. Federal Regulations

TITLE III
HAZARD CLASSIFICATIONS SECTIONS 311,
312

Acute :

Yes

Chronic :

No

Fire :

No
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Reactivity :

No

Pressure :

No

Incompliance with TSCA Inventory requirements.
15. OTHER INFORMATION
Personal Protection rating:
NPCA-HMIS Rating:

Legal Disclaimer:

To be supplied by user depending on use conditions.
Health: 2
Flammability: 1
Reactivity: 1
For R&D use only. Not for drug, household, or other
uses. The previous information is based upon our
current knowledge and experience of our product
and is not exhaustive. It applies to the product as
defined by the specifications. In case of
combinations or mixtures, one must confirm that no
new hazards are likely to exist. In any case, the
user is not exempt from observing all legal,
administrative and regulatory procedures relating to
the product, personal hygiene, and integrity of the
work environment. Unless noted to the contrary,
the technical information applies only to pure
product.
To our actual knowledge, the information contained
herein is accurate as of the date of this document.
However, neither Top Fluorochem, nor any of its
affiliates makes any warranty, express or implied, or
accepts any liability in connection with this
information or its use. This information is for use by
technically skilled persons at their own discretion and
risk and does not relate to the use of this product in
combination with any other substance or any other
process. This is not a license under any patent or
other proprietary right. The user alone must finally
determine suitability of any information or material for
any contemplated use, the manner of use and
whether any patents are infringed. This information
gives typical properties only and is not to be used for
specification purposes.

End Of MSDS
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Material Safety Data Sheet for Hamster Cell Cultures
(Biosafety Level 1)
1. Product Identification
Name of cell line: CHO-K1 (CLS order no. 603480)
Designation: Chinese-Hamster-Ovary cell line, permanent cell line

2. Company Identification
CLS Cell Lines Service GmbH
Dr. Eckener-Str. 8
D-69214 Eppelheim
Germany
Emergency phone number:

+49 (0)6221 700799

3. Composition / Ingredients
Unit: cryovial; frozen liquid
Hazardous Ingredient(s)
Dimethyl Sulfoxide

CAS no.
67-68-5

Non-Hazardous Ingredient(s)
DMEM, supplemented for freezing
FBS (Fetal Bovine Serum)
Cells

Percentage
10

EC no.
200-664-3

Percentage
60-80
10-20
1

4. Hazards Identification
Chinese-Hamster source cell line
Categorized as non-infectious and non-toxic

5. First Aid Measures
Skin contact:
Wash off immediately with plenty of water and soap.
Eye contact:
Flush eyes immediately with water for 10-15 minutes.
Ingestion:
If the material was swallowed, rinse the mouth with water.

6. Accidental Release Measures
Use personal protective equipment
Do not flush into surface water.
Clean contaminated surface thoroughly. Autoclave before disposal into appropriated containers.

CLS Cell Lines Service GmbH
Dr. Rosemarie Steubing
Dr. Eckener-Str. 8
69214 Eppelheim
Germany

Phone: +49 (0)6221 700799
Fax: +49 (0)6221 700717
info@cell-lines-service.de
http://www.cell-lines-service.de
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7. Handling and storage
Handling:
Open only under a sterile workbench. Wear protective equipment. Handle as if containing infectious
material.
Storage:
Keep the cryovial at -150°C (freezer) or at -196°C (liquid nitrogen vapour phase).

8. Personal Protection
Hygienic measures
Avoid the contact with skin, eyes and clothing. Keep away from food and drinks. Wash hands immediately
after handling the product.
Normally, no respiratory protective equipment is required.
Use protective gloves and safety goggles and wear a lab coat while handling the product.

9. Physical and Chemical Properties / Reactivity
Form:
Liquid
DMSO is stable. It is incompatible with a very wide range of materials, including acid chlorides, strong
acids, strong oxidizing agents, strong reducing agents, phosphorus halides, moisture, copper wool +
trichloroacetic acid, hygroscopic.

10. Toxicological Information
Not hazardous according to Directive 67/548/EC.
Toxicity data for DMSO:
-1

ORL-RAT LD50 14500 mg kg
-1
IVN-MAN TDLO 686 mg kg
-1
IVN-MUS LD50 3100 mg kg
IVN-DOG LD50 2500 mg kg

ORL-MAM LD50 21400 mg kg
-1
IPR-RAT LD50 8200 mg kg
-1
ORL-BWD LD50 100 mg kg

-1

11. Transportation Information
Non-hazardous for air, sea and road freight.

12. General Information
Recommended use:
For in vitro research use only.
Disclaimer:
The information provided in the present Material Safety Data Sheet is believed to be correct at the date of
publication. No guarantee is given for its accuracy or completeness, but is intended as guidance only.
Biological material may be hazardous and should be used with caution.
CLS · Cell Lines Service shall not be held liable for any damage resulting from handling or from contact
with the product.

CLS Cell Lines Service GmbH
Dr. Rosemarie Steubing
Dr. Eckener-Str. 8
69214 Eppelheim
Germany

Phone: +49 (0)6221 700799
Fax: +49 (0)6221 700717
info@cell-lines-service.de
http://www.cell-lines-service.de
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